Methods of diagnosing and treating cervical cancer

ABSTRACT

The present invention is related to diagnostic tests or rapid detections of different types of cancer, especially cervical cancer and precancerous lesions. Especially, the invention relates to specific and useful protein biomarkers for the detection of said diseases, and to the methods for determination and detection of said biomarkers.

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a utility application which claims priority and the benefit under 35 USC § 119(a) of International Application, Mexican Patent Application No. MX/a/2019/005940 filed May 21, 2019, the entire contents of which is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION Field of the Invention

The present invention relates generally to methods of diagnosing and treating cervical cancer in a subject and more specifically to biomarkers used to diagnose cervical cancer.

Background Information

Cervical cancer (CC) is one of the most common cancers among women worldwide. Among the risk factors related to this disease are infection with the human papilloma virus (HPV), the microbiome, risky sexual behavior, multiparity, smoking, prolonged use of hormonal contraceptives and environmental factors. Cervical cancer is a disease of slow and progressive evolution. It is preceded by cervical intraepithelial neoplasms, which are the lesions considered to be the prelude to this condition. These malignancies or injuries can occur even 10 years before cervical cancer develops.

Human papillomavirus infection (HPV) causes more than 90% of cases. Other risk factors include smoking, a weak immune system, birth control pills, starting sex at a young age, and having many sexual partners, but these are less important. Cervical cancer typically develops from precancerous changes over 10 to 20 years. About 90% of cervical cancer cases are squamous cell carcinomas, 10% are adenocarcinoma, and a small number are other types. Diagnosis is typically by cervical screening followed by a biopsy. Medical imaging is then done to determine whether or not the cancer has spread.

Current methods of diagnosing cervical cancer are invasive. The most common method of diagnosing cervical cancer is by a smear screening with Papanicolaou staining, i.e. Pap smear. There is a need for non-invasive methods of detecting cervical cancer.

SUMMARY OF THE INVENTION

The present invention is based on the seminal discovery that a collection of biomarkers can be used for the diagnosis of cervical cancer.

In one embodiment, the present invention is directed to methods of detecting at least one polypeptide in a sample from a subject; wherein the at least one polypeptide is selected from Farnesyl pyrophosphate synthase, neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat Shock Protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof; or a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs: 1-20 or a fragment thereof; and diagnosing cervical cancer based on the detection of the at least one polypeptide.

In one aspect, the sample is selected from the group consisting of blood, plasma, urine, saliva, sweat, organ biopsy, cerebrospinal fluid (CSF), tear, vaginal fluid, feces, skin, and hair. In certain aspects the sample is a blood sample and the subject is human.

In another aspect, the at least one polypeptide is Farnesyl pyrophosphate synthase or a fragment thereof and at least one polypeptide selected from neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof. In an additional aspect, the at least one polypeptide is a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof and at least one polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs:2-20 and a fragment thereof.

In a further aspect, the detecting is by protein microarray, fluorescence detection, flow cytometry, microfluidic device, lateral flow assay, vertical flow assay or immunoassay. In a specific aspect, the detecting is by lateral flow assay. In one aspect, the method also includes administering a treatment to the subject. In an additional aspect, the treatment is surgery, radiation, chemotherapy, targeted therapy and/or immunotherapy.

In another embodiment, the present invention provides a method of diagnosing cervical cancer in a subject by detecting at least one polypeptide in a sample from a subject; wherein the at least one polypeptide is selected from Farnesyl pyrophosphate synthase, neurofibromin 1, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat shock protein cognate protein 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof, or a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs: 1-20 or a fragment thereof; and diagnosing cervical cancer based on the detection of at least one polypeptide.

In one aspect, the sample is blood, plasma, urine, saliva, sweat, organ biopsy, cerebrospinal fluid (CSF), tear, vaginal fluid, feces, skin, and hair. In certain aspects, the sample is a blood sample and the subject is human.

In an additional aspect, the at least one polypeptide is Farnesyl pyrophosphate synthase or a fragment thereof and at least one polypeptide selected from neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Cognate thermal shock protein 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof. In a further aspect, the at least one polypeptide is a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof and at least one polypeptide with at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs:2-20 or a fragment thereof.

In another aspect, the detecting is by protein microarray, fluorescence detection, flow cytometry, microfluidic device, lateral flow assay, vertical flow assay or immunoassay. In a specific aspect, the detecting is by lateral flow assay. In one aspect, the method also includes administering a treatment to the subject. In certain aspects, the treatment is surgery, radiation, chemotherapy, targeted therapy and/or immunotherapy.

In an additional embodiment, the present invention provides a method of treating cervical cancer in a subject in need thereof, the method is detecting at least one polypeptide in a sample from a subject; wherein the at least one polypeptide is selected from Farnesyl pyrophosphate synthase, neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type I, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof, or a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs: 1-20 or a fragment thereof, diagnosing cervical cancer based on the detection of the at least one polypeptide; and administering a treatment to the subject. In one aspect, the sample is a blood sample.

In an additional aspect, the at least one polypeptide is Farnesyl pyrophosphate synthase or a fragment thereof and at least one polypeptide selected from neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type I, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof. In a further embodiment, the at least one polypeptides is a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof and at least one polypeptide with at least about 70% sequence identity to a polypeptide with an amino acid sequence selected from SEQ ID NOs:2-20 or a fragment thereof.

In another aspect, the detecting is by protein microarray, fluorescence detection, flow cytometry, microfluidic device, lateral flow assay, vertical flow or immunoassay. In a specific aspect, the detecting is by lateral flow assay. In an additional aspect, the treatment is selected from the group consisting of surgery, radiation, chemotherapy, targeted therapy and immunotherapy.

In a further aspect, the chemotherapy is Cisplatin, Carboplatin, Paclitaxel, Topotecan, docetaxel, ifosfamide, 5-fluorouracil, irinotecan, gemcitabine or mitomycin. In certain aspects, the targeted therapy is bevacizumab and the immunotherapy is pembrolizumab.

In a further embodiment, the present invention provides methods of predicting a response to treatment for a subject having cervical cancer by detecting at least one polypeptide in a sample from a subject; wherein the at least one polypeptide is selected from Farnesyl pyrophosphate synthase, neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof, or a polypeptide with at least about 70% sequence identity to a polypeptide having amino acid sequence selected from SEQ ID NOs: 1-20 or a fragment thereof; and predicting a response to treatment based on the detection of the at least one polypeptide.

In one aspect, the at least one polypeptide is Farnesyl pyrophosphate synthase or a fragment thereof and at least one polypeptide selected from neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof. In another aspect, the at least one polypeptide is a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof and at least one polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs:2-20 or a fragment thereof.

In an additional aspect, the detecting is by protein microarray, fluorescence detection, flow cytometry, microfluidic device, lateral flow assay, vertical flow or immunoassay. In a further aspect, the detecting is by lateral flow assay. In certain aspects, the treatment is surgery, radiation, chemotherapy, targeted therapy and immunotherapy.

In another embodiment, the present invention provides methods for determining the stage of cervical cancer in a subject in need thereof by detecting at least one polypeptide in a sample from the subject; wherein the at least one polypeptide is selected from Farnesyl pyrophosphate synthase, neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type I, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof, or a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs: 1-20 or a fragment thereof; and determining the stage of cervical cancer in the subject based on the detection of the at least one polypeptide.

In one aspect, the at least one polypeptide is Farnesyl pyrophosphate synthase or a fragment thereof and at least one polypeptide selected from neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type I, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof. In another aspect, the at least one polypeptide is a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof and at least one polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs:2-20 or a fragment thereof.

In an additional aspect, the detecting is by protein microarray, fluorescence detection, flow cytometry, microfluidic device, lateral flow assay, vertical assay or immunoassay. In a specific aspect, the detecting is by lateral flow assay. In a further aspect, the method also includes administering a treatment to the subject. In certain aspects, the treatment is surgery, radiation, chemotherapy, targeted therapy or immunotherapy. In one aspect, the cervical cancer is stage L stage II, stage III or stage IV.

In one embodiment, the present invention provides a kit with a sample collection unit; a lateral flow device; and instructions for using the lateral flow device.

In one aspect, the lateral flow device detects at least one polypeptide selected from Farnesyl pyrophosphate synthase, neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type I, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof, or a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs: 1-20 or a fragment thereof.

In an additional aspect, the at least one polypeptide is Farnesyl pyrophosphate synthase or a fragment thereof and at least one polypeptide selected from neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type I, Alph-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof. In a further aspect, the at least one polypeptide is a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof and at least one polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs:2-20 or a fragment thereof.

In another aspect, the lateral flow device detects the at least one polypeptide by an immunoassay. In one aspect, the sample collection unit collects a blood sample.

In an additional aspect, the present invention provides a use of the detection of at least one polypeptide for the diagnosis of cervical cancer in a subject in need thereof, wherein the at least one polypeptide is selected from Farnesyl pyrophosphate synthase, neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof; or a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs: 1-20 or a fragment thereof.

In a further aspect, the at least one polypeptide is detected in a sample from the subject and the sample is a blood sample. In another aspect, the at least one polypeptide is Farnesyl pyrophosphate synthase or a fragment thereof and at least one polypeptide selected from neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alph-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof. In one aspect, the at least one polypeptide is a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof and at least one polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs:2-20 or a fragment thereof.

In another aspect, the detecting is by protein microarray, fluorescence detection, flow cytometry, microfluidic device, lateral flow assay, vertical flow or immunoassay. In certain aspects, the detecting is by lateral flow assay.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the workflows to obtain secreted proteins in vivo or ex vivo.

FIG. 2 is a graph showing the growth kinetics of cell lines with and without fetal bovine serum (FBS).

FIG. 3A show analysis of the cervical cancer line secretome and its negative control.

FIG. 3B illustrates the number of total protein in each cell line, the number of unique protein, and the protein shared between cell lines. FIG. 3C is a graphical representation of the data presented in FIG. 3B.

FIG. 4A shows a dotplot graph illustrating the label-free quantification (LFQ) of 200 CC cell line secretome proteins vs. their negative control. FIG. 4B is a graph bar representing the expression profile of proteins of interest. FIG. 4C is a heat map illustrating the label-free quantification (LFQ) of 200 CC cell line secretome proteins vs. their negative control.

FIG. 5A illustrates the workflow to collect blood and serum samples. FIG. 5B illustrate the western blot analysis of FPS (farnesyl pyrophosphatase) in mouse sera. FIG. 5C illustrates the quantification of the data presented in FIG. 5B.

FIG. 6A illustrates the validation of the candidate protein Farnesyl pyrophosphate synthase in the sera of patients with CC. FIG. 6B illustrates the level of Faresyl pyrophosphate synthase protein detected in the sera of control patients. FIG. 6C illustrates the quantification of the data presented in FIGS. 6A and 6B.

FIG. 7A illustrates the validation of the candidate protein Farnesyl pyrophosphate synthase in precancerous cervical lesions. FIG. 7B illustrates the validation of the candidate protein Ankyrin-3 in precancerous cervical lesions. FIG. 7C illustrates the quantification of the data presented in FIGS. 7A and 7B.

FIG. 8A illustrates the detection of Farnesyl pyrophosphate synthase by western blot in the sera of patients with pr-cancerous lesions L1. FIG. 8B illustrates the detection of Farnesyl pyrophosphate synthase by western blot in the sera of patients with pr-cancerous lesions L2. FIG. 8C illustrates the detection of Farnesyl pyrophosphate synthase by western blot in the sera of control patients. FIG. 8D illustrates the quantification of the data provided in FIG. 8A-8C.

FIG. 9A illustrates the detection of Ankyrin-3 by western blot in the sera of patients with pro-cancerous lesions L1. FIG. 9B illustrates the detection of Ankyrin-3 by western blot in the sera of patients with pre-cancerous lesions 12. FIG. 9C illustrates the detection of Ankyrin-3 by western blot in the sera of control patients. FIG. 9D illustrates the quantification of the data provided in FIG. 9A-9C.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based on the seminal discovery that a collection of biomarkers can be used for the diagnosis of cervical cancer.

Before the present compositions and methods are described, it is to be understood that this invention is not limited to particular compositions, methods, and experimental conditions described, as such compositions, methods, and conditions may vary. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only in the appended claims.

As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, references to “the method” includes one or more methods, and/or steps of the type described herein which will become apparent to those persons skilled in the art upon reading this disclosure and so forth.

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, it will be understood that modifications and variations are encompassed within the spirit and scope of the instant disclosure. The preferred methods and materials are now described.

Cervical cancer (CC) is one of the most common cancers among women worldwide. Among the risk factors related to this disease are infection with the human papilloma virus (HPV), the microbiome, risky sexual behavior, multiparity, smoking, prolonged use of hormonal contraceptives and environmental factors. Cervical cancer is a disease of slow and progressive evolution. It is preceded by cervical intraepithelial neoplasms, which are the lesions considered to be the prelude to this condition.

These lesions are generally asymptomatic, making it difficult to detect the disease in a timely manner, so if they are not detected by any of the conventional methods, there is a risk that they will develop to the state of CC. Due to this, the diagnosis of neoplastic lesions or cancer in early stages, from HPV infection, is extremely important to be able to channel and treat these cases in a timely and adequate manner.

Currently the gold standard for the diagnosis of CC is the Pap test, while for the detection of HPV the most widely used method is detection by PCR and sequencing of the viral genome. Although both methods are an international benchmark, these tests have technical limitations, since highly trained personnel, facilities and specialized equipment are required; Furthermore, it is not easily accessible to the entire female population and the existence of socio-cultural beliefs prevent women from making diagnoses.

Molecular biomarkers would help in the detection of cervical cancer using non-invasive methods. These biomarkers will serve as detection, prognosis, or follow-up of treatment of preneoplastic lesions and cancers in early stages based on patient serum samples. Thus being able to decrease the incidence of the disease that continues to be a public health problem in many low and high income countries.

Due to all of the above, there is an urgent need to develop new and simpler disease detection methods that are applicable in early detection, specific, highly sensitive, inexpensive, and easily accessible to the population.

The methods, compositions, and kits disclosed herein may be used for the diagnosis, prognosis, and/or monitoring the status or outcome of a cancer in a subject. In some embodiments, the diagnosing, predicting, and/or monitoring the status or outcome of a cancer comprises determining the malignancy or malignant potential of the cancer or tumor. Alternatively, the diagnosing, predicting, and/or monitoring the status or outcome of a cancer comprises determining the stage of the cancer. The diagnosing, predicting, and/or monitoring the status or outcome of a cancer can comprise determining the tumor grade. Alternatively, the diagnosing, predicting, and/or monitoring the status or outcome of a cancer comprises assessing the risk of developing a cancer. In some embodiments, the diagnosing, predicting, and/or monitoring the status or outcome of a cancer includes assessing the risk of cancer recurrence. In some embodiments, diagnosing, predicting, and/or monitoring the status or outcome of a cancer may comprise determining the efficacy of treatment.

In one embodiment, the present invention is directed to methods of detecting at least one polypeptide in a sample from a subject; wherein the at least one polypeptide is selected from Farnesyl pyrophosphate synthase, neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat Shock Protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof; or a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs: 1-147 or a fragment thereof, and diagnosing cervical cancer based on the detection of the at least one polypeptide. In one aspect, the at least one polypeptide is a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs:1-20 or a fragment thereof.

As used herein, the terms “detect”, “detecting” or “detection” may describe either the general act of discovering or discerning or the specific observation of a polypeptide. Detecting may comprise determining the presence or absence of a polypeptide. Detecting may comprise quantifying a polypeptide. For example, detecting comprises determining the expression level of a polypeptide. For example, the polypeptide may comprise at least a portion of the polypeptides disclosed herein.

The polypeptides or biomarkers of the present invention can be detected by any method that can be used for the specific detection and/or identification of a protein, peptide, fragment thereof, variant thereof, or mutant thereof. Examples of method of detecting protein include, but are not limited to: spectrometry methods, such as high-performance liquid chromatography (HPLC), partition chromatography, normal-phase chromatography, displacement chromatography, reversed-phase chromatography (RPC), size-exclusion chromatography, ion-exchange chromatography, bioaffinity chromatography, aqueous normal-phase chromatography, liquid chromatography-mass spectrometry (LC/MS); and antibody dependent or immunoassay based methods, such as enzyme-linked immunosorbent assay (ELISA), direct ELISA, sandwich ELISA, competitive ELISA, reverse ELISA, protein immunoprecipitation (direct or indirect), individual protein immunoprecipitation (IP), protein complex immunoprecipitation (Co-IP), chromatin immunoprecipitation (ChIP), RNP Immunoprecipitation (RIP), immunoelectrophoresis, western blot, and protein immunostaining. The polypeptides or biomarkers of the present invention can also be detected using protein microarrays, lateral flow assays or vertical flow assays. In certain aspects, the polypeptides or biomarkers are detected using a lateral flow assay. A lateral flow assay is typically an immunoassay either a sandwich assay or competitive assay. Typically these assays use a conjugated gold, carbon or colored latex nanoparticles. Multiplexed assays may also be performed using these methods.

As used herein, the term “subject” refers to any organisms that are screened using the diagnostic methods and treated using the treatment methods described herein. Such organisms preferably include, but are not limited to, mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and most preferably includes humans.

The term “diagnosed,” as used herein, refers to the recognition of a disease by its signs and symptoms, or genetic analysis, pathological analysis, histological analysis, and the like. Specifically, the term refers to the diagnosis or detection of cervical cancer.

The biomarkers of the present invention serve various functions within cells.

Farnesylpyrophosphate synthase (FPPS), also known as Dimethylallyltranstransferase (DMATT) or as farnesyldiphosphate synthase (FDPS), is an enzyme that in humans is encoded by the FDPS gene and catalyzes the transformation of dimethylallylpyrophosphate (DMAPP) and isopentenyl pyrophosphate (IPP) into farnesylpyrophosphate (FPP).

Neurofibromin 1 (NF1) is a gene in humans that is located on chromosome 17. NF1 codes for neurofibromin, a GTPase-activating protein that negatively regulates RAS/MAPK pathway activity by accelerating the hydrolysis of Ras-bound GTP. NF1 has a high mutation rate and mutations in NF1 can alter cellular growth control, and neural development, resulting in neurofibromatosis type 1 (NF1, also known as von Recklinghausen syndrome).

Glyceraldehyde 3-phosphate dehydrogenase (abbreviated as GAPDH or less commonly as G3PDH) (EC 1.2.1.12) is an enzyme of ˜37 kDa that catalyzes the sixth step of glycolysis and thus serves to break down glucose for energy and carbon molecules. In addition to this long established metabolic function, GAPDH has recently been implicated in several non-metabolic processes, including transcription activation, initiation of apoptosis, ER to Golgi vesicle shuttling, and fast axonal, or axoplasmic transport.

Protein 1 containing fibronectin domain type III also known as Fibronectin type III domain containing protein-1 may be an activator of G protein signaling. Protein 1 containing fibronectin domain type II is encoded by the FNDC1 gene.

Eukaryotic initiation factor 4A-I is an ATP-dependent RNA helicase which is a subunit of the eIF4F complex involved in cap recognition and is required for mRNA binding to ribosome. In the current model of translation initiation, eIF4A unwinds RNA secondary structures in the 5′-UTR of mRNAs which is necessary to allow efficient binding of the small ribosomal subunit, and subsequent scanning for the initiator codon. The protein is encoded by the EIF4A1 gene.

L-lactate dehydrogenase chain B is involved in step 1 of the subpathway that synthesizes (S)-lactate from pyruvate. The protein is encoded by the LDHB gene.

Nuclear heterogeneous Ribonucleoprotein A1, also known as heterogeneous nuclear ribonucleoprteon A1, is involved in the packaging of pr-mRNA into hnRNP particles, transport of poly(A) mRNA from the nucleus to the cytoplasm and may modulate splice site selection. May bind to specific miRNA hairpins. Binds to the IRES and thereby inhibits the translation of the apoptosis protease activating factor APAF. Nuclear heterogeneous Ribonucleoprotein A1 is encoded by the HNRNPA1 gene.

1-like protein 1 polycystic kidney disease, also known as polycystic kidney disease protein 1-like 1, is a component of a ciliary calcium channel that controls calcium concentration within primary cilia without affecting cytoplasmic calcium concentration. Forms a heterodimer with PKD2L1 in primary cilia and forms a calcium-permeant ciliary channel that regulates sonic hedgehog/SHH signaling and GLI2 transcription. Does not constitute the pore-forming subunit. Also involved in left/right axis specification downstream of nodal flow: forms a complex with PKD2 in cilia to facilitate flow detection in left/right patterning. Encoded by the PKD1L1 gene.

Heat Shock Protein Cognate 71 kDa is a molecular chaperone implicated in a wide variety of cellular processes, including protection of the proteome from stress, folding and transport of newly synthesized polypeptides, activation of proteolysis of misfolded proteins and the formation and dissociation of protein complexes. Plays a pivotal role in the protein quality control system, ensuring the correct folding of proteins, the re-folding of misfolded proteins and controlling the targeting of proteins for subsequent degradation. This is achieved through cycles of ATP binding, ATP hydrolysis and ADP release, mediated by co-chaperones. The co-chaperones have been shown to not only regulate different steps of the ATPase cycle of HSP70, but they also have an individual specificity such that one co-chaperone may promote folding of a substrate while another may promote degradation. The affinity of HSP70 for polypeptides is regulated by its nucleotide bound state. In the ATP-bound form, it has a low affinity for substrate proteins. However, upon hydrolysis of the ATP to ADP, it undergoes a conformational change that increases its affinity for substrate proteins. HSP70 goes through repeated cycles of ATP hydrolysis and nucleotide exchange, which permits cycles of substrate binding and release. The HSP70-associated co-chaperones are of three types: J-domain co-chaperones HSP40s (stimulate ATPase hydrolysis by HSP70), the nucleotide exchange factors (NEF) such as BAG1/2/3 (facilitate conversion of HSP70 from the ADP-bound to the ATP-bound state thereby promoting substrate release), and the TPR domain chaperones such as HOPX and STUB1. Acts as a repressor of transcriptional activation. Inhibits the transcriptional coactivator activity of CITED1 on Smad-mediated transcription. Component of the PRP19-CDC5L complex that forms an integral part of the spliceosome and is required for activating pre-mRNA splicing. May have a scaffolding role in the spliceosome assembly as it contacts all other components of the core complex. Binds bacterial lipopolysaccharide (LPS) and mediates LPS-induced inflammatory response, including TNF secretion by monocytes. Participates in the ER-associated degradation (ERAD) quality control pathway in conjunction with J domain-containing co-chaperones and the E3 ligase STUB1. Interacts with VGF-derived peptide TLQP-21. This protein is encoded by the HSPA8 gene.

Ankyrin 3 is found in skeletal muscle and is required for costamere localization of DMD and betaDAG1 (By similarity). Membrane-cytoskeleton linker. The protein may participate in the maintenance/targeting of ion channels and cell adhesion molecules at the nodes of Ranvier and axonal initial segments. Regulates KCNA1 channel activity in function of dietary Mg²⁺ levels, and thereby contributes to the regulation of renal Mg²⁺ reabsorption. Ankyrin-3 is encoded by the ANK3 gene.

Rho 23 GTPase-activating protein, also known as Rho GTPase activating protein 23, is part of the RHO family of small GTPases which are involved in signal transduction through transmembrane receptors, and they are inactive in the GDP-bound form and active in the GTP-bound form. GTPase-activating proteins, such as ARHGAP23, inactivate RHO family proteins by stimulating their hydrolysis of GTP. Rho GTPase-activating protein 23 is encoded by the ARHGAP23 gene.

Keratins are the major structural proteins in epithelial cells, forming a cytoplasmic network of 10 to 12 nm wide intermediate filaments and creating a scaffold that gives cells the ability to withstand mechanical and non-mechanical stresses. There are two types of cytoskeletal and microfibrillar keratin, I (acidic) and II (neutral to basic), i.e. Cytoskeletal Keratin 78 type II, also known as keratin, type II cytoskeletal 78. Cytoskeletal keratin 78 type II is encoded by the KRT78 gene.

Alpha 3 collagen chain (VI), also known as collagen alpha-3 (VI) chain, acts as a cell-binding protein. Collagen alpha-3 (VI) chain is encoded by the COL6A3 gene.

Beta subunit of proteasome type-5, also known as Proteasome subunit beta type-5 and 20S proteasome subunit beta-5 is a protein that in human is encoded by the PSMB5 gene. This protein is one of the 17 essential subunits (alpha subunits 1-7, constitutive beta subunits 1-7, and inducible subunits including beta1i, beta2i, beta5i) that contributes to the complete assembly of 20S proteasome complex. In particular, proteasome subunit beta type-5, along with other beta subunits, assemble into two heptameric rings and subsequently a proteolytic chamber for substrate degradation. This protein contains “chymotrypsin-like” activity and is capable of cleaving after large hydrophobic residues of peptide. The eukaryotic proteasome recognized degradable proteins, including damaged proteins for protein quality control purpose or key regulatory protein components for dynamic biological processes. An essential fumction of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. Beta subunit of proteasome type −5 is encoded by the PSMB5 gene.

Heterogeneous nuclear ribonucleoprotein (hnRNP) that associates with nascent pre-mRNAs, packaging them into hnRNP particles. The hnRNP particle arrangement on nascent hnRNA is non-random and sequence-dependent and serves to condense and stabilize the transcripts and minimize tangling and knotting. Packaging plays a role in various processes such as transcription, pre-mRNA processing, RNA nuclear export, subcellular location, mRNA translation and stability of mature mRNAs. Forms hnRNP particles with at least 20 other different hnRNP and heterogeneous nuclear RNA in the nucleus. Involved in transport of specific mRNAs to the cytoplasm in oligodendrocytes and neurons: acts by specifically recognizing and binding the A2RE (21 nucleotide hnRNP A2 response element) or the A2RE11 (derivative 11 nucleotide oligonucleotide) sequence motifs present on some mRNAs, and promotes their transport to the cytoplasm. Specifically binds single-stranded telomeric DNA sequences, protecting telomeric DNA repeat against endonuclease digestion (By similarity). Also binds other RNA molecules, such as primary miRNA (pri-miRNAs): acts as a nuclear ‘reader’ of the N6-methyladenosine (m6A) mark by specifically recognizing and binding a subset of nuclear m6A-containing pri-miRNAs. Binding to m6A-containing pri-miRNAs promotes pri-miRNA processing by enhancing binding of DGCR8 to pri-miRNA transcripts. Involved in miRNA sorting into exosomes following sumoylation, possibly by binding (m6A)-containing pr-miRNAs. Acts as a regulator of efficiency of mRNA splicing, possibly by binding to m6A-containing pre-mRNAs. Plays also a role in the activation of the innate immune response. Mechanistically, senses the presence of viral DNA in the nucleus, homodimerizes and is demethylated by JMJD6. In turn, translocates to the cytoplasm where it activates the TBK1-IRF3 pathway, leading to interferon alpha/beta production. Heterogeneous nuclear ribonucleoproteins A2/B1 is a protein that in humans is encoded by the HNRNPA2B1 gene.

Histone H2B type 1-B is a core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. Histone H2B type 1-B is encoded by the H2BC3 gene.

Homolog of DnaJ subfamily C member 13, also known as DnaJ homolog subfamily C member 13, is involved in membrane trafficking through early endosomes, such as the early endosome to recycling endosome transport implicated in the recycling of transferrin and the early endosome to late endosome transport implicated in degradation of EGF and EGFR. Involved in the regulation of endosomal membrane tubulation and regulates the dynamics of SNX1 on the endosomal membrane; via association with WASHC2 may link the WASH complex to the retromer SNX-BAR subcomplex. DnaJ homolog subfamily member 13 is encoded by the DNAJC13 gene.

Enolase 3 (ENO3), more commonly known as beta-enolase (ENO-P), is an enzyme that in humans is encoded by the ENO3 gene. This gene encodes one of the three enolase isoenzymes found in mammals. This isoenzyme is found in skeletal muscle cells in the adult where it may play a role in muscle development and regeneration. A switch from alpha enolase to beta enolase occurs in muscle tissue during development in rodents. Mutations in this gene have been associated with glycogen storage disease. Alternatively spliced transcript variants encoding different isoforms have been described.

Glutathione S-transferases (GSTs) are a family of enzymes that play an important role in detoxification by catalyzing the conjugation of many hydrophobic and electrophilic compounds with reduced glutathione. Based on their biochemical, immunologic, and structural properties, the soluble GSTs are categorized into four main classes: alpha, mu, pi, and theta. The glutathione S-transferase pi gene (GSTP1) is a polymorphic gene encoding active, functionally different GSTP1 variant proteins that are thought to function in xenobiotic metabolism and play a role in susceptibility to cancer, and other diseases. Glutathione S-transferase P is an enzyme that in humans is encoded by the GSTP1 gene.

Glutathione S-transferase Mu 3 may govern uptake and detoxification of both endogenous compounds and xenobiotics at the testis and brain blood barriers. Glutathione S-transferase Mu 3 is encoded by the GSTM3 gene.

The amino acid sequences for the biomarkers of the present invention and variants thereof are shown in Table 1.

TABLE 1 Protein name/SEQ ID NO. Amino acid sequence Famesyl pyrophosphate synthase MPLSRWLRSVGVFLLPAPYWAPRERWLGSLRRPSLVHGYPVLAW (FDPS) HSARCWCQAWTEEPRALCSSLRMNGDQNSDVYAQEKQDFVQHFS SEQ ID NO: 1 QIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVA FRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTR RGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIE LFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFY SFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLF GDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKE AEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAV FLGLARKIYKRRK Neurofibromin 1 MAAHRPVEWVQAVVSRFDEQLPIKTGQQNTHTKVSTEHNKECLIN (NF1) ISKYKFSLVISGLTTILKNVNNMRIFGEAAEKNLYLSQLIILDTLEKC SEQ ID NO: 2 LAGQPKDTMRLDETMLVKQLLPEICHFLHTCREGNQHAAELRNSA SGVLFSLSCNNFNAVFSRISTRLQELTVCSEDNVDVHDIELLQYINV DCAKLKRLLKETAFKFKALKKVAQLAVINSLEKAFWNWVENYPD EFTKLYQIPQTDMAECAEKLFDLVDGFAESTKRKAAVWPLQIILLI LCPEIIQDISKDVVDENNMNKKLFLDSLRKALAGHGGSRQLTESAA IACVKLCKASTYINWEDNSVIFLLVQSMVVDLKNLLFNPSKPFSRG SQPADVDLMIDCLVSCFRISPHNNQHFKICLAQNSPSTFHYVLVNS LHRIITNSALDWWPKIDAVYCHSVELRNMFGETLHKAVQGCGAHP AIRMAPSLTFKEKVTSLKFKEKPTDLETRSYKYLLLSMVKLIHADP KLLLCNPRKQGPETQGSTAELITGLVQLVPQSHMPEIAQEAMEALL VLHQLDSIDLWNPDAPVETFWEISSQMLFYICKKLTSHQMLSSTEIL KWLREILICRNKFLLKNKQADRSSCHFLLFYGVGCDIPSSGNTSQM SMDHEELLRTPGASLRKGKGNSSMDSAAGCSGTPPICRQAQTKLE VALYMILWNPDTEAVLVAMSCFRHLCEEADIRCGVDEVSVHNLL PNYNTFMEFASVSNMMSTGRAALQKRVMALLRRIEHPTAGNTEA WEDTHAKWEQATKLILNYPKAKMEDGQAAESLHKTIVKRRMSHV SGGGSIDLSDTDSLQEWINMTGFLCALGGVCLQQRSNSGLATYSPP MGPVSERKGSMISVMSSEGNADTPVSKFMDRLLSLMVCNHEKVG LQIRTNVKDLVGLELSPALYPMLFNKLKNTISKFFDSQGQVLLTDT NTQFVEQTIAIMKNLLDNHTEGSSEHLGQASIETMMLNLVRYVRV LGNMVHAIQIKTKLCQLVEVMMARRDDLSFCQEMKFRNKMVEYL TDWVMGTSNQAADDDVKCLTRDLDQASMEAVVSLLAGLPLQPEE GDGVELMEAKSQLFLKYFTLFMNLLNDCSEVEDESAQTGGRKRG MSRRLASLRHCTVLAMSNLLNANVDSGLMHSIGLGYHKDLQTRA TFMEVLTKILQQGTEFDTLAETVLADRFERLVELVTMMGDQGELPI AMALANVVPCSQWDELARVLVTLFDSRHLLYQLLWNMFSKEVEL ADSMQTLFRGNSLASKIMTFCFKVYGATYLQKLLDPLLRIVITSSD WQHVSFEVDPTRLEPSESLEENQRNLLQMTEKFFHAIISSSSEFPPQ LRSVCHCLYQATCHSLLNKATVKEKKENKKSVVSQRFPQNSIGAV GSAMFLRFINPAIVSPYEAGILDKKPPPRIERGLKLMSKILQSIANHV LFTKEEHMRPFNDFVKSNFDAARRFFLDIASDCPTSDAVNHSLSFIS DGNVLALHRLLWNNQEKIGQYLSSNRDHKAVGRRPFDKMATLLA YLGPPEHKPVADTHWSSLNLTSSKFEEFMTRHQVHEKEEFKALKT LSIFYQAGTSKAGNPIFYYVARRFKTGQINGDLLIYHVLLTLKPYY AKPYEIVVDLTHTGPSNRFKTDFLSKWFVVFPGFAYDNVSAVYIY NCNSWVREYTKYHERLLTGLKGSKRLVFIDCPGKLAEHTEHEQQK LPAATLALEEDLKVFHNALKLAHKDTKVSIKVGSTAVQVTSAERT KVLGQSVFLNDIYYASEIEEICLVDENQFTLTIANQGTPLTFMHQEC EAIVQSIIHIRTRWELSQPDSIPQHTKIRPKDVPGTLLNIALLNLGSSD PSLRSAAYNLLCALTCTFNLKIEGQLLETSGLCIPANNTLFIVSISKT LAANEPHLTLEFLEECISGFSKSSIELKHLCLEYMTPWLSNLVRFCK HNDDAKRQRVTAILDKLITMTINEKQMYPSIQAKIWGSLGQITDLL DVVLDSFIKTSATGGLGSIKAEVMADTAVALASGNVKLVSSKVIG RMCKIIDKTCLSPTPTLEQHLMWDDIAILARYMLMLSFNNSLDVA AHLPYLFHVVTFLVATGPLSLRASTHGLVINIIHSLCTCSQLHFSEET KQVLRLSLTEFSLPKFYLLFGISKVKSAAVIAFRSSYRDRSFSPGSYE RETFALTSLETVTEALLEIMEACMRDIPTCKWLDQWTELAQRFAF QYNPSLQPRALVVFGCISKRVSHGQIKQIIRILSKALESCLKGPDTY NSQVLIEATVIALTKLQPLLNKDSPLHKALFWVAVAVLQLDEVNL YSAGTALLEQNLHTLDSLRIFNDKSPEEVFMAIRNPLEWHCKQMD HFVGLNFNSNFNFALVGHLLKGYRHPSPAIVARTVRILHTLLTLVN KHRNCDKFEVNTQSVAYLAALLTVSEEVRSRCSLKHRKSLLLTDIS MENVPMDTYPIHHGDPSYRTLKETQPWSSPKGSEGYLAATYPTVG QTSPRARKSMSLDMGQPSQANTKKLLGTRKSFDHLISDTKAPKRQ EMESGITTPPKMRRVAETDYEMETQRISSSQQHPHLRKVSVSESNV LLDEEVLTDPKIQALLLTVLATLVKYTTDEFDQRILYEYLAEASVV FPKVFPVVHNLLDSKINTLLSLCQDPNLLNPIHGIVQSVVYHEESPP QYQTSYLQSFGFNGLWRFAGPFSKQTQIPDYAELIVKFLDALIDTY LPGIDEETSEESLLTPTSPYPPALQSQLSITANLNLSNSMTSLATSQH SPGIDKENVELSPTTGHCNSGRTRHGSASQVQKQRSAGSFKRNSIK KIV Glyceraldehyde-3 phosphate MGKVKVGVNGFGRIGRLVTRAAFNSGKVDIVAINDPFIDLNYMVY dehydrogenase MFQYDSTHGKFHGTVKAENGKLVINGNPITIFQERDPSKIKWGDA (GAPDH) GAEYVVESTGVFTTMEKAGAHLQGGAKRVIISAPSADAPMFVMG SEQ ID NO: 3 VNHEKYDNSLKIISNASCTTNCLAPLAKVIHDNFGIVEGLMTTVHA ITATQKTVDGPSGKLWRDGRGALQNIIPASTGAAKAVGKVIPELNG KLTGMAFRVPTANVSVVDLTCRLEKPAKYDDIKKVVKQASEGPL KGILGYTEHQVVSSDFNSDTHSSTFDAGAGIALNDHFVKLISWYDN EFGYSNRVVDLMAHMASKE Protein 1 containing fibronectin MAPEAGATLRAPRRLSWAALLLLAALLPVASSAAASVDHPLKPRH domain type BI VKLLSTKMGLKVTWDPPKDATSRPVEHYNIAYGKSLKSLKYIKVN or Fibronectin Type BI Domain AETYSFLIEDVEPGVVYFVLLTAENHSGVSRPVYRAESPPGGEWIEI Containing protein 1 DGFPIKGPGPFNETVTEKEVPNKPLRVRVRSSDDRLSVAWKAPRLS (FNDC1) GAKSPRRSRGFLLGYGESGRKMNYVPLTRDERTHEIKKLASESVY SEQ ID NO: 4 VVSLQSMNSQGRSQPVYRAALTKRKISEEDELDVPDDISVRVMSS QSVLVSWVDPVLEKQKKVVASRQYTVRYREKGELARWDYKQIA NRRVLIENLIPDTVYEFAVRISQGERDGKWSTSVFQRTPESAPTTAP ENLNVWPVNGKPTVVAASWDALPETEGKVKEYILSYAPALKPFG AKSLTYPGDTTSALVDGLQPGERYLFKIRATNRRGLGPHSKAFIVA MPTTSKADVEQNTEDNGKPEKPEPSSPSPRAPASSQIIPSVPASPQG RNAKDLLLDLKNKILANGGAPRKPQLRAKKAEELDLQSTEITGEEE LGSREDSPMSPSDTQDQKRTLRPPSRHGHSVVAPGRTAVRARMPA LPRREGVDKPGFSLATQPRPGAPPSASASPAHHASTQGTSHRPSLP ASLNDNDLVDSDEDERAVGSLHPKGAFAQPRPALSPSRQSPSSVLR DRSSVIIPGAKPASPARRTPHSGAAEEDSSASAPPSRLSPPHGGSSRL LPTQPHLSSPLSKGGKDGEDAPATNSNAPSRSTMSSSVSSHLSSRTQ VSEGAEASDGESHGDGDREDGGRQAEATAQTLRARPASGHFHLL RHKPFAANGRSPSRFSIGRGPRLQPSSSPQSTVPSRAHPRVPSHSDS HPKLSSGIHGDEEDEKPLPATVVNDHVPSSSRQPISRGWEDLRRSP QRGASLHRKEPIPENPKSTGADTHPQGKYSSLASKAQDVQQSTDA DTEGHSPKAQPGSTDRHASPARPPAARSQQIIPSVPRRMTPGRAPQ QQPPPPVATSQHHPGPQSRDAGRSPSQPRLSLTQAGRPRPTSQGRS HSSSDPYTASSRGMLPTALQNQDEDAQGSYDDDSTEVEAQDVRAP AHAARAKEAAASLPKHQQVESPTGAGAGGDHRSQRGHAASPARP SRPGGPQSRARVPSRAAPGKSEPPSKRPLSSKSQQSVSAEDDEEED AGFFKGGKEDLLSSSVPKWPSSSTPRGGKDADGSLAKEEREPAIAL APRGGSLAPVKRPLPPPPGSSPRASHVPSRLPPRSAATVSPVAGTHP WPQYTTRAPPGHFSTTPMLSLRQRMMHARFRNPLSRQPARPSYRQ GYNGRPNVEGKVLPGSNGKPNGQRIINGPQGTKWVVDLDRGLVL NAEGRYLQDSHGNPLRIKLGGDGRTIVDLEGTPVVSPDGLPLFGQG RHGTPLANAQDKPILSLGGKPLVGLEVIKKTTHIPPTTTMQPTTITTP LPTTTTPRPTTATTRRTTTTRRTTTRRPTTTVRTTTRTTTTTTFTPTT PIPTCPPGTLERHDDDGNLIMSSNGIPECYAEEDEFSGLETDTAVPT EEAYVIYDEDYEFETSRPPTTTEPSTTATTPRVIPEEGAISSFPEEEFD LAGRKRFVAPYVTYLNKDPSAPCSLTDALDHFQVDSLDEIIPNDLK KSDLPPQHAPRNITVVAVEGCHSFVIVDWDKATPGDVVTGYLVYS ASYEDFIRNKWSTQASSVTHLPIENLKPNTRYYFKVQAQNPHGYG PISPSVSFVTESDNPLLVVRPPGGEPIWIPFAFKHDPSYTDCHGRQY VKRTWYRKFVGVVLCNSLRYKIYLSDNLKDTFYSIGDSWGRGED HCQFVDSHLDGRTGPQSYVEALPTIQGYYRQYRQEPVRFGNIGFGT PYYYVGWYECGVSIPGKW Eukaryotic initiation factor 4A-I MSASQDSRSRDNGPDGMEPEGVIESNWNEIVDSFDDMNLSESLLR (EIF4A1) GIYAYGFEKPSAIQQRAILPCIKGYDVIAQAQSGTGKTATFAISILQQ SEQ ID NO: 5 IELDLKATQALVLAPTRELAQQIQKVVMALGDYMGASCHACIGGT NVRAEVQKLQMEAPHIIVGTPGRVFDMLNRRYLSPKYIKMFVLDE ADEMLSRGFKDQIYDIFQKLNSNTQVVLLSATMPSDVLEVTKKFM RDPIRILVKKEELTLEGIRQFYINVEREEWKLDTLCDLYETLTITQA VIFINTRRKVDWLTEKMHARDFTVSAMHGDMDQKERDVIMREFR SGSSRVLITTDLLARGIDVQQVSLVINYDLPTNRENYIHRIGRGGRF GRKGVAINMVTEEDKRTLRDIETFYNTSIEEMPLNVADLI L-lactate dehydrogenase chain B MATLKEKLIAPVAEEEATVPNNKITVVGVGQVGMACAISILGKSLA (LDHB) DELALVDVLEDKLKGEMMDLQHGSLFLQTPKIVADKDYSVTANS SEQ ID NO: 6 KIVVVTAGVRQQEGESRLNLVQRNVNVFKFIIPQIVKYSPDCIIIVVS NPVDILTYVTWKLSGLPKHRVIGSGCNLDSARFRYLMAEKLGIHPS SCHGWILGEHGDSSVAVWSGVNVAGVSLQELNPEMGTDNDSEN WKEVHKMVVESAYEVIKLKGYTNWAIGLSVADLIESMLKNLSRIH PVSTMVKGMYGIENEVFLSLPCILNARGLTSVINQKLKDDEVAQLK KSADTLWDIQKDLKDL Nuclear heterogeneous MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVM Ribonucleoprotein A1 RDPNTKRSRGFGFVTYATVEEVDAAMNARPHKVDGRVVEPKRAV (BNRNPA1) SREDSQRPGAHLTVKKIFVGGIKEDTEEHHLRDYFEQYGKIEVIEIM SEQ ID NO: 7 TDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGHNCEVRKALS KQEMASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRG GFGGSRGGGGYGGSGDGYNGFGNDGGYGGGGPGYSGGSRGYGS GGQGYGNQGSGYGGSGSYDSYNNGGGGGFGGGSGSNFGGGGSY NDFGNYNNQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGG YGGSSSSSSYGSGRRF Polycystic kidney disease protein 1- MAEEAAQNISDDQERCLQAACCLSFGGELSVSTDKSWGLHLCSCS like 1 PPGGGLWVEVYANHVLLMSDGKCGCPWCALNGKAEDRESQSPSS (PKD1L1) SASRQKNIWKTTSEAALSVVNEKTQAVVNEKTQAPLDCDNSADRI SEQ ID NO: 8 PHKPFIIIARAWSSGGPRFHHRRLCATGTADSTFSALLQLQGTTSAA APCSLKMEASCCVLRLLCCAEDVATGLLPGTVTMETFTKVARPTQ TSSQRVPLWPISHFPTSPRSSHGLPPGIPRTPSFTASQSGSEILYPPTQ HPPVAILARNSDNFMNPVLNCSLEVEARAPPNLGFRVHMASGEAL CLMMDFGDSSGVEMRLHNMSEAMAVTAYHQYSKGIFFHLLHFQL DMSTYKEAETQNTTLNVYLCQSENSCLEDSDPSNLGYELISAFVTK GVYMLKAVIYNEFHGTEVELGPYYVEIGHEAVSAFMNSSSVHEDE VLVFADSQVNQKSTVVIHHFPSIPSYNVSFISQTQVGDSQAWHSMT VWYKMQSVSVYTNGTVFATDTDITFTAVTKETIPLEFEWYFGEDP PVRTTSRSIKKRLSIPQWYRVMVKASNRMSSVVSEPHVIRVQKKIV ANRLTSPSSALVNASVAFECWINFGTDVAYLWDFGDGTVSLGSSS SSHVYSREGEFTVEVLAFNNVSASTLRQQLFIVCEPCQPPLVKNMG PGKVQIWRSQPVRLGVTFEAAVFCDISQGLSYTWNLMDSEGLPVS LPAAVDTHRQTLILPSHTLEYGNYTALAKVQIEGSVVYSNYCVGLE VRAQAPVSVISEGTHLFFSRTTSSPIVLRGTQSFDPDDPGATLRYHW ECATAGSPAHPCFDSSTAHQLDAAAPTVSFEAQWLSDSYDQFLVM LRVSSGGRNSSETRVFLSPYPDSAFRFVHISWVSFKDTFVNWNDEL SLQAMCEDCSEIPNLSYSWDLFLVNATEKNRIEVPFCRVVGLLGSL GLGAISESSQLNLLPTEPGTADPDATTTPFSREPSPVTLGQPATSAPR GTPTEPMTGVYWIPPAGDSAVLGEAPEEGSLDLEPGPQSKGSLMT GRSERSQPTHSPDPHLSDFEAYYSDIQEAIPSGGRQPAKDTSFPGSG PSLSAEESPGDGDNLVDPSLSAGRAEPVLMIDWPKALLGRAVFQG YSSSGITEQTVTIKPYSLSSGETYVLQVSVASKHGLLGKAQLYLTV NPAPRDMACQVQPHHGLEAHTVFSVFCMSGKPDFHYEFSYQIGNT SKHTLYHGRDTQYYFVLPAGEHLDNYKVMVSTEITDGKGSKVQP CTVVVTVLPRYHGNDCLGEDLYNSSLKNLSTLQLMGSYTEIRNYIT VITRILSRLSKEDKTASCNQWSRIQDALISSVCRLAFVDQEEMIGSV LMLRDLVSFSNKLGFMSAVLILKYTRALLAQGQFSGPFVIDKGVRL ELIGLISRVWEVSEQENSKEEVYRHEEGITVISDLLLGCLSLNHVST GQMEFRTLLHYNLQSSVQSLGSVQVHLPGDLAGHSPAGAETQSPC YISQLILFKKNPYPGSQAPGQIGGVVGLNLYTCSSRRPINRQWLRKP VMVEFGEEDGLDNRRNKTTFVLLRDKVNLHQFTELSENPQESLQIE IEFSKPVTRAFPVMLLVRFSEKPTPSDFLVKQIYFWDESIVQIYIPAA SQKDASVGYLSLLDADYDRKPPNRYLAKAVNYTVHFQWIRCLFW DKREWKSERFSPQPGTSPEKVNCSYHRLAAFALLRRKLKASFEVS DISKLQSHPENLLPSIFTMGSVILYGFLVAKSRQVDHHEKKKAGYIF LQEASLPGHQLYAVVIDTGFRAPARLTSKVYIVLCGDNGLSETKEL SCPEKPLFERNSRHTFILSAPAQLGLLRKIRLWHDSRGPSPGWFISH VMVKELHTGQGWFFPAQCWLSAGRHDGRVERELTCLQGGLGFR KLFYCKFTEYLEDFHVWLSVYSRPSSSRYLHTPRLTVSFSLLCVYA CLTALVAAGGQEQPHLDVSPTLGSFRVGLLCTLLASPGAQLLSLLF RLSKEAPGSARVEPHSPLRGGAQTEAPHGPNSWGRIPDAQEPRKQP ASAILSGSGRAQRKAASDNGTACPAPKLQVHGADHSRTSLMGKSH CCPPHTQAPSSGLEGLMPQWSRALQPWWSSAVWAICGTASLACSL GTGFLAYRFGQEQCVQWLHLLSLSVVCCIFITQPLMVCLMALGFA WKRRADNHFFTESLCEATRDLDSELAERSWTRLPFSSSCSIPDCAG EVEKVLAARQQARHLRWAIIPPSKAQLRGTRQRMRRESRTRAALR DISMDILMLLLLLCVIYGRFSQDEYSLNQAIRKEFTRNARNCLGGL RNIADWWDWSLTTLLDGLYPGGTPSARVPGAQPGALGGKCYLIGS SVIRQLKVFPRHLCKPPRPFSALIEDSIPTCSPEVGGPENPYLIDPEN QNVTLNGPGGCGTREDCVLSLGRTRTEAHTALSRLRASMWIDRST RAVSVHFTLYNPPTQLFTSVSLRVEILPTGSLVPSSLVESFSIFRSDS ALQYHLMLPQLVFLALSLIHLCVQLYRMMDKGVLSYWRKPRNWL ELSVVGVSLTYYAVSGHLVTLAGDVTNQFHRGLCRAFMDLTLMA SWNQRARWLRGILLFLFTLKCVYLPGIQNTMASCSSMMRHSLPSIF VAGLVGALMLAALSHLHRFLLSMWVLPPGTFTDAFPGLLFHFPRR SQKDCLLGLSKSDQRAMACYFGILLIVSATLCFGMLRGFLMTLPQ KRKSFQSKSFVRLKDVTAYMWEKVLTFLRLETPKLEEAEMVENH NYYLDEFANLLDELLMKINGLSDSLQLPLLEKTSNNTGEARTEESP LVDISSYQAAEPADIKDF Cognate thermal shock protein 71 kDa MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFT or heat shock protein cognate 71 kDa DTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKH (HSPA8) WPFMVVNDAGRPKVQVEYKGETKSFYPEEVSSMVLTKMKEIAEA SEQ ID NO: 9 YLGKTVTNAVVTVPAYFNDSQRQATKDAGTIAGLNVLRIINEPTA AAIAYGLDKKVGAERNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGD THLGGEDFDNRMVNHFIAEFKRKHKKDISENKRAVRRLRTACERA KRTLSSSTQASIEIDSLYEGIDFYTSITRARFEELNADLFRGTLDPVE KALRDAKLDKSQIHDIVLVGGSTRIPKIQKLLQDFFNGKELNKSINP DEAVAYGAAVQAAILSGDKSENVQDLLLLDVTPLSLGIETAGGVM TVLIKRNTTIPTKQTQTFTTYSDNQPGVLIQVYEGERAMTKDNNLL GKFELTGIPPAPRGVPQIEVTFDIDANGILNVSAVDKSTGKENKITIT NDKGRLSKEDIERMVQEAEKYKAEDEKQRDKVSSKNSLESYAFN MKATVEDEKLQGKINDEDKQKILDKCNEIINWLDKNQTAEKEEFE HQQKELEKVCNPITTKLYQSAGGMPGGMPGGFPGGGAPPSGGASS GPTIEEVD Anikirina-3 MAHAASQLKKNRDLEINAEEEPEKKRKHRKRSRDRKKKSDANAS or Ankyrin-3 YLRAARAGHLEKALDYIKNGVDINICNQNGLNALHLASKEGHVEV (ANK3) VSELLQREANVDAATKKGNTALHEASLAGQAEVVKVLVTNGANV SEQ ID NO: 10 NAQSQNGFTPLYMAAQENHLEVVKFLLDNGASQSLATEDGFTPLA VALQQGHDQVVSLLLENDTKGKVRLPALHIAARKDDTKAAALLL QNDNNADVESKSGFTPLHIAAHYGNINVATLLLNRAAAVDFTARN DITPLHVASKRGNANMVKLLLDRGAKIDAKTRDGLTPLHCGARSG HEQVVEMLLDRAAPILSKTKNGLSPLHMATQGDHLNCVQLLLQH NVPVDDVTNDYLTALHVAAHCGHYKVAKVLLDKKANPNAKALN GFTPLHIACKKNRIKVMELLLKHGASIQAVTESGLTPIHVAAFMGH VNIVSQLMHHGASPNTTNVRGETALHMAARSGQAEVVRYLVQDG AQVEAKAKDDQTPLHISARLGKADIVQQLLQQGASPNAATTSGYT PLHLSAREGHEDVAAFLLDHGASLSITTKKGFTPLHVAAKYGKLE VANLLLQKSASPDAAGKSGLTPLHVAAHYDNQKVALLLLDQGAS PHAAAKNGYTPLHMAKKNQMDIATTLLEYGADANAVTRQGIASV HLAAQEGHVDMVSLLLGRNANVNLSNKSGLTPLHLAAQEDRVNV AEVLVNQGAHVDAQTKMGYTPLHVGCHYGNIKIVNFLLQHSAKV NAKTKNGYTPLHQAAQQGHTHIINVLLQNNASPNELTVNGNTALG IARRLGYISVVDTLKIVTEETMITTTVTEKHKMNVPETMNEVLDM SDDEVRKANAPEMLSDGEYISDVEEGEDAMTGDTDKYLGPQDLK ELGDDSLPAEGYMGFSLGARSASLRSFSSDRSYTLNRSSYARDSM MIEELLVPSKEQHLTFTREFDSDSLRHYSWAADTLDNVNLVSSPIH SGFLVSFMVDARGGSMRGSRHHGMRDIPPRKCTAPTRITCRLVKR HKLANPPPMVEGEGLASRLVEMGPAGAQFLGPVIVEIPHFGSMRG KERELIVLRSENGETWKEHQFDSKNEDLTELLNGMDEELDSPEELG KKRICRIITKDFPQYFAVVSRIKQESNQIGPEGGILSSTTVPLVQASFP EGALTKRIRVGLQAQPVPDEIVKKILGNKATFSPIVTVEPRRRKFHK PITMTIPVPPPSGEGVSNGYKGDTTPNLRLLCSITGGTSPAQWEDIT GTTPLTFIKDCVSFTTNVSARFWLADCHQVLETVGLATQLYRELIC VPYMAKFVVFAKMNDPVESSLRCFCMTDDKVDKTLEQQENFEEV ARSKDIEVLEGKPIYVDCYGNLAPLTKGGQQLVFNFYSFKENRLPF SIKIRDTSQEPCGRLSFLKEPKTTKGLPQTAVCNLNITLPAHKKETE SDQDDEIEKTDRRQSFASLALRKRYSYLTEPGMIERSTGATRSLPTT YSYKPFFSTRPYQSWTTAPITVPGPAKSGFTSLSSSSSNTPSASPLKS IWSVSTPSPIKSTLGASTTSSVKSISDVASPIRSFRTMSSPIKTVVSQS PYNIQVSSGTLARAPAVTEATPLKGLASNSTFSSRTSPVTTAGSLLE RSSITMTPPASPKSNINMYSSSLPFKSITTSAAPLISSPLKSVVSPVKS AVDVISSAKTTMASSLSSPVKQMPGHAEVALVNGSISPLKYPSSSTL INGCKATATLQEKISSATNSVSSVVSAATDTVEKVFSTTTAMPFSPL RSYVSAAPSAFQSLRTPSASALYTSLGSSISATTSSVTSSITTVPVYSV VNVLPEPALKKLPDSNSFTKSAAALLSPIKTLTTETHPQPHFSRTSSP VKSSLFLAPSALKLSTPSSLSSSQEILKDVAEMKEDLMRMTAILQTD VPEEKPFQPELPKEGRIDDEEPFKIVEKVKEDLVKVSEILKKDVCVD NKGSPKSPKSDKGHSPEDDWIEFSSEEIREARQQAAASQSPSLPERV QVKAKAASEKDYNLTKVIDYLTNDIGSSSLTNLKYKFEDAKKDGE ERQKRVLKPAIALQEHKLKMPPASMRTSTSEKELCKMADSFFGTD TILESPDDFSQHDQDKSPLSDSGFETRSEKTPSAPQSAESTGPKPLFH EVPIPPVITETRTEVVHVIRSYDPSAGDVPQTQPEEPVSPKPSPTFME LEPKPTTSSIKEKVKAFQMKASSEEDDHNRVLSKGMRVKEETHITT TTRMVYHSPPGGEGASERIEETMSVHDIMKAFQSGRDPSKELAGLF EHKSAVSPDVHKSAAETSAQHAEKDNQMKPKLERDEVHIEKGNQ AEPTEVIIRETKKHPEKEMYVYQKDLSRGDINLKDFLPEKHDAFPC SEEQGQQEEEELTAEESLPSYLESSRVNTPVSQEEDSRPSSAQLISD DSYKTLKLLSQHSIEYHDDELSELRGESYRFAEKMLLSEKLDVSHS DTEESVTDHAGPPSSELQGSDKRSREKIATAPKKEILSKIYKDVSEN GVGKVSKDEHFDKVTVLHYSGNVSSPKHAMWMRFTEDRLDRGR EKLIYEDRVDRTVKEAEEKLTEVSQFFRDKTEKLNDELQSPEKKAR PKNGKEYSSQSPTSSSPEKVLLTELLASNDEWVKARQHGPDGQGF PKAEEKAPSLPSSPEKMVLSQQTEDSKSTVEAKGSISQSKAPDGPQ SGFQLKQSKLSSIRLKFEQGTHAKSKDMSQEDRKSDGQSRIPVKKI QESKLPVYQVFAREKQQKAIDLPDESVSVQKDFMVLKTKDEHAQS NEIVVNDSGSDNVKKQRTEMSSKAMPDSFSEQQAKDLACHITSDL ATRGPWDKKVFRTWESSGATNNKSQKEKLSHVLVHDVRENIIIGH PESKSVDQKNEFMSVTERERKLLTNGSLSEIKEMTVKSPSKKVLYR EYVVKEGDHPGGLLDQPSRRSESSAYSHIPVRVADERRMLSSNIPD GFCEQSAFPKHELSQKLSQSSMSKETVETQHFNSIEDEKVTYSEISK VSKHQSYVGLCPPLEETETSPTKSPDSLEFSPGKESPSSDVFDHSPID GLEKLAPLAQTEGGKEIKTLPVYVSFVQVGKQYEKEIQQGGVKKII SQECKTVQETRGTFYTTRQQKQPPSPQGSPEDDTLEQVSFLDSSGK SPLTPETPSSEEVSYEFTSKTPDSLIAYIPGKPSPIPEVSEESEEEEQA KSTSLKQTTVEETAVEREMPNDVSKDSNQRPKNNRVAYIEFPPPPP LDADQIESDKKHHYLPEKEVDMIEVNLQDEHDKYQLAEPVIRVQP PSPVPPGADVSDSSDDESIYQPVPVKKYTFKLKEVDDEQKEKPKAS AEKASNQKELESNGSGKDNEFGLGLDSPQNEIAQNGNNDQSITECS IATTAEFSHDTDATEIDSLDGYDLQDEDDGLTESDSKLPIQAMEIKK DIWNTEGILKPADRSFSQSKLEVIEEEGKVGPDEDKPPSKSSSSEKT PDKTDQKSGAQFFTLEGRHPDRSVFPDTYFSYKVDEEFATPFKTVA TKGLDFDPWSNNRGDDEVFDSKSREDETKPFGLAVEDRSPATTPD TTPARTPTDESTPTSEPNPFPFHEGKMFEMTRSGAIDMSKRDFVEE RLQFFQIGEHTSEGKSGDQGEGDKSMVTATPQPQSGDTTVETNLE RNVETPTVEPNPSIPTSGECQEGTSSSGSLEKSAAATNTSKVDPKLR TPIKMGISASTMTMKKEGPGEITDKIEAVMTSCQGLENETITMISNT ANSQMGVRPHEKHDFQKDNFNNNNNLDSSTIQTDNIMSNIVLTEH SAPTCTTEKDNPVKVSSGKKTGVLQGHCVRDKQKVLGEQQKTKE LIGIRQKSKLPIKATSPKDTFPPNHMSNTKASKMKQVSQSEKTKAL TTSSCVDVKSRIPVKNTHRDNIIAVRKACATQKQGQPEKGKAKQL PSKLPVKVRSTCVTTITTTATTITTITTTITTSCTVKVRKSQLKEV CKHSIEYFKGISGETLKLVDRLSEEEKKMQSELSDEEESTSRNTSLS ETSRGGQPSVTTKSARDKKTEAAPLKSKSEKAGSEKRSSRRTGPQS PCERTDIRMAIVADHLGLSWTELARELNFSVDEINQIRVENPNSLIS QSFMLLKKWVTRDGKNATTDALTSVLTKINRIDIVTLLEGPIFDYG NISGTRSFADENNVFHDPVDGWQNETSSGNLESCAQARRVTGGLL DRLDDSPDQCRDSITSYLKGEAGKFEANGSHTEITPEAKTKSYFPES QNDVGKQSTKETLKPKIHGSGHVEEPASPLAAYQKSLEETSKLIIEE TKPCVPVSMKKMSRTSPADGKPRLSLHEEEGSSGSEQKQGEGFKV KTKKEIRHVEKKSHS Rho 23 MNGVAFCLVGIPPRPEPRPPQLPLGPRDGCSPRRPFPWQGPRTLLL or Rho GTPase-activating protein 23 YKSPQDGFGFTLRHFIVYPPESAVHCSLKEEENGGRGGGPSPRYRL (ARHGAP23) EPMDTIFVKNVKEDGPAHRAGLRTGDRLVKVNGESVIGKTYSQVI SEQ ID NO: 11 ALIQNSDDTLELSIMPKDEDILQLAYSQDAYLKGNEPYSGEARSIPE PPPICYPRKTYAPPARASTRATMVPEPTSALPSDPRSPAAWSDPGLR VPPAARAHLDNSSLGMSQPRPSPGAFPHLSSEPRTPRAFPEPGSRVP PSRLECQQALSHWLSNQVPRRAGERRCPAMAPRARSASQDRLEEV AAPRPWPCSTSQDALSQLGQEGWHRARSDDYLSRATRSAEALGPG ALVSPRFERCGWASQRSSARTPACPTRDLPGPQAPPPSGLQGLDDL GYIGYRSYSPSFQRRTGLLHALSFRDSPFGGLPTFNLAQSPASFPPE ASEPPRVVRPEPSTRALEPPAEDRGDEVVLRQKPPTGRKVQLTPAR QMNLGFGDESPEPEASGRGERLGRKVAPLATTEDSLASIPFIDEPTS PSIDLQAKHVPASAVVSSAMNSAPVLGTSPSSPTFTFTLGRHYSQD CSSIKAGRRSSYLLAITTERSKSCDDGLNTFRDEGRVLRRLPNRIPS LRMLRSFFTDGSLDSWGTSEDADAPSKRHSTSDLSDATFSDIRREG WLYYKQILTKKGKKAGSGLRQWKRVYAALRARSLSLSKERREPG PAAAGAAAAGAGEDEAAPVCIGSCLVDISYSETKRRHVFRLTTAD FCEYLFQAEDRDDMLGWIRAIRENSRAEGEDPGCANQALISKKLN DYRKVSHSSGPKADSSPKGSRGLGGLKSEFLKQSAARGLRTQDLP AGSKDDSAAAPKTPWGINIIKKNKKAAPRAFGVRLEECQPATENQ RVPLIVAACCRIVEARGLESTGIYRVPGNNAVVSSLQEQLNRGPGD INLQDERWQDLNVISSLLKSFFRKLPEPLFTDDKYNDFIEANRIEDA RERMRTLRKLIRDLPGHYYETLKFLVGHLKTIADHSEKNKMEPRN LALVFGPTLVRTSEDNMTDMVTHMPDRYKIVETLIQHSDWFFSDE EDKGERTPVGDKEPQAVPNIEYLLPNIGRTVPPGDPGSDSTTCSSAK SKGSWAPKKEPYAREMLAISFISAVNRKRKKRREARGLGSSTDDD SEQEAHKPGAGATAPGTQERPQGPLPGAVAPEAPGRLSPPAAPEER PAADTRSIVSGYSTLSTMDRSVCSGASGRRAGAGDEADDERSELS HVETDTEGAAGAGPGGRLTRRPSFSSIAHLMPCDTLARRRLARGRP DGEGAGRGGPRAPEPPGSASSSSQESLRPPAAALASRPSRMEALRL RLRGTADDMLAVRLRRPLSPETRRRRSSWRRHTVVVQSPLTDLNF NEWKELGGGGPPEPAGARAHSDNKDSGLSSLESTKARAPSSAASQ PPAPGDTGSLQSQPPRRSAASRLHQCL Cytoskeletal Keratin 78 type II MSLSPCRAQRGFSARSACSARSRGRSRGGFSSRGGFSSRSLNSFGG or Keratin, type II cytoskeletal 78 CLEGSRGSTWGSGGRLGVRFGEWSGGPGLSLCPPGGIQEVTINQNL (KRT78) LTPLKIEIDPQFQVVRTQETQEIRTLNNQFASFIDKVRFLEQQNKVL SEQ ID NO: 12 ETKWHLLQQQGLSGSQQGLEPVFEACLDQLRKQLEQLQGERGAL DAELKACRDQEEEYKSKYEEEAHRRATLENDFVVLKKDVDGVFL SKMELEGKLEALREYLYFLKHLNEEELGQLQTQASDTSVVLSMDN NRYLDFSSITIEVRARYEEIARSSKAEAEALYQTKYQELQVSAQLH GDRMQETKVQISQLHQEIQRLQSQTENLKKQNASLQAAITDAEQR GELALKDAQAKVDELEAALRMAKQNLARLLCEYQELTSTKLSLD VEIATYRRLLEGEECRMSGECTSQVTISSVGGSAVMSGGVGGGLG STCGLGSGKGSPGSCCTSIVTGGSNIILGSGKDPVLDSCSVSGSSAG SSCHTILKKTVESSLKTSITY Alpha-3 collagen chain (VI) MRKHRHLPLVAVFCLFLSGFPTTHAQQQQADVKNGAAADIIFLVD or Collagen type VI, alpha 3 SSWTIGEEHFQLVREFLYDVVKSLAVGENDFHFALVQFNGNPHTE (COL6A3) FLLNTYRTKQEVLSHISNMSYIGGTNQTGKGLEYIMQSHLTKAAGS SEQ ID NO: 13 RAGDGVPQVIVVLTDGHSKDGLALPSAELKSADVNVFAIGVEDAD EGALKEIASEPLNMHMFNLENFTSLHDIVGNLVSCVHSSVSPERAG DTETLKDITAQDSADIIFLIDGSNNTGSVNFAVILDFLVNLLEKLPIG TQQIRVGVVQFSDEPRTMFSLDTYSTKAQVLGAVKALGFAGGELA NIGLALDFVVENHFTRAGGSRVEEGVPQVLVLISAGPSSDEIRYGV VALKQASVFSFGLGAQAASRAELQHRTDDNLVFTVPEFRSFGDLQ EKLLPYIVGVAQRHWLKPPTIVTQVIEVNKRDIVFLVDGSSALGLA NFNAIRDFIAKVIQRLEIGQDLIQVAVAQYADTVRPEFYFNTHPTKR EVITAVRKMKPLDGSALYTGSALDFVRNNLFTSSAGYRAAEGIPKL LVLITGGKSLDEISQPAQELKRSSIMAFAIGNKGADQAELEEIAFDS SLVFIPAEFRAAPLQGMLPGLLAPLRTLSGTPEVHSNKRDIIFLLDGS ANVGKTNFPYVRDFVMNLVNSLDIGNDNIRVGLVQFSDTPVTEFS LNTYQTKSDILGHLRQLQLQGGSGLNTGSALSYVYANHFTEAGGS RIREHVPQLLLLLTAGQSEDSYLQAANALTRAGILTFCVGASQANK AELEQIAFNPSLVYLMDDFSSLPALPQQLIQPLTTYVSGGVEEVPLA QPESKRDILFLFDGSANLVGQFPVVRDFLYKIIDELNVKPEGTRIAV AQYSDDVKVESRFDEHQSKPEILNLVKRMKIKTGKALNLGYALDY AQRYIFVKSAGSRIEDGVLQFLVLLVAGRSSDRVDGPASNLKQSGV VPFIFQAKNADPAELEQIVLSPAFILAAESLPKIGDLIVQIVNLLKSV HNGAPAPVSGEKDVVFLLDGSEGVRSGFPLLKEFVQRVVESLDVG QDRVRVAVVQYSDRTRPEFYLNSYMNKQDVVNAVRQLTLLGGPT PNTGAALEFVLRNILVSSAGSRITEGVPQLLIVLTADRSGDDVRNPS VVVKRGGAVPIGIGIGNADITEMQTISFIPDFAVAIPTFRQLGTVQQ VISERVTQLTREELSRLQPVLQPLPSPGVGGKRDVVFLIDGSQSAGP EFQYVRTLIERLVDYLDVGFDTTRVAVIQFSDDPKVEFLLNAHSSK DEVQNAVQRLRPKGGRQINVGNALEYVSRNIFKRPLGSRIEEGVPQ FLVLISSGKSDDEVDDPAVELKQFGVAPFTIARNADQEELVKISLSP EYVFSVSTFRELPSLEQKLLTPITTLTSEQIQKLLASTRYPPPAVESD AADIVFLIDSSEGVRPDGFAHIRDFVSRIVRRLNIGPSKVRVGVVQF SNDVFPEFYLKTYRSQAPVLDAIRRLRLRGGSPLNTGKALEFVARN LFVKSAGSRIEDGVPQHLVLVLGGKSQDDVSRFAQVIRSSGIVSLG VGDRNIDRTELQTITNDPRLVFTVREFRELPNIEERIMNSFGPSAATP APPGVDTPPPSRPEKKKADIVFLLDGSINFRRDSFQEVLRFVSEIVD TVYEDGDSIQVGLVQYNSDPTDEFFLKDFSTKRQIIDAINKVVYKG GRHANTKVGLEHLRVNHFVPEAGSRLDQRVPQIAFVITGGKSVED AQDVSLALTQRGVKVFAVGVRNIDSEEVGKIASNSATAFRVGNVQ ELSELSEQVLETLHDAMHETLCPGVTDAAKACNLDVILGFDGSRD QNVFVAQKGFESKVDAILNRISQMHRVSCSGGRSPTVRVSVVANT PSGPVEAFDFDEYQPEMLEKFRNMRSQHPYVLTEDTLKVYLNKFR QSSPDSVKVVIHFTDGADGDLADLHRASENLRQEGVRALILVGLE RVVNLERLMHLEFGRGFMYDRPLRLNLLDLDYELAEQLDNIAEKA CCGVPCKCSGQRGDRGPIGSIGPKGIPGEDGYRGYPGDEGGPGERG PPGVNGTQGFQGCPGQRGVKGSRGFPGEKGEVGEIGLDGLDGEDG DKGLPGSSGEKGNPGRRGDKGPRGEKGERGDVGIRGDPGNPGQDS QERGPKGETGDLGPMGVPGRDGVPGGPGETGKNGGFGRRGPPGA KGNKGGPGQPGFEGEQGTRGAQGPAGPAGPPGLIGEQGISGPRGS GGAAGAPGERGRTGPLGRKGEPGEPGPKGGIGNRGPRGETGDDGR DGVGSEGRRGKKGERGFPGYPGPKGNPGEPGLNGTTGPKGIRGRR GNSGPPGIVGQKGDPGYPGPAGPKGNRGDSIDQCALIQSIKDKCPC CYGPLECPVFPTELAFALDTSEGVNQDTFGRMRDVVLSIVNDLTIA ESNCPRGARVAVVTYNNEVTTEIRFADSKRKSVLLDKIKNLQVAL TSKQQSLETAMSFVARNTFKRVRNGFLMRKVAVFFSNTPTRASPQ LREAVLKLSDAGITPLFLTRQEDRQLINALQINNTAVGHALVLPAG RDLTDFLENVLTCHVCLDICNIDPSCGFGSWRPSFRDRRAAGSDVD IDMAFILDSAETTTLFQFNEMKKYIAYLVRQLDMSPDPKASQHFAR VAVVQHAPSESVDNASMPPVKVEFSLTDYGSKEKLVDFLSRGMTQ LQGTRALGSAIEYTIENVFESAPNPRDLKIVVLMLTGEVPEQQLEEA QRVILQAKCKGYFFVVLGIGRKVNIKEVYTFASEPNDVFFKLVDKS TELNEEPLMRFGRLLPSFVSSENAFYLSPDIRKQCDWFQGDQPTKN LVKFGHKQVNVPNNVTSSPTSNPVTTTKPVTTTKPVTTTTKPVTTT TKPVTIINQPSVKPAAAKPAPAKPVAAKPVATKMATVRPPVAVKP ATAAKPVAAKPAAVRPPAAAAAKPVATKPEVPRPQAAKPAATKP ATTKPMVKMSREVQVFEITENSAKLHWERAEPPGPYFYDLTVTSA HDQSLVLKQNLTVTDRVIGGLLAGQTYHVAVVCYLRSQVRATYH GSFSTKKSQPPPPQPARSASSSTINLMVSTEPLALTETDICKLPKDEG TCRDFILKWYYDPNTKSCARFWYGGCGGNENKFGSQKECEKVCA PVLAKPGVISVMGT Beta subunit of proteasome type-5 MALASVLERPLPVNQRGFFGLGGRADLLDLGPGSLSDGLSLAAPG or Proteasome subunit beta type-5 WGVPEEPGIEMLHGTTTLAFKFRHGVIVAADSRATAGAYIASQTV (PSMB5) KKVIEINPYLLGTMAGGAADCSFWERLLARQCRIYELRNKERISVA SEQ ID NO: 14 AASKLLANMVYQYKGMGLSMGTMICGWDKRGPGLYYVDSEGNR ISGATFSVGSGSVYAYGVMDRGYSYDLEVEQAYDLARRAIYQATY RDAYSGGAVNLYHVREDGWIRVSSDNVADLHEKYSGSTP Heterogeneous nuclear MEKTLETVPLERKKREKEQFRKLFIGGLSFETTEESLRNYYEQWGK ribonucleoproteins A2/B1 LTDCVVMRDPASKRSRGFGFVTFSSMAEVDAAMAARPHSIDGRV (HNRNPA2B1) VEPKRAVAREESGKPGAHVTVKKLFVGGIKEDTEEHHLRDYFEEY SEQ ID NO: 15 GKIDTIEITIDRQSGKKRGFGFVTFDDHDPVDKIVLQKYHTINGHNA EVRKALSRQEMQEVQSSRSGRGGNFGFGDSRGGGGNFGPGPGSNF RGGSDGYGSGRGFGDGYNGYGGGPGGGNFGGSPGYGGGRGGYG GGGPGYGNQGGGYGGGYDNYGGGNYGSGNYNDFGNYNQQPSN YGPMKSGNFGGSRNMGGPYGGGNYGPGGSGGSGGYGGRSRY Histone H2B type 1-B MPEPSKSAPAPKKGSKKATTKAQKKDGKKRKRSRKESYSIYVYKV (HIST1H2BB) LKQVIIPDTGISSKAMGIMNSFVNDIFERIAGEASRLAHYNKRSTITS SEQ ID NO: 16 REIQTAVRLLLPGELAKHAVSEGTKAVTKYTSSK homolog of DnaJ subfamily C member MNIIRENKDLACFYTTKHSWRGKYKRVFSVGTHATITYNPNTLEV 13 TNQWPYGDICSISPVGKGQGTEFNLTFRKGSGKKSETLKFSTEHRT or DnaJ homolog subfamily C member ELLTEALRFRTDFSEGKITGRRYNCYKHHWSDSRKPVILEVTPGGF 13 DQINPATNRVLCSYDYRNIEGFVDLSDYQGGFCILYGGFSRLHLFA (DNAJC13) SEQREEIIKSAIDHAGNYIGISLRIRKEPLEFEQYLNLRFGKYSTDESI SEQ ID NO: 17 TSLAEFVVQKISPRHSEPVKRVLALTETCLVERDPATYNIATLKPLG EVFALVCDSENPQLFTIEFIKGQVRKYSSTERDSLLASLLDGVRASG NRDVCVKMTPTHKGQRWGLLSMPVDEEVESLHLRFLATPPNGNF ADAVFRFNANISYSGVLHAVTQDGLFSENKEKLINNAITALLSQEG DVVASNAELESQFQAVRRLVASKAGFLAFTQLPKFRERLGVKVVK ALKRSNNGIIHAAVDMLCALMCPMHDDYDLRQEQLNKASLLSSK KFLENLLEKFNSHVDHGTGALVISSLLDFLTFALCAPYSETTEGQQF DMLLEMVASNGRTLFKLFQIIPSMAIIKGAGLVMKAIIEEGDKEIAT KMQELALSEGALPRHLHTAMFTISSDQRMLTNRQLSRHLVGLWTA DNATATNLLKRILPPGLLAYLESSDLVPEKDADRMHVRDNVKIAM DQYGKFNKVPEWQRLAGKAAKEVEKFAKEKVDLVLMHWRDRM GIAQKENINQKPVVLRKRRQRIKIEANWDLFYYRFGQDHARSNLI WNFKTREELKDTLESEMRAFNIDRELGSANVISWNHHEFEVKYEC LAEEIKIGDYYLRLLLEEDENEESGSIKRSYEFFNELYHRFLLTPKV NMKCLCLQALAIVYGRCHEEIGPFTDTRYIIGMLERCTDKLERDRLI LFLNKLILNKKNVKDLMDSNGIRILVDLLTLAHLHVSRATVPLQSN VIEAAPDMKRESEKEWYFGNADKERSGPYGFHEMQELWTKGML NAKTRCWAQGMDGWRPLQSIPQLKWCLLASGQAVLNETDLATLI LNMLITMCGYFPSRDQDNAIIRPLPKVKRLLSDSTCLPHIIQLLLTFD PILVEKVAILLYHEMQDNPQLPRLYLSGVFFFIMMYTGSNVLPVAR FLKYTHTKQAFKSEETKGQDIFQRSILGHILPEAMVCYLENYEPEKF SEIFLGEFDTPEAIWSSEMRRLMIEKIAAHLADFTPRLQSNTRALYQ YCPIPIINYPQLENELFCNIYYLKQLCDTLRFPDWPIKDPVKLLKDTL DAWKKEVEKKPPMMSIDDAYEVLNLPQGQGPHDESKIRKAYFRL AQKYHPDKNPEGRDMFEKVNKAYEFLCTKSAKIVDGPDPENIILIL KTQSILFNRHKEDLQPYKYAGYPMLIRTITMETSDDLLFSKESPLLP AATELAFHTVNCSALNAEELRRENGLEVLQEAFSRCVAVLTRASK PSDMSVQVCGYISKCYSVAAQFEECREKTIEMPSIIKDLCRVLYFG KSIPRVAALGVECVSSFAVDFWLQTHLFQAGILWYLLGFLFNYDY TLEESGIQKSEETNQQEVANSLAKLSVHALSRLGGYLAEEQATPEN PTIRKSLAGMLTPYVARKLAVASVTEILKMLNSNTESPYLIWNNST RAELLEFLESQQENMIKKGDCDKTYGSEFVYSDHAKELIVGEIFVR VYNEVPTFQLEVPKAFAASLLDYIGSQAQYLHTFMAITHAAKVESE QHGDRLPRVEMALEALRNVIKYNPGSESECIGHFKLIFSLLRVHGA GQVQQLALEVVNIVTSNQDCVNNIAESMVLSSLLALLHSLPSSRQL VLETLYALTSSTKIIKEAMAKGALIYLLDMFCNSTHPQVRAQTAEL FAKMTADKLIGPKVRITLMKFLPSVFMDAMRDNPEAAVHIFEGTH ENPELIWNDNSRDKVSTTVREMMLEHFKNQQDNPEANWKLPEDF AVVFGEAEGELAVGGVFLRIFIAQPAWVLRKPREFLIALLEKLTELL EKNNPHGETLETLTMATVCLFSAQPQLADQVPPLGHLPKVIQAMN HRNNAIPKSAIRVIHALSENELCVRAMASLETIGPLMNGMKKRADT VGLACEAINRMFQKEQSELVAQALKADLVPYLLKLLEGIGLENLD SPAATKAQIVKALKAMTRSLQYGEQVNEILCRSSVWSAFKDQKHD LFISESQTAGYLTGPGVAGYLTAGTSTSVMSNLPPPVDHEAGDLGY QT Beta enolase MAMQKIFAREILDSRGNPTVEVDLHTAKGRFRAAVPSGASTGIYE (ENO3) ALELRDGDKGRYLGKGVLKAVENINNTLGPALLQKKLSVVDQEK SEQ ID NO: 18 VDKFMIELDGTENKSKFGANAILGVSLAVCKAGAAEKGVPLYRHI ADLAGNPDLILPVPAPNVINGGSHAGNKLAMQEFAMILPVGASSFKE AMRIGAEVYHHLKGVIKAKYGKDATNVGDEGGFAPNILENNEAL ELLKTAIQAAGYPDKVVIGMDVAASEFYRNGKYDLDFKSPDDPAR HITGEKLGELYKSFIKNYPVVSIEDPFDQDDWATWTSFLSGVNIQIV GDDLTVTNPKRIAQAVEKKACNCLLLKVNQIGSVTESIQACKLAQS NGWGVMVSHRSGETEDTFIADLVVGLCTGQIKTGAPCRSERLAKY NQLMRIEEALGDKAIFAGRKFRNPKAK Glutathione S-transferase P MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGS (GSTP1) LKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAA SEQ ID NO: 19 LVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETL LSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAY VGRLSARPKLKAFLASPEYVNLPINGNGKQ Glutathione 5-transferase Mu 3 MSCESSMVLGYWDIRGLAHAIRLLLEFTDTSYEEKRYTCGEAPDY (GSTM3) DRSQWLDVKFKLDLDFPNLPYLLDGKNKITQSNAILRYIARKHNM SEQ ID NO: 20 CGETEEEKIRVDIIENQVMDFRTQLIRLCYSSDHEKLKPQYLEELPG QLKQFSMFLGKFSWFAGEKLTFVDFLTYDILDQNRIFDPKCLDEFP NLKAFMCRFEALEKIAAYLQSDQFCKMPINNKMAQWGNKPVC Farnesyl pyrophosphate synthase MPLSRWLRSVGVFLLPAPYWAPRERWLGSLRRPSLVHGYPVLAW Variant 2 HSARCWCQAWTEEPRALCSSLRMNGDQNSDVYAQEKQDFVQHFS SEQ ID NO: 21 QIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVA FRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTR RGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIE LFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFY SFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLF GDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKE AEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAV FLGLARKIYKRRK Farnesyl pyrophosphate synthase MNGDQNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARL Variant 3 KEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVG SEQ ID NO: 22 WCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANL LEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQG NVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHA NAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVV QCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQY EEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK Farnesyl pyrophosphate synthase MNGDQNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARL Variant 4 KEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVG SEQ ID NO: 23 WCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANL LEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQG NVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHA NAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVV QCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQY EEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK Famesyl pyrophosphate synthase MDSSLTRRGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQ Variant 5 PYYLNLIELFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIV SEQ ID NO: 24 KYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQ DDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILK ENYGQKEAEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQY AAPLPPAVFLGLARKIYKRRK Famesyl pyrophosphate synthase MNGDQNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARL Variant 6 KEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVG SEQ ID NO: 25 WCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANL LEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQG NVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHA NAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVV QCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQY EEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK Famesyl pyrophosphate synthase MPLSRWLRSVGVFLLPAPYWAPRERWLGSLRRPSLVHGYPVLAW Variant 7 HSARCWCQAWTEEPRALCSSLRMNGDQNSDVYAQEKQDFVQHFS SEQ ID NO: 26 QIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVA FRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTR RGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIE LFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFY SFYL Famesyl pyrophosphate synthase MPLSRWLRSVGVFLLPAPYWAPRERWLGSLRRPSLVHGYPVLAW Variant 8 HSARCWCQAWTEEPRALCSSLRMNGDQNSDVYAQEKQDFVQHFS SEQ ID NO: 27 QIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVA Neurofibromin 1 FRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDS Variant 2 MAAHRPVEWVQAVVSRFDEQLPIKTGQQNTHTKVSTEHNKECLIN SEQ ID NO: 28 ISKYKFSLVISGLTTILKNVNNMRIFGEAAEKNLYLSQLIILDTLEKC LAGQPKDTMRLDETMLVKQLLPEICHFLHTCREGNQHAAELRNSA SGVLFSLSCNNFNAVFSRISTRLQELTVCSEDNVDVHDIELLQYINV DCAKLKRLLKETAFKFKALKKVAQLAVINSLEKAFWNWVENYPD EFTKLYQIPQTDMAECAEKLFDLVDGFAESTKRKAAVWPLQIILLI LCPEIIQDISKDVVDENNMNKKLFLDSLRKALAGHGGSRQLTESAA IACVKLCKASTYINWEDNSVIFLLVQSMVVDLKNLLFNPSKPFSRG SQPADVDLMIDCLVSCFRISPHNINQHFKICLAQNSPSTFHYVLVNS LHRIITNSALDWWPKIDAVYCHSVELRNMFGETLHKAVQGCGAHP AIRMAPSLTFKEKVTSLKFKEKPTDLETRSYKYLLLSMVKLIHADP KLLLCNPRKQGPETQGSTAELITGLVQLVPQSHMPEIAQEAMEALL VLHQLDSIDLWNPDAPVETFWEISSQMLFYICKKLTSHQMLSSTEIL KWLREILICRNKFLLKNKQADRSSCHFLLFYGVGCDIPSSGNTSQM SMDHEELLRTPGASLRKGKGNSSMDSAAGCSGTPPICRQAQTKLE VALYMFLWNPDTEAVLVAMSCFRHLCEEADIRCGVDEVSVHNLL PNYNTFMEFASVSNMMSTGRAALQKRVMALLRRIEHPTAGNTEA WEDTHAKWEQATKLILNYPKAKMEDGQAAESLHKTIVKRRMSHV SGGGSIDLSDTDSLQEWINMTGFLCALGGVCLQQRSNSGLATYSPP MGPVSERKGSMISVMSSEGNADTPVSKFMDRLLSLMVCNHEKVG LQIRTNVKDLVGLELSPALYPMLFNKLKNTISKFFDSQGQVLLTDT NTQFVEQTIAIMKNLLDNHTEGSSEHLGQASIETNIMLNLVRYVRV LGNMVHAIQIKTKLCQLVEVMMARRDDLSFCQEMKFRNKMVEYL TDWVMGTSNQAADDDVKCLTRDLDQASMEAVVSLLAGLPLQPEE GDGVELMEAKSQLFLKYFTLFMNLLNDCSEVEDESAQTGGRKRG MSRRLASLRHCTVLAMSNLLNANVDSGLMHSIGLGYHKDLQTRA TFMEVLTKILQQGTEFDTLAETVLADRFERLVELVTMMGDQGELPI AMALANVVPCSQWDELARVLVTLFDSRHLLYQLLWNMFSKEVEL ADSMQTLFRGNSLASKIMTFCFKVYGATYLQKLLDPLLRIVITSSD WQHVSFEVDPTRLEPSESLEENQRNLLQMTEKFFHAIISSSSEFPPQ LRSVCHCLYQVVSQRFPQNSIGAVGSAMFLRFINPAIVSPYEAGILD KKPPPRIERGLKLMSKILQSIANHVLFTKEEHMRPFNDFVKSNFDA ARRFFLDIASDCPTSDAVNHSLSFISDGNVLALHRLLWNNQEKIGQ YLSSNRDHKAVGRRPFDKMATLLAYLGPPEHKPVADTHWSSLNL TSSKFEEFMTRHQVHEKEEFKALKTLSIFYQAGTSKAGNPIFYYVA RRFKTGQINGDLLIYHVLLTLKPYYAKPYEIVVDLTHTGPSNRFKT DFLSKWFVVFPGFAYDNVSAVYIYNCNSWVREYTKYHERLLTGL KGSKRLVFIDCPGKLAEHLEHEQQKLPAATLALEEDLKVFHNALKL AHKDTKVSIKVGSTAVQVTSAERTKVLGQSVFLNDIYYASEIEEICL VDENQFTLTIANQGTPLTFMHQECEAIVQSIIHIRTRWELSQPDSIPQ HTKIRPKDVPGTLLNIALLNLGSSDPSLRSAAYNLLCALTCTFNLKI EGQLLETSGLCIPANNTLFIVSISKTLAANEPHLTLEFLEECISGFSKS SIELKHLCLEYMTPWLSNLVRFCKIINDDAKRQRVTAILDKLITMTI NEKQMYPSIQAKIWGSLGQITDLLDVVLDSFIKTSATGGLGSIKAE VMADTAVALASGNVKLVSSKVIGRMCKIIDKTCLSPTPTLEQHLM WDDIAILARYMLMLSFNNSLDVAAHLPYLFHVVTFLVATGPLSLR ASTHGLVINIIHSLCTCSQLHFSEETKQVLRLSLTEFSLPKFYLLFGIS KVKSAAVIAFRSSYRDRSFSPGSYERETFALTSLETVTEALLEIMEA CMRDIPTCKWLDQWTELAQRFAFQYNPSLQPRALVVFGCISKRVS HGQIKQIIRILSKALESCLKGPDTYNSQVLIEATVIALTKLQPLLNKD SPLHKALFWVAVAVLQLDEVNLYSAGTALLEQNLHTLDSLRIFND KSPEEVFMAIRNPLEWHCKQMDHFVGLNFNSNFNFALVGHLLKG YRHPSPAIVARTVRILHTLLTLVNKHRNCDKFEVNTQSVAYLAALL TVSEEVRSRCSLKHRKSLLLTDISMENVPMDTYPIHHGDPSYRTLK ETQPWSSPKGSEGYLAATYPTVGQTSPRARKSMSLDMGQPSQANT KKLLGTRKSFDHLISDTKAPKRQEMESGITTPPKMRRVAETDYEM ETQRISSSQQHPHLRKVSVSESNVLLDEEVLTDPKIQALLLTVLATL VKYTTDEFDQRILYEYLAEASVVFPKVFPVVIINLLDSKINTLLSLC QDPNLLNPIHGIVQSVVYHEESPPQYQTSYLQSFGFNGLWRFAGPF SKQTQIPDYAELIVKFLDALIDTYLPGIDEETSEESLLTPTSPYPPAL QSQLSITANLNLSNSMTSLATSQHSPGIDKENVELSPTTGHCNSGRT RHGSASQVQKQRSAGSFKRNSIKKIV Neurofibromin 1 MAAHRPVEWVQAVVSRFDEQLPIKTGQQNTHTKVSTEHNKECLIN Variant 3 ISKYKFSLVISGLTTILKNVNNMRIFGEAAEKNLYLSQLIILDTLEKC SEQ ID NO: 29 LAGQPKDTMRLDETMLVKQLLPEICHFLHTCREGNQHAAELRNSA SGVLFSLSCNNFNAVFSRISTRLQELTVCSEDNVDVHDIELLQYINV DCAKLKRLLKETAFKFKALKKVAQLAVINSLEKAFWNWVENYPD EFTKLYQIPQTDMAECAEKLFDLVDGFAESTKRKAAVWPLQIILLI LCPEIIQDISKDVVDENNMNKKLFLDSLRKALAGHGGSRQLTESAA IACVKLCKASTYINWEDNSVIFLLVQSMVVDLKNLLFNPSKPFSRG SQPADVDLMIDCLVSCFRISPHNNQHFKICLAQNSPSTFHYVLVNS LHRIITNSALDWWPKIDAVYCHSVELRNMFGETLHKAVQGCGAHP AIRMAPSLTFKEKVTSLKFKEKPTDLETRSYKYLLLSMVKLIHADP KLLLCNPRKQGPETQGSTAELITGLVQLVPQSHMPEIAQEAMEALL VLHQLDSIDLWNPDAPVETFWEIRYMYFYFLNSTFKFYFVFLS Neurofibromin 1 NWEDNSVIFLLVQSMVVDLKNLLFNPSKPFSRGSQPADVDLMIDC Variant 4 LVSCFRISPHNINQHFKICLAQNSPSTFHYVLVNSLHRIITNSALDWW SEQ ID NO: 30 PKIDAVYCHSVELRNMFGETLHKAVQGCGAHPAIRMAPSLTFKEK VTSLKFKEKPTDLETRSYKYLLLSMVKLIHADPKLLLCNPRKQGPE TQGSTAELITGLVQLVPQSHMPEIAQEAMEALLVLHQLDSIDLWNP DAPVETFWEISSQMLFYICKKLTSHQMLSSTEILKWLREILICRNKF LLKNKQADRSSCHFLLFYGVGCDIPSSGNTSQMSMDHEELLRTPG ASLRKGKGNSSMDSAAGCSGTPPICRQAQTKLEVALYMFLWNPDT EAVLVAMSCFRHLCEEADIRCGVDEVSVIINLLPNYNTFMEFASVS NMMSTGRAALQKRVMALLRRIEHPTAGNTEAWEDTHAKWEQAT KLILNYPKAKMEDGQAAESLHKTIVKRRMSHVSGGGSIDLSDTDS LQEWINMTGFLCALGGVCLQQRSNSGLATYSPPMGPVSERKGSMI SVMSSEGNADTPVSKFMDRLLSLMVCNHEKVGLQIRTNVKDLVG LELSPALYPMLFNKLKNTISKFFDSQGQVLLTDTNTQFVEQTIAIIVIK NLLDNHTEGSSEHLGQASIETNIMLNLVRYVRVLGNMVHAIQIKTK LCQLVEVMMARRDDLSFCQEMKFRNKMVEYLTDWVMGTSNQA ADDDVKCLTRDLDQASMEAVVSLLAGLPLQPEEGDGVELMEAKS QLFLKYFTLFMNLLNDCSEVEDESAQTGGRKRGMSRRLASLRHCT VLAMSNLLNANVDSGLMHSIGLGYHKDLQTRATFMEVLTKILQQ GTEFDTLAETVLADRFERLVELVTMMGDQGELPIAMALANVVPCS QWDELARVLVTLFDSRHLLYQLLWNMFSKEVELADSMQTLFRGN SLASKIMTFCFKVYGATYLQKLLDPLLRIVITSSDWQHVSFEVDPT RLEPSESLEENQRNLLQMTEKFFHAIISSSSEFPPQLRSVCHCLYQV VSQRFPQNSIGAVGSAMFLRFINPAIVSPYEAGILDKKPPPRIERGLK MSKILQSIANHVLFTKEEHMRPFNDFVKSNFDAARRFFLDIASDC PTSDAVNHSLSFISDGNVLALHRLLWNNQEKIGQYLSSNRDHKAV GRRPFDKMATLLAYLGPPEHKPVADTHWSSLNLTSSKFEEFMTRH QVHEKEEFKALKTLSIFYQAGTSKAGNPIFYYVARRFKTGQINGDL LIYHVLLTLKPYYAKPYEIVVDLTHTGPSNRFKTDFLSKWFVVFPG FAYDNVSAVYIYNCNSWVREYTKYHERLLTGLKGSKRLVFIDCPG KLAEHIEHEQQKLPAATLALEEDLKVFIINALKLAHKDTKVSIKVG STAVQVTSAERTKVLGQSVFLNDIYYASEIEEICLVDENQFTLTIAN QGTPLTFMHQECEAIVQSIIHIRTRWELSQPDSIPQHTKIRPKDVPGT LLNIALLNLGSSDPSLRSAAYNLLCALTCTFNLKIEGQLLETSGLCIP ANNTLFIVSISKTLAANEPHLTLEFLEECISGFSKSSIELKHLCLEYM TPWLSNLVRFCKHNIDDAKRQRVTAILDKLITMTINEKQMYPSIQA KIWGSLGQITDLLDVVLDSFIKTSATGGLGSIKAEVMADTAVALAS GNVKLVSSKVIGRMCKIIDKTCLSPTPTLEQHLMWDDIAILARYML MLSFNNSLDVAAHLPYLFHVVTFLVATGPLSLRASTHGLVINHEISL CTCSQLHFSEETKQVLRLSLTEFSLPKFYLLFGISKVKSAAVIAFRSS YRDRSFSPGSYERETFALTSLETVTEALLEIMEACMRDIPTCKWLD QWTELAQRFAFQYNPSLQPRALVVFGCISKRVSHGQIKQIIRILSKA LESCLKGPDTYNSQVLIEATVIALTKLQPLLNKDSPLHKALFWVAV AVLQLDEVNLYSAGTALLEQNLHTLDSLRIFNDKSPEEVFMAIRNP LEWHCKQMDHFVGLNFNSNFNFALVGHLLKGYRHPSPAIVARTV RILHTLLTLVNKHRNCDKFEVNTQSVAYLAALLTVSEEVRSRCSLK HRKSLLLTDISMENVPMDTYPIHHGDPSYRTLKETQPWSSPKGSEG YLAATYPTVGQTSPRARKSMSLDMGQPSQANTKKLLGTRKSFDHL ISDTKAPKRQEMESGITTPPKMRRVAETDYEMETQRISSSQQIIPHL RKVSVSESNVLLDEEVLTDPKIQALLLTVLATLVKYTTDEFDQRIL YEYLAEASVVFPKVFPVVIINILLDSKINTLLSLCQDPNLLNPIHGIVQ SVVYHEESPPQYQTSYLQSFGFNGLWRFAGPFSKQTQIPDYAELIV KFLDALIDTYLPGIDEETSEESLLTPTSPYPPALQSQLSITANLNLSNS MTSLATSQHSPASLPCSKSAVFMQLFPHQGIDKENVELSPTTGHCN SGRTRHGSASQVQKQRSAGSFKRNSIKKIV Neurofibromin 1 MAAHRPVEWVQAVVSRFDEQLPIKTGQQNTHTKVSTEHNKECLIN Variant 5 ISKYKFSLVISGLTTILKNVNNMRIFGEAAEKNLYLSQLBLDTLEKC SEQ ID NO: 31 LAGQPKDTMRLDETMLVKQLLPEICHFLHTCREGNQHAAELRNSA SGVLFSLSCNNFNAVFSRISTRLQELTVCSEDNVDVHDIELLQYINV DCAKLKRLLKETAFKFKALKKVAQLAVINSLEKAFWNWVENYPD EFTKLYQIPQTDMAECAEKLFDLVDGFAESTKRKAAVWPLQIILLI LCPEIIQDISKDVVDENNMNKKLFLDSLRKALAGHGGSRQLTESAA IACVKLCKASTYINWEDNSVIFLLVQSMVVDLKNLLFNPSKPFSRG SQPADVDLMIDCLVSCFRISPHNNQHFKICLAQNSPSTFHYVLVNS LHRIITNSALDWWPKIDAVYCHSVELRNMFGETLHKAVQGCGAHP AIRMAPSLTFKEKVTSLKFKEKPTDLETRSYKYLLLSMVKLIHADP KLLLCNPRKQGPETQGSTAELITGLVQLVPQSHMPEIAQEAMEVRG K Neurofibromin 1 MHQECEAIVQSIIHIRTRWELSQPDSIPQHTKIRPKDVPGTLLNIALL Variant 6 NLGSSDPSLRSAAYNLLCALTCTFNLKIEGQLLETSGLCIPANNTLFI SEQ ID NO: 32 VSISKTLAANEPHLTLEFLEECISGFSKSSIELKHLCLEYMTPWLSNL VRFCKIINDDAKRQRVTAILDKLITMTINEKQMYPSIQAKIWGSLG QITDLLDVVLDSFIKTSATGGLGSIKAEVMADTAVALASGNVKLVS SK Neurofibromin 1 MKRCWSNSCCQKSAIFFTPVVKETSMQLNFGILPLGFYFLSAATTS Variant 7 MQSLVAFLPETAFKFKALKKVAQLAVINSLEKAFWNWVENYPDE SEQ ID NO: 33 FTKLYQIPQTDMAECAEKLFDLVDGFAESTKRKAAVWPLQIILLIL CPEIIQDISKDVVDENNMNKVRRAKLFPLYLDVKQFILLKVCITLGL LFKQSISGNHLNDHFRFLCLMDLEETYSYIILFGRGKIIPGNEQRFKII P Neurofibromin 1 XIHGIVQSVVYHEESPPQYQTSYLQSFGFNGLWRFAGPFSKQTQIP Variant 8 DYAELIVKFLDALIDTYLPGIDEETSEESLLTPTSPYPPALQSQLSITA SEQ ID NO: 34 NLNLSNSMTSLATSQHSPGQ Glyceraldehyde-3 phosphate MVYMFQYDSTHGKFHGTVKAENGKLVINGNPITIFQERDPSKIKW dehydrogenase GDAGAEYVVESTGVFTTMEKAGAHLQGGAKRVIISAPSADAPMFV Variant 2 MGVNHEKYDNSLKIISNASCTTNCLAPLAKVIHDNFGIVEGLMTTV SEQ ID NO: 35 HAITATQKTVDGPSGKLWRDGRGALQNIIPASTGAAKAVGKVIPEL NGKLTGMAFRVPTANVSVVDLTCRLEKPAKYDDIKKVVKQASEG PLKGILGYTEHQVVSSDFNSDTHSSTFDAGAGIALNDHFVKLISWY DNEFGYSNRVVDLMAHMASKE Glyceraldehyde-3 phosphate MGKVKVGVNGFGRIGRLVTRAAFNSGKVDIVAINDPFIDLNYMVY dehydrogenase MFQYDSTHGKFHGTVKAENGKLVINGNPITIFQERDPSKIKWGDA Variant 3 GAEYVVESTGVFTTMEKAGAHLQGGAKRVIISAPSADAPMFVMG SEQ ID NO: 36 VNHEKYDNSLKIISNASCTTNCLAPLAKVIHDNFGIVEGLMTTVHA ITATQKTVDGPSGKLWRDGRGALQNIIPASTGAAKAVGKVIPELNG KLTGMAFRVPTANVSVVDLTCRLEKPAKYDDIKKVVKQASEGPL KGILGYTEHQVVSSDFNSDTHSSTFDAGAGIALNDHFVKLISWYDN EFGYSNRVVDLMAHMASKE Glyceraldehyde-3 phosphate MGKVKVGVNGFGRIGRLVTRAAFNSGKVDIVAINDPFIDLNYMVY dehydrogenase MFQYDSTHGKFHGTVKAENGKLVINGNPITIFQERDPSKIKWGDA Variant 4 GAEYVVESTGVFTTMEKAGAHLQGGAKRVIISAPSADAPMFVMG SEQ ID NO: 37 VNHEKYDNSLKIISNASCTTNCLAPLAKVIHDNFGIVEGLMTTVHA ITATQKTVDGPSGKLWRDGRGALQNIIPASTGAAKAVGKVIPELNG KLTGMAFRVPTANVSVVDLTCRLEKPAKYDDIKKVVKQASEGPL KGILGYTEHQVVSSDFNSDTHSSTFDAGAGIALNDHFVKLISWYDN EFGYSNRVVDLMAHMASKE Glyceraldehyde-3 phosphate MEEMRDPSKIKWGDAGAEYVVESTGVFTTMEKAGAHLQGGAKR dehydrogenase VIISAPSADAPMFVMGVNHEKYDNSLKIISNASCTTNCLAPLAKVIH Variant 5 DNFGIVEGLMTTVHAITATQKTVDGPSGKLWRDGRGALQNIIPAST SEQ ID NO: 38 GAAKAVGKVIPELNGKLTGMAFRVPTANVSVVDLTCRLEKPAKY DDIKKVVKQASEGPLKGILGYTEHQVVSSDFNSDTHSSTFDAGAGI ALNDHFVKLISWYDNEFGYSNRVVDLMAHMASKE Glyceraldehyde-3 phosphate MVYMFQYDSTHGKFHGTVKAENGKLVINGNPITIFQERDPSKIKW dehydrogenase GDAGAEYVVESTGVFTTMEKAGAHLQGGAKRVIISAPSADAPMFV Variant 6 MGVNHEKYDNSLKIISNASCTTNCLAPLAKVIHDNFGIVEGLMTTV SEQ ID NO: 39 HAITATQKTVDGPSGKLWRDGRGALQNIIPASTGAAKAVGKVIPEL NGKLTGMAFRVPTANVSVVDLTCRLEKPAKYDDIKKVVKQASEG PLKGILGYTEHQVVSSDFNSDTHSSTFDAGAGIALNDHFVKLISWY DNEFGYSNRVVDLMAHMASKE Fibronectin Type BI Domain XPRHVKLLSTKMGLKVTWDPPKDATSRPVEHYNIAYGKSLKSLKY Containing protein 1 IKVNAETYSFLIEDVEPGVVYFVLLTAENHSGVSRPVYRAESPPGG Variant 2 EWIEIDGFPIKGPGPFNETVTEKEVPNKPLRVRVRSSDDRLSVAWK SEQ ID NO: 40 APRLSGAKSPRRSRGFLLGYGESGRKMNYVPLTRDERTHEIKKLAS ESVYVVSLQSMNSQGRSQPVYRAALTKRKISEEDELDVPDDISVRV MSSQSVLVSWVDPVLEKQKKVVASRQYTVRYREKGELARWDYK QIANRRVLIENLIPDTVYEFAVRISQGERDGKWSTSVFQRTPESAPT TAPENLNVWPVNGKPTVVAASWDALPETEGKVKASKADVEQNTE DNGKPEKPEPSSPSPRAPASSQIIPSVPASPQGRNAKDLLLDLKNKIL ANGGAPRKPQLRAKKAEELDLQSTEITGEEELGSREDSPMSPSDTQ DQKRTLRPPSRHGHSVVAPGRTAVRARMPALPRREGVDKPGFSLA TQPRPGAPPSASASPAHHASTQGTSHRPSLPASLNDNDLVDSDEDE RAVGSLIIPKGAFAQPRPALSPSRQSPSSVLRDRSSVIIPGAKPASPA RRTPHSGAAEEDSSASAPPSRLSPPHGGSSRLLPTQPHLSSPLSKGG KDGEDAPATNSNAPSRSTMSSSVSSHLSSRTQVSEGAEASDGESHG DGDREDGGRQAEATAQTLRARPASGHFHLLRHKPFAANGRSPSRF SIGRGPRLQPSSSPQSTVPSRAHPRVPSHSDSHIPKLSSGIHGDEEDEK PLPATVVNDHVPSSSRQPISRGWEDLRRSPQRGASLHRKEPIPENPK STGADTHPQGKYSSLASKAQDVQQSTDADTEGHSPKAQPGSTDRH ASPARPPAARSQQHPSVPRRMTPGRAPQQQPPPPVATSQHHPGPQS RDAGRSPSQPRLSLTQAGRPRPTSQGRSHSSSDPYTASSRGMLPTA LQNQDEDAQGSYDDDSTEVEAQDVRAPAHAARAKEAAASLPKHQ QVESPTGAGAGGDHRSQRGHAASPARPSRPGGPQSRARVPSRAAP GKSEPPSKRPLSSKSQQSVSAEDDEEEDAGFFKGGKEDLLSSSVPK WPSSSTPRGGKDADGSLAKEEREPAIALAPRGGSLAPVKRPLPPPP GSSPRASHVPSRLPPRSAATVSPVAGTHPWPQYTTRAPPGHFSTTP MLSLRQRMMHARFRNPLSRQPARPSYRQGYNGRPNVEGKVLPGS NGKPNGQRIINGPQGTKWVVDLDRGLVLNAEGRYLQDSHGNPLRI KLGGDGRTIVDLEGTPVVSPDGLPLFGQGRHGTPLANAQDKPILSL GGKPLVGLEVIKKTTHIPPTTTMQPTITTTPLPTITTPRPTTATTRRT TTTRRTTTRRPTTTVRTTTRITITTTPTFTTPIPTCPPGTLERHDDDG NLIMSSNGIPECYAEEDEFSGLETDTAVPTEEAYVIYDEDYEFETSR PPTTTEPSTTATTPRVIPEEGAISSFPEEEFDLAGRKRFVAPYVTYLN KDPSAPCSLTDALDHFQVDSLDEIIPNDLKKSDLPPQHAPRNITVVA VEGCHSFVIVDWDKATPGDVVTGYLVYSASYEDFIRNKWSTQASS VTHLPIENLKPNTRYYFKVQAQNPHGYGPISPSVSFVTESDNPLLV VRPPGGEPIWIPFAFKHDPSYTDCHGRQYVKRTWYRKFVGVVLCN SLRYKIYLSDNLKDTFYSIGDSWGRGEDHCQFVDSHLDGRTGPQS YVEALPTIQGYYRQYRQEPVRFGNIGFGTPYYYVGWYECGVSIPG KW Eukaryotic initiation factor 4A-I MSASQDSRSRDNGPDGMEPEGVIESNWNEIVDSFDDMNLSESLLR Variant 2 GIYAYGFEKPSAIQQRAILPCIKGYDVIAQAQSGTGKTATFAISILQQ SEQ ID NO: 41 IELDLKATQALVLAPTRELAQQIQKVVMALGDYMGASCHACIGGT NVRAEVQKLQMEAPHIIVGTPGRVFDMLNRRYLSPKYIKMFVLDE ADEMLSRGFKDQIYDIFQKLNSNTQVVLLSATMPSDVLEVTKKFM RDPIRILVKKEELTLEGIRQFYINVEREEWKLDTLCDLYETLTITQA VIFINTRRKVDWLTEKMHARDFTVSAMHGDMDQKERDVIMREFR SGSSRVLITTDLLGKLYPQNRSRWTVWP Eukaryotic initiation factor 4A-I MSASQDSRSRDNGPDGMEPEGVIESNWNEIVDSFDDMNLSESLLR Variant 3 GIYAYGFEKPSAIQQRAILPCIKGYDVIAQAQSGTGKTATFAISILQQ SEQ ID NO: 42 IELDLKATQALVLAPTRELAQQIQKVVMALGDYMGASCHACIGGT NVRAEVQKLQMEAPHIIVGTPGRVFDMLNRRYLSPKYIKMFVLDE ADEMLSRGFKDQIYDIFQKLNSNTQVVLLSATMPSDVLEVTKKFM RDPIRILVKKEELTLEGIRQFYINVEREEWKLDTLCDLYETLTITQA VIFINTRRKVDWLTEKMHARDFTVSAMHGDMDQKERDVIMREFR SGSSRVLITTDLLNRSRWTVWP Eukaryotic initiation factor 4A-I MEPEGVIESNWNEIVDSFDDMNLSESLLRGIYAYGFEKPSAIQQRAI Variant 4 LPCIKGYDVIAQAQSGTGKTATFAISILQQIELDLKATQALVLAPTR SEQ ID NO: 43 ELAQQIQKVVMALGDYMGASCHACIGGTNVRAEVQKLQMEAPHI IVGTPGRVFDMLNRRYLSPKYIKMFVLDEADEMLSRGFKDQIYDIF QKLNSNTQVVLLSATMPSDVLEVTKKFMRDPIRILVKKEELTLEGI RQFYINVEREEWKLDTLCDLYETLTIT Eukaryotic initiation factor 4A-I XVVMALGDYMGASCHACIGGTNVRAEVQKLQMEAPHIIVGTPGR Variant 5 VFDMLNRRYLSPKYIKMFVLDEADEMLSRGFKDQIYDIFQKLNSN SEQ ID NO: 44 TQVVLLSATMPSDVLEVTKKFMRDPIRILVKKEELTLEGIRQFYINV EREEWKLDTLCDLYETLTITQAVIFINTRRKVDWLTEKMHARDFT VSAMHGDMDQKERDVIMREFRSGSSRVLITTDLLGKLYPQNRSRW TVWP Eukaryotic initiation factor 4A-I MSASQDSRSRDNGPDGMEPEGVIESNWNEIVDSFDDMNLSESLLR Variant 6 GIYAYGFEKPSAIQQRAILPCIKGYDVIAQAQSGTGKTATFAISILQQ SEQ ID NO: 45 IELDLKATQALVLAPTRELAQQKVVMALGDYMGASCHACIGGTN VRAEVQKLQMEAPHIIVGTPGRVFDMLNRRYLSPKYIKMFVLDEA DEMLSRGFKDQIYDIFQKLNSNTQVVLLSATMPSDVLEVTKKFMR DPIRILVKKEELTLEGIRQFYINVEREEWKLDTLCDLYETLTITQAVI FINTRRKVDWLTEKMHARDFTVSAM Eukaryotic initiation factor 4A-I MSASQDSRSRDNGPDGMEPEGVIESNWNEIVDSFDDMNLSESLLR Variant 7 GIYAYGFEKPSAIQQRAILPCIKGYDVIAQAQSGTGKTATFAISILQQ SEQ ID NO: 46 IELDLKATQALVLAPTRELAQQIQKVVMALGDYMGASCHACIGGT NVRAEVQKLQMEAPHIIVGTPGRVFDMLNRRYLSPKYIKMFVLDE ADEMLSRGFKDQIYDIFQKLNSNTQEELTLEGIRQFYINVEREEWK LDTLCDLYETLTITQAVIFINTRRKVDWLTEKMHARDFTVSA Eukaryotic initiation factor 4A-I MEPEGVIESNWNEIVDSFDDMNLSESLLRGIYAYGFEKPSAIQQRAI Variant 8 LPCIKGYDVIAQAQSGTGKTATFAISILQQIELDLKAT SEQ ID NO: 47 Eukaryotic initiation factor 4A-I XAWAHCARGRHRPRPPTSGSRDNGPDGMEPEGVIESNWNEIVDSF Variant 9 DDMNLSESLLRGIYAYGFEKPSAIQQRAILPCIKGYDVIAQAQSGTG SEQ ID NO: 48 KTATFAISILQQIELDLKATQALVLAPTRELAQQIQKVVMALGDYM GASCHACIGGTNVRAEVQKLQMEAPHIIVGTPGRVFDMLNRRYLS PKYIKMFVLDEADEMLSRGFKDQIYDIFQKL Eukaryotic initiation factor 4A-I MSASQDSRDNGPDGMEPEGVIESNWNEIVDSFDDMNLSESLLRGI Variant 10 YAYGFEKPSAIQQRAILPCIKGYDVIAQAQSGTGKTATFAISILQQIE SEQ ID NO: 49 LDLKATQALVLAPTRELAQQIQKVVMALGDYMGASCHACIGGTN VRAEVQKLQMEAPHIIVGTPGRVFDMLNRRYLSPKYIKMFVLDEA DEMLS Eukaryotic initiation factor 4A-I MNLSESLLRGIYAYGFEKPSAIQQRAILPCIKGYDVIAQAQSGTGKT Variant 11 ATFAISILQQIELDLKATQALVLAPTRELAQQIQKVVMALGDYMG SEQ ID NO: 50 ASCHACIGGTNVRAEVQKLQMEAPHIIVGTPGRVFDMLNRRYLSP KYIKMFVLDEADEMLSRGFKDQIYDI Eukaryotic initiation factor 4A-I MNLSESLLRGIYAYGFEKPSAIQQRAILPCIKGYDVIAQAQSGTGKT Variant 12 ATFAISILQQIELDLKATQALVLAPTRELAQQIQKVVMALGDYMG SEQ ID NO: 51 ASCHACIGGTNVRAEVQKLQMEAPHIIVGTPGRVFDMLNRRY Eukaryotic initiation factor 4A-I MFVLDEADEMLSRGFKDQIYDIFQKLNSNTQVVLLSATMPSDVLE Variant 13 VTKKFMRDPIRILVKKEELTLEGIRQFYINVEREEWKLDTLCDLYE SEQ ID NO: 52 TLTITQAVIFINTRRKVDWLTEKMHA Eukaryotic initiation factor 4A-I MGRSTFLRGSRDNGPDGMEPEGVIESNWNEIVDSFDDMNLSESLL Variant 14 RGIYAYGFEKPSAIQQRAILPCIKGYDVIAQAQSGTGKTA SEQ ID NO: 53 L-lactate dehydrogenase chain B MATLKEKLIAPVAEEEATVPNNKITVVGVGQVGMACAISILGKSLA Variant 2 DELALVDVLEDKLKGEMMDLQHGSLFLQTPKIVADKDYSVTANS SEQ ID NO: 54 KIVVVTAGVRQQEGESRLNLVQRNVNVFKFIIPQIVKYSPDCIIIVVS NPVDILTYVTWKLSGLPKHRVIGSGCNLDSARFRYLMAEKLGIHPS SCHGWILGEHGDSSVAVWSGVNVAGVSLQELNPEMGTDNDSEN WKEVHKMVVESAYEVIKLKGYTNWAIGLSVADLIESMLKNLSRIH PVSTMVKGMYGIENEVFLSLPCILNARGLTSVINQKLKDDEVAQLK KSADTLWDIQKDLKDL L-lactate dehydrogenase chain B MATLKEKLIAPVAEEEATVPNNKITVVGVGQVGMACAISILGKSLA Variant 3 DELALVDVLEDKLKGEMMDLQHGSLFLQTPKIVADKDYSVTANS SEQ ID NO: 55 KIVVVTAGVRQQEGESRLNLVQRNVNVFKFIIPQIVKYSPDCIIIVVS NPVDILTYVTWKLSGLPKHRVIGSGCNLDSARFRYLMAEKLGIHPS SCHGWILGEHGDSSVAVWSGVNVAGVSLQELNPEMGTDNDSEN WKEVHKMVVESAYEVIKLKGYTNWAIGLSVADLIESMLKNLSRIH PVSTMVKGMYGIENEVFLSLPCILNARGLTSVINQKLKDDEVAQLK KSADTLWDIQKDLKDLXLVSSRL L-lactate dehydrogenase chain B MATLKEKLIAPVAEEEATVPNNKITVVGVGQVGMACAISILGKSLA Variant 4 DELALVDVLEDKLKGEMMDLQHGSLFLQTPKIVADKDYSVTANS SEQ ID NO: 56 KIVVVTAGVRQQEGESRLNLVQRNVNVFKFIIPQIVKYSPDCIIIVVS NPVDILTYVTWKLSGLPKHRVIGSGCNLDSARFRYLMAEKLGIHPS SCHGWILGEHGDSSVAVWSGVNVAGVSLQELNPEMGTDNDSEN WKEVH L-lactate dehydrogenase chain B MATLKEKLIAPVAEEEATVPNNKITVVGVGQVGMACAISILGKSLA Variant 5 DELALVDVLEDKLKGEMMDLQHGSLFLQTPKIVADKDYSVTANS SEQ ID NO: 57 KIVVVTAGVRQQEGESRLNLVQRNVNVFKFIIPQIVKYSPDCIIIV L-lactate dehydrogenase chain B MATLKEKLIAPVAEEEATVPNNKITVVGVGQVGMACAISILGKSLA Variant 6 DELALVDVLEDKLKGEMMDLQHGSLFLQTPKIVADKDYSVTANS SEQ ID NO: 58 KIVVVTAGVRQQ Nuclear heterogeneous MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVM Ribonucleoprotein A1 RDPNTKRSRGFGFVTYATVEEVDAAMNARPHKVDGRVVEPKRAV Variant 2 SREDSQRPGAHLTVKKIFVGGIKEDTEEHHLRDYFEQYGKIEVIEIM SEQ ID NO: 59 TDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGIINCEVRKALS KQEMASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRG GFGGSRGGGGYGGSGDGYNGFGNDGSNFGGGGSYNDFGNYNNQ SSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGYGGSSSSSSY GSGRRF Nuclear heterogeneous MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVM Ribonucleoprotein A1 RDPNTKRSRGFGFVTYATVEEVDAAMNARPHKVDGRVVEPKRAV Variant 3 SREDSQRPGAHLTVKKIFVGGIKEDTEEHHLRDYFEQYGKIEVIEIM SEQ ID NO: 60 TDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGIINCEVRKALS KQEMASASSSQRGRSGSGNFGGGSYNDFGNYNNQSSNFGPMKGG NFGGRSSGPYGGGGQYFAKPRNQGGYGGSSSSSSYGSGRRF Nuclear heterogeneous MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVM Ribonucleoprotein A1 RDPNTKRSRGFGFVTYATVEEVDAAMNARPHKVDGRVVEPKRAV Variant 4 SREDSQRPGAHLTVKKIFVGGIKEDTEEHHLRDYFEQYGKIEVIEIM SEQ ID NO: 61 TDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGIINCEVRKALS KQEMASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRG IGDGYNGFGNDGSNFGGGGSYNDFGNYNNQSSNFGPMKGGNFGG RSSGPYGGGGQYFAKPRNQGGYGGSSSSSSYGSGRRF Nuclear heterogeneous KIEVIEIMTDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGHNIC Ribonucleoprotein A1 EVRKALSKQEMASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRG Variant 5 GNFSGRGGFGGSRGGGGYGGSGDGYNGFGNDGSNFGGGGSYNDF SEQ ID NO: 62 GNYNNQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGYG GSSSSSSYGSGRRF Nuclear heterogeneous MRDSLLVAKFLGTQDLCLFLNLALSPKEPEQLRKLFIGGLSFETTDE Ribonucleoprotein A1 SLRSHFEQWGTLTDCVVMRDPNTKRSRGFGFVTYATVEEVDAAM Variant 6 NARPHKVDGRVVEPKRAVSREDSQRPGAHLTVKKIFVGGIKEDTE SEQ ID NO: 63 EHHLRDYFEQYGKIEVIEIMTDRGSGKKRGFAFVTFDDHDSVDKIV IQKYHTVNGIINCEVRKALSKQEMASASSSQRGRSGSGNFGGGRG GGFGG Nuclear heterogeneous MRDPNTKRSRGFGFVTYATVEEVDAAMNARPHKVDGRVVEPKR Ribonucleoprotein A1 AVSREDSQRPGAHLTVKKIFVGGIKEDTEEHHLRDYFEQYGKIEVI Variant 7 EIMTDRGSGKKRGFAFVTFDDHDS SEQ ID NO: 64 Nuclear heterogeneous MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVM Ribonucleoprotein A1 RDPNTKRSRGFGFVTYATVEEVDAAMNARPHKVDGRVVEPKRAV Variant 8 SREDSQRPGAHLTVKKIFVGGFGGSRGGGGYGGSGDGYNGFGND SEQ ID NO: 65 GSNFGGGGSYNDFGNYNNQSSN Nuclear heterogeneous MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVDS Ribonucleoprotein A1 QRPGAHLTVKKIFVGGIKEDTEEHHLRDYFEQYGKIEVIEIMTDRG Variant 9 SGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGHNCEVRKALSKQE SEQ ID NO: 66 MASASSSQR Polycystic kidney disease protein 1- XSRLRASMWIDRSTRAVSVHFTLYNPPTQLFTSVSLRVEILPTGSLV like 1 PSSLVESFSIFRSDSALQYHLMLPQLVFLALSLIHLCVQLYRNIMDK Variant 2 GVLSYWRKPRNWLELSVVGVSLTYYAVSGHLVTLAGDVTNQFHR SEQ ID NO: 67 GLCRAFMDLTLMASWNQRARWLRGILLFLFTLKCVYLPGIQNTM ASCSSMIMRHSLPSIFVAGLVGALMLAALSHLHRFLLSMWVLPPGT FTDAFPGLLFHFPRRSQKDCLLGLSKSDQRAMACYFGILLIVSATL CFGMLRGFLMTLPQKRKSFQSKSFVRLKDVTAYMWEKVLTFLRL ETPKLEEAEMVENIANYYLDEFANLLDELLMKINGLSDSLQLPLLE KTSNNTGEARTEESPLVDISSYQAAESLTLVTQTEVQWHDLGSLQP PHPRFKQFSCLSLPSSWDYRRVPLCLANF Polycystic kidney disease protein 1- XVGGPENPYLIDPENQNVTLNGPGGCGTREDCVLSLGRTRTEAHT like 1 ALSRLRASMWIDRSTRAVSVHFTLYNPPTQLFTSVSLRVEILPTGSL Variant 3 VPSSLVESFSIFRSDSALQYHLMLPQLVFLALSLIHLCVQLYRMMD SEQ ID NO: 68 KGVLSYWRKPRNWLEVASLVSFSFEK Heat shock protein cognate 71 kDa MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFT Variant 2 DTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKH SEQ ID NO: 69 WPFMVVNDAGRPKVQVEYKGETKSFYPEEVSSMVLTKMKEIAEA YLGKTVTNAVVTVPAYFNDSQRQATKDAGTIAGLNVLRIINEPTA AAIAYGLDKKVGAERNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGD THLGGEDFDNRMVNHFIAEFKRKHKKDISENKRAVRRLRTACERA KRTLSSSTQASIEIDSLYEGIDFYTSITRARFEELNADLFRGTLDPVE KALRDAKLDKSQIHDIVLVGGSTRIPKIQKLLQDFFNGKELNKSINP DEAVAYGAAVQAAILSGDKSENVQDLLLLDVTPLSLGIETAGGVM TVLIKRNTTIPTKQTQTFTTYSDNQPGVLIQVYEGERAMTKDNNLL GKFELTGIPPAPRGVPQIEVTFDIDANGILNVSAVDKSTGKENKITIT NDKGRLSKEDIERMVQEAEKYKAEDEKQRDKVSSKNSLESYAFN MKATVEDEKLQGKINDEDKQKILDKCNEIINWLDKNQTAEKEEFE HQQKELEKVCNPIITKLYQSAGGMPGGMPGGFPGGGAPPSGGASS GPTIEEVD Heat shock protein cognate 71 kDa MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFT Variant 3 DTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKH SEQ ID NO: 70 WPFMVVNDAGRPKVQVEYKGETKSFYPEEVSSMVLTKMKEIAEA YLGKTVTNAVVTVPAYFNDSQRQATKDAGTIAGLNVLRIINEPTA AAIAYGLDKKVGAERNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGD THLGGEDFDNRMVNHFIAEFKRKHKKDISENKRAVRRLRTACERA KRTLSSSTQASIEIDSLYEGIDFYTSITRARFEELNADLFRGTLDPVE KALRDAKLDKSQIHDIVLVGGSTRIPKIQKLLQDFFNGKELNKSINP DEAVAYGAAVQAAILSGDKSENVQDLLLLDVTPLSLGIETAGGVM TVLIKRNTTIPTKQTQTFTTYSDNQPGVLIQVYEGERAMTKDNNLL GKFELTGIPPAPRGVPQIEVTFDIDANGILNVSAVDKSTGKENKITIT NDKGRLSKEDIERMVQEAEKYKAEDEKQRDKVSSKNSLESYAFN MKATVEDEKLQGKINDEDKQKILDKCNEIINWLDKNQTAEKEEFE HQQKELEKVCNPIITKLYQSAGGMPGGMPGGFPGGGAPPSGGASS GPTIEEVD Heat shock protein cognate 71 kDa MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFT Variant 4 DTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKH SEQ ID NO: 71 WPFMVVNDAGRPKVQVEYKGETKSFYPEEVSSMVLTKMKEIAEA YLGKTVTNAVVTVPAYFNDSQRQATKDAGTIAGLNVLRIINEPTA AAIAYGLDKKVGAERNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGD THLGGEDFDNRMVNHFIAEFKRKHKKDISENKRAVRRLRTACERA KRTLSSSTQASIEIDSLYEGIDFYTSITRARFEELNADLFRGTLDPVE KALRDAKLDKSQIHDIVLVGGSTRIPKIQKLLQDFFNGKELNKSINP DEAVAYGAAVQAAILSGDKSENVQDLLLLDVTPLSLGIETAGGVM TVLIKRNTTIPTKQTQTFTTYSDNQPGVLIQVYEGERAMTKDNNLL GKFELTGMPGGMPGGFPGGGAPPSGGASSGPTIEEVD Heat shock protein cognate 71 kDa MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFT Variant 5 DTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKH SEQ ID NO: 72 WPFMVVNDAGRPKVQVEYKGETKSFYPEEVSSMVLTKMKEIAEA YLGKATKDAGTIAGLNVLRIINEPTAAAIAYGLDKKVGAERNVLIF DLGGGTFDVSILTIEDGIFEVKSTAGDTHLGGEDFDNRMVNHFIAE FKRKHKKDISENKRAVRRLRTACERAKRTLSSSTQASIEIDSLYEGI DFYTSITRARFEELNADLFRGTLDPVEKALRDAKLDKSQIHDIVLV GGSTRIPKIQKLLQDFFNGKELNKSINPDEAVAYGAAVQAAILSGD KSENVQDLLLLDVTPLSLGIETAGGVMTVLIKRNTTIPTKQTQTFTT YSDNQPGVLIQVYEGERAMTKDNNLLGKFELTGIPPAPRGVPQIEV TFDIDANGILNVSAVDKSTGKENKITITNDKGRLSKEDIERMVQEA EKYKAEDEKQRDKVSSKNSLESYAFNMKATVEDEKLQGKINDED KQKILDKCNEIINWLDKNQTAEKEEFEHQQKELEKVCNPITTKLYQ SAGGMPGGMPGGFPGGGAPPSGGASSGPTIEEVD Heat shock protein cognate 71 kDa MVNHFIAEFKRKHKKDISENKRAVRRLRTACERAKRTLSSSTQASI Variant 6 EIDSLYEGIDFYTSITRARFEELNADLFRGTLDPVEKALRDAKLDKS SEQ ID NO: 73 QIHDIVLVGGSTRIPKIQKLLQDFFNGKELNKSINPDEAVAYGAAV QAAILSGDKSENVQDLLLLDVTPLSLGIETAGGVMTVLIKRNTTIPT KQTQTFTTYSDNQPGVLIQVYEGERAMTKDNNLLGKFELTGIPPAP RGVPQIEVTFDIDANGILNVSAVDKSTGKENKITITNDKGRLSKEDI ERMVQEAEKYKAEDEKQRDKVSSKNSLESYAFNMKATVEDEKLQ GKINDEDKQKILDKCNEIINWLDKNQTAEKEEFEHQQKELEKVCN PITTKLYQSAGGMPGGMPGGFPGGGAPPSGGASSGPTIEEVD Heat shock protein cognate 71 kDa MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFT Variant 7 DTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKH SEQ ID NO: 74 WPFMVVNDAGRPKHKKDISENKRAVRRLRTACERAKRTLSSSTQ ASIEIDSLYEGIDFYTSITRARFEELNADLFRGTLDPVEKALRDAKL DKSQIHDIVLVGGSTRIPKIQKLLQDFFNGKELNKSINPDEAVAYGA AVQAAILSGDKSENVQDLLLLDVTPLSLGIETAGGVMTVLIKRNTT IPTKQTQTFTTYSDNQPGVLIQVYEGERAMTKDNNLLGKFELTGIP PAPRGVPQIEVTFDIDANGILNVSAVDKSTGKENKITITNDKGRLSK EDIERMVQEAEKYKAEDEKQRDKVSSKNSLESYAFNMKATVEDE KLQGKINDEDKQKILDKCNEIINWLDKNQTAEKEEFEHQQKELEK VCNPITTKLYQSAGGMPGGMPGGFPGGGAPPSGGASSGPTIEEVD Heat shock protein cognate 71 kDa MNPTNTVFDAKRLIGRRFDDAVVQSDMKHWPFMVVNDAGRPKV Variant 8 QVEYKGETKSFYPEEVSSMVLTKMKEIAEAYLGKTVTNAVVTVPA SEQ ID NO: 75 YFNDSQRQATKDAGTIAGLNVLIINEPTAAAIAYGLDKKVGAER NVLIFDLGGGTFDVSILTIEDGIFEVKSTAGDTHLGGEDFDNRMVN HFIAEFKRKHKKDISENKRAVRRLRTACERAKRTLSSSTQASIEIDS LYEGIDFYTSITRARFEELNADLFRGTLDPVEKALRDAKLDKSQIH DIVLVGGSTRIPKIQKLLQDFFNGKELNKSINPDEAVAYG Heat shock protein cognate 71 kDa MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFT Variant 9 DTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKH SEQ ID NO: 76 WPFMVVNDAGRPKVQVEYKGETKSFYPEEVSSMVLTKMKEIAEA YLGKTVTNAVVTVPAYFNDSQRQATKDAGTIAGLNVLRIINEPTA AAIAYGLDK Heat shock protein cognate 71 kDa MTVLIKRNTTIPTKQTQTFTTYSDNQPGVLIQVYEGERAMTKDNNL Variant 10 LGKFELTGIPPAPRGVPQIEVTFDIDANGILNVSAVDKSTGKENKITI SEQ ID NO: 77 TNDKGRLSKEDIERMVQEAEKYKAEDEKQRDKVSSKNSLESYAFN MKATVEDEKLQGKINDEDKQKILDKCNEIINWLDKNQTAEKEEFE HQQKELEKVCNPITTKLYQSAGGMPGGMPGGFPGGGAPP Heat shock protein cognate 71 kDa MTKDNNLLGKFELTGIPPAPRGVPQIEVTFDIDANGILNVSAVDKST Variant 11 GKENKITITNDKGRLSKEDIERMVQEAEKYKAEDEKQRDKVSSKN SEQ ID NO: 78 SLESYAFNMKATVEDEKLQGKINDEDKQKILDKCNEIINWLDKNQ TAEKEEFEHQQKE Heat shock protein cognate 71 kDa MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFT Variant 12 DTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKH SEQ ID NO: 79 WPFMVVNDAGRPKVQVEYKGETKSFYPEEVSSMVLTKMKEIAEA YLGKTVTNAVVTVPAYFNDSQRQATKDAGTIAGLNVLR Heat shock protein cognate 71 kDa MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFT Variant 13 DTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKH SEQ ID NO: 80 WPFMVVNDAGRPKVQVEYKGETKSFYPEEVSSMVLTKMKEIAE Heat shock protein cognate 71 kDa MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFT Variant 14 DTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKH SEQ ID NO: 81 WPFMVVNDAGRPKVQVEYKGETKSFYPEEVSSMVLTKMKEIAEA YLGKTVTNAVVTVPAYFNDSQRQATKDAGTIAGLNVLRIINEPTA AAIAY Heat shock protein cognate 71 kDa MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFT Variant 15 DTERLIGDAAKNQVAMNPTNTVFETKSFYPEEVSSMVLTKMKEIA SEQ ID NO: 82 EAYLGKTVTNAVVTVPAYFNDSQRQATKDAGTIAGLNVLRIINEPT AAAIAYGLDKKVGAERNVLIFDLGGGTFDVSI Heat shock protein cognate 71 kDa MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFT Variant 16 DTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKH SEQ ID NO: 83 WPFMVVNDAGRPKVQVEYKGETKSFYPEEVSSMVLTKMKEIAEA YLGKTVTNAVVTVPAYFNDSQRQATKDAGTIAGLNVLRIINEPTA Heat shock protein cognate 71 kDa MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFT Variant 17 DTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKH SEQ ID NO: 84 WPFMVVNDAGRPKVQVEYKGETKSFYPEEVSSMVLTKMKEIAEA YLGK Ankyrin-3 MASSASSSPAGTEDSAPAQGGFGSDYSRSSRKSDANASYLRAARA Variant 2 GHLEKALDYIKNGVDINICNQNGLNALHLASKEGHVEVVSELLQR SEQ ID NO: 85 EANVDAATKKGNTALHIASLAGQAEVVKVLVTNGANVNAQSQN GFTPLYMAAQENHLEVVKFLLDNGASQSLATEDGFTPLAVALQQG HDQVVSLLLENDTKGKVRLPALIIIAARKDDTKAAALLLQNDNNA DVESKSGFTPLIIIAAHYGNINVATLLLNRAAAVDFTARNDITPLHV ASKRGNANMVKLLLDRGAKIDAKTRDGLTPLHCGARSGHEQVVE MLLDRAAPILSKTKNGLSPLHMATQGDHLNCVQLLLQIINVPVDD VTNDYLTALHVAAHCGHYKVAKVLLDKKANPNAKALNGFTPLIII ACKKNRIKVMELLLKHGASIQAVTESGLTPIHVAAFMGHVNIVSQL MHHGASPNTTNVRGETALHMAARSGQAEVVRYLVQDGAQVEAK AKDDQTPLIIISARLGKADIVQQLLQQGASPNAATTSGYTPLHLSAR EGHEDVAAFLLDHGASLSITTKKGFTPLHVAAKYGKLEVANLLLQ KSASPDAAGKSGLTPLHVAAHYDNQKVALLLLDQGASPHAAAKN GYTPLIIIAAKKNQMDIATTLLEYGADANAVTRQGIASVHLAAQEG HVDMVSLLLGRNANVNLSNKSGLTPLHLAAQEDRVNVAEVLVNQ GAHVDAQTKMGYTPLHVGCHYGNIKIVNFLLQHSAKVNAKTKNG YTPLHQAAQQGHTHIINVLLQNNASPNELTVNGNTALGIARRLGYI SVVDTLKIVTEETMITTTVTEKHKMNVPETMNEVLDMSDDEVRK ANAPEMLSDGEYISDVEEGEDAMTGDTDKYLGPQDLKELGDDSLP AEGYMGFSLGARSASLRSFSSDRSYTLNRSSYARDSMMIEELLVPS KEQHLTFTREFDSDSLRHYSWAADTLDNVNLVSSPIHSGFLVSFMV DARGGSMRGSRHHGMRICIPPRKCTAPTRITCRLVKRHKLANPPPM VEGEGLASRLVEMGPAGAQFLGPVIVEIPHFGSMRGKERELIVLRS ENGETWKEHQFDSKNEDLTELLNGMDEELDSPEELGKKRICRIITK DFPQYFAVVSRIKQESNQIGPEGGILSSTTVPLVQASFPEGALTKRIR VGLQAQPVPDEIVKKILGNKATFSPIVTVEPRRRKFHKPITMTIPVPP PSGEGVSNGYKGDTTPNLRLLCSITGGTSPAQWEDITGTTPLTFIKD CVSFTTNVSARFWLADCHQVLETVGLATQLYRELICVPYMAKFVV FAKMNDPVESSLRCFCMTDDKVDKTLEQQENFEEVARSKDIEVLE GKPIYVDCYGNLAPLTKGGQQLVFNFYSFKENRLPFSIKIRDTSQEP CGRLSFLKEPKTTKGLPQTAVCNLNITLPAHKKIEKTDRRQSFASL ALRKRYSYLTEPGMSPQSPCERTDIRMAIVADHLGLSWTELARELN FSVDEINQIRVENPNSLISQSFMLLKKWVTRDGKNATTDALTSVLT KINRIDIVTLLEGPIFDYGNISGTRSFADENNVFHDPVDGYPSLQVE LETPTGLHYTPPTPFQQDDYFSDISSIESPLRTPSRLSDGLVPSQGNIE HSADGPPVVTAEDASLEDSKLEDSVPLTEMPEAVDVDESQLENVC LSWQNETSSGNLESCAQARRVTGGLLDRLDDSPDQCRDSITSYLK GEAGKFEANGSHTEITPEAKTKSYFPESQNDVGKQSTKETLKPKIH GSGHVEEPASPLAAYQKSLEETSKLIIEETKPCVPVSMKKMSRTSPA DGKPRLSLHEEEGSSGSEQKQGEGFKVKTKKEIRHVEKKSHS Ankyrin-3 MSEEPKEKNAKPAHRKRKGKKSDANASYLRAARAGHLEKALDYI Variant 3 KNGVDINICNQNGLNALHLASKEGHVEVVSELLQREANVDAATK SEQ ID NO: 86 KGNTALHIASLAGQAEVVKVLVTNGANVNAQSQNGFTPLYMAAQ ENHLEVVKFLLDNGASQSLATEDGFTPLAVALQQGHDQVVSLLLE NDTKGKVRLPALHIAARKDDTKAAALLLQNDNNADVESKSGFTPL HIAAHYGNINVATLLLNRAAAVDFTARNDITPLHVASKRGNANMV KLLLDRGAKIDAKTRDGLTPLHCGARSGHEQVVEMLLDRAAPILS KTKNGLSPLHMATQGDHLNCVQLLLQIINVPVDDVTNDYLTALHV AAHCGHYKVAKVLLDKKANPNAKALNGFTPLHIACKKNRIKVME LLLKHGASIQAVTESGLTPIHVAAFMGHVNIVSQLMHHGASPNTT NVRGETALHMAARSGQAEVVRYLVQDGAQVEAKAKDDQTPLHIS ARLGKADIVQQLLQQGASPNAATTSGYTPLHLSAREGHEDVAAFL LDHGASLSITTKKGFTPLHVAAKYGKLEVANLLLQKSASPDAAGK SGLTPLHVAAHYDNQKVALLLLDQGASPHAAAKNGYTPLHIAAK KNQMDIATTLLEYGADANAVTRQGIASVHLAAQEGHVDMVSLLL GRNANVNLSNKSGLTPLHLAAQEDRVNVAEVLVNQGAHVDAQT KMGYTPLHVGCHYGNIKIVNFLLQHSAKVNAKTKNGYTPLHQAA QQGHTHIINVLLQNNASPNELTVNGNTALGIARRLGYISVVDTLKI VTEETMTITTVTEKHKMNVPETMNEVLDMSDDEVRKANAPEMLS DGEYISDVEEGNRCTWYKIPKVQEFTVKSEDAMTGDTDKYLGPQD LKELGDDSLPAEGYMGFSLGARSASLRSFSSDRSYTLNRSSYARDS MMTEELLVPSKEQHLTFTREFDSDSLRHYSWAADTLDNVNLVSSPI HSGFLVSFMVDARGGSMRGSRHHGMRHIPPRKCTAPTRITCRLVK RHKLANPPPMVEGEGLASRLVEMGPAGAQFLGPVIVEIPHFGSMR GKERELIVLRSENGETWKEHQFDSKNEDLTELLNGMDEELDSPEEL GKKRICRITTKDFPQYFAVVSRIKQESNQIGPEGGILSSTTVPLVQAS FPEGALTKRIRVGLQAQPVPDEIVKKILGNKATFSPIVTVEPRRRKF HKPITMTIPVPPPSGEGVSNGYKGDTTPNLRLLCSITGGTSPAQWED ITGTTPLTFIKDCVSFTTNVSARFWLADCHQVLETVGLATQLYRELI CVPYMAKFVVFAKMNDPVESSLRCFCMTDDKVDKTLEQQENFEE VARSKDIEVLEGKPIYVDCYGNLAPLTKGGQQLVFNFYSFKENRLP FSIKIRDTSQEPCGRLSFLKEPKTTKGLPQTAVCNLNITLPAHKKIEK TDRRQSFASLALRKRYSYLTEPGMSPQSPCERTDIRMAIVADHLGL SWTELARELNFSVDEINQIRVENPNSLISQSFMLLKKWVTRDGKNA TTDALTSVLTKINRIDIVTLLEGPIFDYGNISGTRSFADENNVFHDPV DGYPSLQVELETPTGLHYTPPTPFQQDDYFSDISSIESPLRTPSRLSD GLVPSQGNIEHSADGPPVVTAEDASLEDSKLEDSVPLTEMPEAVDV DESQLENVCLSWQNETSSGNLESCAQARRVTGGLLDRLDDSPDQC RDSITSYLKGEAGKFEANGSHTEITPEAKTKSYFPESQNDVGKQST KETLKPKIHGSGHVEEPASPLAAYQKSLEETSKLIIEETKPCVPVSM KKMSRTSPADGKPRLSLHEEEGSSGSEQKQGEGFKVKTKKEIRHV EKKSHS Ankyrin-3 MALPQSEDAMTGDTDKYLGPQDLKELGDDSLPAEGYMGFSLGAR Variant 4 SASLRSFSSDRSYTLNRSSYARDSMMTEELLVPSKEQHLTFTREFDS SEQ ID NO: 87 DSLRHYSWAADTLDNVNLVSSPIHSGFLVSFMVDARGGSMRGSR HHGMRHIPPRKCTAPTRITCRLVKRHKLANPPPMVEGEGLASRLVE MGPAGAQFLGPVIVEIPHFGSMRGKERELIVLRSENGETWKEHQFD SKNEDLTELLNGMDEELDSPEELGKKRICRITTKDFPQYFAVVSRIK QESNQIGPEGGILSSTTVPLVQASFPEGALTKRIRVGLQAQPVPDEI VKKILGNKATFSPIVTVEPRRRKFHKPITMTIPVPPPSGEGVSNGYK GDTTPNLRLLCSITGGTSPAQWEDITGTTPLTFIKDCVSFTTNVSAR FWLADCHQVLETVGLATQLYRELICVPYMAKFVVFAKMNDPVES SLRCFCMTDDKVDKTLEQQENFEEVARSKDIEVLEGKPIYVDCYG NLAPLTKGGQQLVFNFYSFKENRLPFSIKIRDTSQEPCGRLSFLKEP KTTKGLPQTAVCNLNITLPAHKKIEKTDRRQSFASLALRKRYSYLT EPGMSPQSPCERTDIRMAIVADHLGLSWTELARELNFSVDEINQIR VENPNSLISQSFMLLKKWVTRDGKNATTDALTSVLTKINRIDIVTL LEGPIFDYGNISGTRSFADENNVFHDPVDGYPSLQVELETPTGLHY TPPTPFQQDDYFSDISSIESPLRTPSRLSDGLVPSQGNIEHSADGPPV VTAEDASLEDSKLEDSVPLTEMPEAVDVDESQLENVCLSWQNETS SGNLESCAQARRVTGGLLDRLDDSPDQCRDSITSYLKGEAGKFEA NGSHTEITPEAKTKSYFPESQNDVGKQSTKETLKPKIHGSGHVEEP ASPLAAYQKSLEETSKLIIEETKPCVPVSMKKMSRTSPADGKPRLSL HEEEGSSGSEQKQGEGFKVKTKKEIRHVEKKSHS Ankyrin-3 XFLVSFMVDARGGSMRGSRHHGMRHIPPRKCTAPTRITCRLVKRH Variant 5 KLANPPPMVEGEGLASRLVEMGPAGAQFLGPVIVEIPHFGSMRGK SEQ ID NO: 88 ERELIVLRSENGETWKEHQFDSKNEDLTELLNGMDEELDSPEELGK KRICRITTKDFPQYFAVVSRIKQESNQIGPEGGILSSTTVPLVQASFPE GALTKRIRVGLQAQPVPDEIVKKILGNKATFSPIVTVEPRRRKFHKP ITMTIPVPPPSGEGVSNGYKGDTTPNLRLLCSITGGTSPAQWEDITG TTPLTFIKDCVSFTINVSARFWLADCHQVLETVGLATQLYRELICV PYMAKFVVFAKMNDPVESSLRCFCMTDDKVDKTLEQQENFEEVA RSKDIEVLEGKPIYVDCYGNLAPLTKGGQQLVFNFYSFKENRLPFSI KIRDTSQEPCGRLSFLKEPKTTKGLPQTAVCNLNITLPAHKKIEKTD RRQSFASLALRKRYSYLTEPGMKTVERSTGATRSLPTTYSYKPFFS TRPYQSWTTAPITVPGPAKSGFTSLSSSSSNTPSASPLKSIWSVSTPS PIKSTLGASTTSSVKSISDVASPIRSFRTMSSPIKTVVSQSPYNIQVSS GTLARAPAVTEATPLKGLASNSTFSSRTSPVTTAGSLLERSSITMTP PASPKSNINMYSSSLPFKSIITSAAPLISSPLKSVVSPVKSAVDVISSA KITMASSLSSPVKQMPGHAEVALVNGSISPLKYPSSSTLINGCKATA TLQEKISSATNSVSSVVSAATDTVEKVFSTTTAMPFSPLRSYVSAAP SAFQSLRTPSASALYTSLGSSISATTSSVTSSITIVPVYSVVNVLPEPA LKKLPDSNSFTKSAAALLSPIKTLTTETHPQPHFSRTSSPVKSSLFLA PSALKLSTPSSLSSSQEILKDVAEMKEDLMRMTAILQTDVPEEKPFQ PELPKEGRIDDEEPFKIVEKVKEDLVKVSEILKKDVCVDNKGSPKSP KSDKGHSPEDDWIEFSSEEIREARQQAAASQSPSLPERVQVKAKAA SEKDYNLTKVIDYLTNDIGSSSLTNLKYKFEDAKKDGEERQKRVL KPAIALQEHKLKMPPASMRTSTSEKELCKMADSFFGTDTILESPDD FSQHDQDKSPLSDSGFETRSEKTPSAPQSAESTGPKPLFHEVPIPPVI TETRTEVVHVIRSYDPSAGDVPQTQPEEPVSPKPSPTFMELEPKPTT SSIKEKVKAFQMKASSEEDDIINTRVLSKGMRVKEETHITTTTRMVY HSPPGGEGASERIEETMSVHDIMKAFQSGRDPSKELAGLFEHKSAV SPDVHKSAAETSAQHAEKDNQMKPKLERIIEVIIIEKGPQSPCERTDI RMAIVADHLGLSWTELARELNFSVDEINQIRVENPNSLISQSFMLL KKWVTRDGKNATTDALTSVLTKINRIDIVTLLEGPIFDYGNISGTRS FADENNVFHDPVDGWQNETSSGNLESCAQARRVTGGLLDRLDDS PDQCRDSITSYLKGEAGKFEANGSHTEITPEAKTKSYFPESQNDVG KQSTKETLKPKIEIGSGHVEEPASPLAAYQKSLEETSKLIIEETKPCV PVSMKKMSRTSPADGKPRLSLHEEEGSSGSEQKQGEGFKVKTKKE IRHVEKKSHS Ankyrin-3 XPVIVEIPHFGSMRGKERELIVLRSENGETWKEHQFDSKNEDLTEL Variant 6 LNGMDEELDSPEELGKKRICRIITKDFPQYFAVVSRIKQESNQIGPE SEQ ID NO: 89 GGILSSTTVPLVQASFPEGALTKRIRVGLQAQPVPDEIVKKILGNKA TFSPIVTVEPRRRKFHKPITMTIPVPPPSGEGVSNGYKGDTTPNLRL LCSITGGTSPAQWEDITGTTPLTFIKDCVSFTINVSARFWLADCHQ VLETVGLATQLYRELICVPYMAKFVVFAKMNDPVESSLRCFCMTD DKVDKTLEQQENFEEVARSKDIEVLEGKPIYVDCYGNLAPLTKGG QQLVFNFYSFKENRLPFSIKIRDTSQEPCGRLSFLKEPKTTKGLPQT AVCNLNITLPAHKKETESDQDDEIEKTDRRQSFASLALRPQSPCERT DIRMAIVADHLGLSWTELARELNFSVDEINQIRVENPNSLISQSFML LKKWVTRDGKNATTDALTSVLTKINRIDIVTLLEGPIFDYGNISGTR SFADENNVFHDPVDGYPSLQVELETPTGLHYTPPTPFQQDDYFSDI SSIESPLRTPSRLSDGLVPSQGNIEHSADGPPVVTAEDASLEDSKLE DSVPLTEMPEAVDVDESQLENVCLSEYPQYLGNLAGSPKDVKPAE PRKLGVSSEQQEKGKSGPDEEMMEEKLKSLFEDIQLEEGVESEEMT EEKVQAILKRVQQAELEMSSITGWQNETSSGNLESCAQARRVTGG LLDRLDDSPDQCRDSITSYLKGEAGKFEANGSHTEITPEAKTKSYFP ESQNDVGKQSTKETLKPKIEIGSGHVEEPASPLAAYQKSLEETSKLII EETKPCVPVSMKKMSRTSPADGKPRLSLHEEEGSSGSEQKDLKDS ESDSSSEEERRVTTRVIRRRLIIKGEEAKNIPGESVTEEQFTDEEGNLI TRKITRKVLRRIVIPQERKRDDVQGEGFKVKTKKEIRHVEKKSHS Ankyrin-3 PKTTKGLPQTAVCNLNITLPAHKKETESDQDDEIEKTDRRQSFASL Variant 7 ALRKRYSYLTEPGMSPQSPCERTDIRMAIVADHLGLSWTELARELN SEQ ID NO: 90 FSVDEINQIRVENPNSLISQSFMLLKKWVTRDGKNATTDALTSVLT KINRIDIVTLLEGPIFDYGNISGTRSFADENNVFHDPVDGYPSLQVE LETPTGLHYTPPTPFQQDDYFSDISSIESPLRTPSRLSDGLVPSQGNIE HSADGPPVVTAEDASLEDSKLEDSVPLTEMPEAVDVDESQLENVC LSWQNETSSGNLESCAQARRVTGGLLDRLDDSPDQCRDSITSYLK GEAGKFEANGSHTEITPEAKTKSYFPESQNDVGKQSTKETLKPKIH GSGHVEEPASPLAAYQKSLEETSKLIIEETKPCVPVSMKKMSRTSPA DGKPRLSLHEEEGSSGSEQKQGEGFKVKTKKEIRHVEKKSHS Ankyrin-3 XLARELNFSVDEINQIRVENPNSLISQSFMLLKKWVTRDGKNATTD Variant 8 ALTSVLTKINRIDIVTLLEGPIFDYGNISGTRSFADENNVFHDPVDG SEQ ID NO: 91 NRI Ankyrin-3 XGPDEDKPPSKSSSSEKTPDKTDQKSGAQFFTLEGRHPDRSVFPDT Variant 9 YFSYKVDEEFATPFKTVATKGLDFDPWSNNRGDDEVFDSKSREDE SEQ ID NO: 92 TKPFGLAVEDRSPATTPDTTPARTPTDESTFTSEPNPFPFHEGKMFE MTRSGAIDMSKRDFVEERLQFFQIGPQSPCERTDIRMAIVADHLGL SWTELARELNFSVDEINQIRVENPNSLISQSFMLLKKWVTRDGKNA TTDALTSVLTKINRIDIVTLLEGPIFDYGNISGTRSFADENNVFHDPV DGWQNETSSGNLESCAQARRVTGGLLDRLDDSPDQCRDSITSYL Ankyrin-3 MAVEEGESFPEQSDANASYLRAARAGHLEKALDYIKNGVDINICN Variant 10 QNGLNALHLASKEGHVEVVSELLQREANVDAATKKGNTALIITAS SEQ ID NO: 93 LAGQAEVVKVLVTNGANVNAQSQNGFTPLYMAAQENHLEVVKF LLDNGASQSLATEDGFTPLAVALQQGHDQVVSLLLENDTKGKVRL PALIIIAARKDDTKAAALLLQNDNNADVESKSGFTPLHAAHYGNI NVATLLLNRAAAVDFTARNDITPLHVASKRGNANMVKLLLDRGA KIDAKTR Ankyrin-3 MAVEEGESFPEQSDANASYLRAARAGHLEKALDYIKNGVDINICN Variant 11 QNGLNALHLASKEGHVEVVSELLQREANVDAATKKGNTALIITAS SEQ ID NO: 94 LAGQAEVVKVLVTNGANVNAQSQNGFTPLYMAAQENHLEVVKF LLDNGASQSLATEDGFTPLAVALQQGHDQVVSLLLENDTKGKVRL PALIIIAARKDDTKAAALLLQNDNNADVESKSGFTPLHAAHYGNI NVATLLLNRAAAVDFTARNDITPLHVASKRGNANMVKLLLDRGA KIDAKTR Ankyrin-3 XTVATKGLDFDPWSNNRGDDEVFDSKSREDETKPFGLAVEDRSPA Variant 12 TTPDTTPARTPTDESTPTSEPNPFPFHEGKMFEMTRSGAIDMSKRDF SEQ ID NO: 95 VEERLQFFQIGPQSPCERTDIRMAIVADHLGLSWTELARELNFSVD EINQIRVENPNSLISQSFMLLKKWVTRDGKNATTDALTSVLTKINRI DIVTLLEGPIFDYGNISGTRSFADENNVFHDPVDGYPSLQVELETPT GLHYTPPTP Ankyrin-3 XWQNETSSGNLESCAQARRVTGGLLDRLDDSPDQCRDSITSYLKG Variant 13 EAGKFEANGSHTEITPEAKTKSYFPESQNDVGKQSTKETLKPKIHG SEQ ID NO: 96 SGHVEEPASPLAAYQKSLEETSKLIIEETKPCVPVSMKKMSRTSPAD GKPRLSLHEEEGSSGSEQKGEGFKVKTKKEIRHVEKKSHS Ankyrin-3 MNVPETMNEVLDMSDDEGNRCTWYKIPKVQEFTVKSEDAMTGD Variant 14 TDKYLGPQDLKELGDDSLPAEGYMGFSLGARSARYFVVAVFHS SEQ ID NO: 97 Ankyrin-3 MTGDTDKYLGPQDLKELGDDSLPAEGYMGFSLGARSASLRSFSSD Variant 15 RSYTLNRSSYARDSMMTEELLVPSKEQHLTFTREFDSDSLRHYSWA SEQ ID NO: 98 ADTLDNVNLVSSPIHSGFLVSFMVDARGGSMRGSRHHGMRIUPPR KCTAPTRITCRLVKRHKLANPPPMVEGEGLASRLVEMGPAGAQFL GPVIVEIPHFGSM Ankyrin-3 SPDQCRDSITSYLKGEAGKFEANGSHTEITPEAKTKSYFPESQNDV Variant 16 GKQSTKETLKPKIHGSGHVEEPASPLAAYQKSLEETSKLIIEETKPC SEQ ID NO: 99 VPVSMKKMSRTSPADGKPRLSLHEEEGSSGSEQKVKSPGAAPTRM TACCYKQGEGFKVKTKKEIRHVEKKSHS Ankyrin-3 XLARELNFSVDEINQIRVENPNSLISQSFMLLKKWVTRDGKNATTD Variant 17 ALTSVLTKINRIDIVTLLEGPIFDYGNISGTRSFADENNVFHDPVDVS SEQ ID NO: 100 PNVLSSIGYPSLQVELETPTGLHYTPPTPFQQDDYFSDISSIESPLRTP SRLSDGLVPSQGNIEHSADGPPVVTAEDASLEDSKLEDSVPLTEMP EAVDVDESQLENVCLSWQNETSSGNLES Ankyrin-3 XEDAMTGDTDKYLGPQDLKELGDDSLPAEGYMGFSLGARSASPKI Variant 18 SLRSFSSDRSYTLNRSSYARDSMMTEELLVPSKEQHLTFTREFDSDS SEQ ID NO: 101 LRHYSWAADTLDNVNLVSSPIHSGYSSPLPQYDSRFLVSFMVDAR GGSMRGSRHHGMRICIPPRKCTAPTRITCRLVKRHKLANPPPMVEG EGLASRLVEMGPAGAQFL Ankyrin-3 XSSPIHSGFLVSFMVDARGGSMRGSRHHGMRICIPPRKCTAPTRITC Variant 19 RLVKRHKLANPPPMVEGEGLASRLVEMGPAGAQFLGKLHLPTNPP SEQ ID NO: 102 PVNEGESLVSRILQLGPQGTKFIGPVIVEIPHFGSMRGKERELIVLRS ENGETWKEHQFDSKNEDLTELLNGMDEELDSPEELGKKRICRIITK DFPQYFAVVS Ankyrin-3 MTGDTDKYLGPQDLKELGDDSLPAEGYMGFSLGARSASLRSFSSD Variant 20 RSYTLNRSSYARDSMMTEELLVPSKEQ SEQ ID NO: 103 Ankyrin-3 XIEKTDRRQSFASLALRKRYSYLTEPGMSPQSPCERTDIRMAIVAD Variant 21 HLGLSWTELARELNFSVDEINQIRVENPNSLISQSFMLLKKWVTRD SEQ ID NO: 104 GKNATTDALTSVLTKINRIDIVTLLEGPIFDYGNISGTRSFADENNV FHDPVDDGPPVVTAEDASLEDSKLEDSVPLTEMPEAVDVDESQLE NYC Ankyrin-3 XSPLAAYQKSLEETSKLIIEETKPCVPVSMKKMSRTSPADGKPRLSL Variant 22 HEEEGSSGSEQKVKSPGAAPTRMTACCYKDLKDSESDSSSEEERR SEQ ID NO: 105 VTTRVIRRRLIIKGEEAKNIPGESVTEEQFTDEEGNLITRKITRKVLR RIVIPQERKRDDVQGEGFKVKTKKEIRHVEKKSHS Ankyrin-3 MTGDTDKYLGPQDLKELGDDSLPAEGYMGFSLGARSASLRSFSSD Variant 23 RSYTLNRSSYARDSMMTEELLVPSKEQHLTFTREFDSDSLRHYSWA SEQ ID NO: 106 ADTLDNVNLVSSPIHSGFLVSFMVDARGGSMRGSRHHGMRIUPPR KCTAPTRITCRLVKRHKLANPP Ankyrin-3 MTGDTDKYLGPQDLKELGDDSLPAEGYMGFSLGARSASHAASTV Variant 24 AKELTDKTGRTNLSHIFQN SEQ ID NO: 107 Rho GTPase-activating protein 32 MKSRPTKQKLKQRGILKERVFGCDLGEHLLNSGFEVPQVLQSCTA Variant 2 FIERYGIVDGIYRLSGVASNIQRLRHEFDSEHVPDLTKEPYVQDIHS SEQ ID NO: 108 VGSLCKLYFRELPNPLLTYQLYEKFSDAVSAATDEERLIKIHDVIQQ LPPPHYRTLEFLMRHLSLLADYCSITNMHAKNLAIVWAPNLLRSK QIESACFSGTAAFMEVRIQSVVVEFILNHVDVLFSGRISMAMQEGA ASLSRPKSLLVSSPSTKLLTLEEAQARTQAQVNSPIVTENKYIEVGE GPAALQGKFHTBEFPLERKRPQNKMKKSPVGSWRSFFNLGKSSSV SKRKLQRNESEPSEMKAMALKGGRAEGTLRSAKSEESLTSLHAVD GDSKLFRPRRPRSSSDALSASFNGEMLGNRCNSYDNLPHDNESEEE GGLLHIPALMSPHSAEDVDLSPPDIGVASLDFDPMSFQCSPPKAESE CLESGASFLDSPGYSKDKPSANKKDAETGSSQCQTPGSTASSEPVS PLQEKLSPFFTLDLSPTEDKSSKPSSFTEKVVYAFSPKIGRKLSKSPS MSISEPISVTLPPRVSEVIGTVSNTTAQNASSSTWDKCVEERDATNR SPTQIVKMKTNETVAQEAYESEVQPLDQVAAEEVELPGKEDQSVS SSQSKAVASGQTQTGAVTHDPPQDSVPVSSVSLIPPPPPPKNVARM LALALAESAQQASTQSLKRPGTSQAGYTNYGDIAVATTEDNLSSS YSAVALDKAYFQTDRPAEQFHLQNNAPGNCDHPLPETTATGDPTH SNTTESGEQHHQVDLTGNQPHQAYLSGDPEKARITSVPLDSEKSDD HVSFPEDQSGKNSMPTVSFLDQDQSPPRFYSGDQPPSYLGASVDKL HHPLEFADKSPTPPNLPSDKIYPPSGSPEENTSTATMTYMTTTPATA QMSTKEASWDVAEQPTTADFAAATLQRTHRTNRPLPPPPSQRSAE QPPVVGQVQAATNIGLNNSHKVQGVVPVPERPPEPRAMDDPASAF ISDSGAAAAQCPMATAVQPGLPEKVRDGARVPLLHLRAESVPAHP CGFPAPLPPTRMMESKMIAAIHSSSADATSSSNYHSFVTASSTSVD DALPLPLPVPQPKHASQKTVYSSFARPDVTTEPFGPDNCLHFNMTP NCQYRPQSVPPHHNKLEQHQVYGARSEPPASMGLRYNTYVAPGR NASGHHSKPCSRVEYVSSLSSSVRNTCYPEDIPPYPTIRRVQSLHAP PSSMIRSVPISRTEVPPDDEPAYCPRPLYQYKPYQSSQARSDYHVTQ LQPYFENGRVHYRYSPYSSSSSSYYSPDGALCDVDAYGTVQLRPL HRLPNRDFAFYNPRLQGKSLYSYAGLAPRPRANVTGYFSPNDIINV VSMPPAADVKHTYTSWDLEDMEKYRMQSIRRESRARQKVKGPV MSQYDNMTPAVQDDLGGIYVIHLRSKSDPGKTGLLSVAEGKESRH AAKAISPEGEDRFYRRHPEAEMDRAHHHGGHGSTQPEKPSLPQKQ SSLRSRKLPDMGCSLPEHRAHQEASHRQFCESKNGPPYPQGAGQL DYGSKGIPDTSEPVSYHNSGVKYAASGQESLRLNHKEVRLSKEME RPWVRQPSAPEKHSRDCYKEEEHLTQSIVPPPKPERSHSLKLHHTQ NVERDPSVLYQYQPHGKRQSSVTVVSQYDNLEDYHSLPQHQRGV FGGGGMGTYVPPGFPHPQSRTYATALGQGAFLPAELSLQHPETQIH AE Rho GTPase-activating protein 32 MKSRPTKQKLKQRGILKERVFGCDLGEHLLNSGFEVPQVLQSCTA Variant 3 FIERYGIVDGIYRLSGVASNIQRLRHEFDSEHVPDLTKEPYVQDIHS SEQ ID NO: 109 VGSLCKLYFRELPNPLLTYQLYEKFSDAVSAATDEERLIKIHDVIQQ LPPPHYRTLEFLMRHLSLLADYCSITNMHAKNLAIVWAPNLLRSK QIESACFSGTAAFMEVRIQSVVVEFILNHVDVLFSGRISMAMQEGA ASLSRPKSLLVSSPSTKLLTLEEAQARTQAQVNSPIVTENKYIEVGE GPAALQGKFHTIIEFPLERKRPQNKMKKSPVGSWRSFFNLGKSSSV SKRKLQRNESEPSEMKAMALKGGRAEGTLRSAKSEESLTSLHAVD GDSKLFRPRRPRSSSDALSASFNGEMLGNRCNSYDNLPHDNESEEE GGLLHIPALMSPHSAEDVDLSPPDIGVASLDFDPMSFQCSPPKAESE CLESGASFLDSPGYSKDKPSANKKDAETGSSQCQTPGSTASSEPVS PLQEKLSPFFTLDLSPTEDKSSKPSSFTEKVVYAFSPKIGRKLSKSPS MSISEPISVTLPPRVSEVIGTVSNTTAQNASSSTWDKCVEERDATNR SPTQIVKMKTNETVAQEAYESEVQPLDQVAAEEVELPGKEDQSVS SSQSKAVASGQTQTGAVTHDPPQDSVPVSSVSLIPPPPPPKNVARM LALALAESAQQASTQSLKRPGTSQAGYTNYGDIAVATTEDNLSSS YSAVALDKAYFQTDRPAEQFHLQNNAPGNCDHPLPETTATGDPTH SNTTESGEQHHQVDLTGNQPHQAYLSGDPEKARITSVPLDSEKSDD HVSFPEDQSGKNSMPTVSFLDQDQSPPRFYSGDQPPSYLGASVDKL HHPLEFADKSPTPPNLPSDKIYPPSGSPEENTSTATMTYMTTTPATA QMSTKEASWDVAEQPTTADFAAATLQRTHRTNRPLPPPPSQRSAE QPPVVGQVQAATNIGLNNSHKVQGVVPVPERPPEPRAMDDPASAF ISDSGAAAAQCPMATAVQPGLPEKVRDGARVPLLHLRAESVPAHP CGFPAPLPPTRMMESKMIAAIHSSSADATSSSNYHSFVTASSTSVD DALPLPLPVPQPKHASQKTVYSSFARPDVTTEPFGPDNCLHFNMTP NCQYRPQSVPPHHNKLEQHQVYGARSEPPASMGLRYNTYVAPGR NASGHHSKPCSRVEYVSSLSSSVRNTCYPEDIPPYPTIRRVQSLHAP PSSMIRSVPISRTEVPPDDEPAYCPRPLYQYKPYQSSQARSDYHVTQ LQPYFENGRVHYRYSPYSSSSSSYYSPDGALCDVDAYGTVQLRPL HRLPNRDFAFYNPRLQGKSLYSYAGLAPRPRANVTGYFSPNDIINV VSMPPAADVKHTYTSWDLEDMEKYRMQSIRRESRARQKVKGPV MSQYDNMTPAVQDDLGGIYVIHLRSKSDPGKTGLLSVAEGKESRH AAKAISPEGEDRFYRRHPEAEMDRAHHHGGHGSTQPEKPSLPQKQ SSLRSRKLPDMGCSLPEHRAHQEASHRQFCESKNGPPYPQGAGQL DYGSKGIPDTSEPVSYHNSGVKYAASGQESLRLNHKEVRLSKEME RPWVRQPSAPEKHSRDCYKEEEHLTQSIVPPPKPERSHSLKLHHTQ NVERDPSVLYQYQPHGKRQSSVTVVSQYDNLEDYHSLPQHQRGV FGGGGMGTYVPPGFPHPQSRTYATALGQGAFLPAELSLQIIPETQM AE Rho GTPase-activating protein 32 MARGADVPEIPGDLTLKTCGSTASMKVKHVKKLPFTKGHFPKMA Variant 4 ECAHFHYENVEFGSIQLSLSEEQNEVMKNGCESKELVYLVQIACQ SEQ ID NO: 110 GKSWIVKRSYEDFRVLDKHLHLCIYDRRFSQLSELPRSDTLKDSPE SVTQMLMAYLSRLSAIAGNKINCGPALTWMEIDNKGNHLLVHEES SINTPAVGAAHVIKRYTARAPDELTLEVGDIVSVIDMPPKVLSTWW RGKHGFQVGLFPGHCVELINQKVPQSVTNSVPKPVSKKHGKLITFL RTFMKSRPTKQKLKQRGILKERVFGCDLGEHLLNSGFEVPQVLQS CTAHERYGIVDGIYRLSGVASNIQRLRHEFDSEHVPDLTKEPYVQD IHSVGSLCKLYFRELPNPLLTYQLYEKFSDAVSAATDEERLIKIHDV IQQLPPPHYRTLEFLMRHLSLLADYCSITNMITAKNLAIVWAPNLLR SKQIESACFSGTAAFMEVRIQSVVVEFILNHVDVLFSGRISMAMQE GAASLSRPKSLLVSSPSTKLLTLEEAQARTQAQVNSPIVTENKYIEV GEGPAALQGKFHTIIEFPLERKRPQNKMKKSPVGSWRSFFNLGKSS SVSKRKLQRNESEPSEMKAMALKGGRAEGTLRSAKSEESLTSLHA VDGDSKLFRPRRPRSSSDALSASFNGEMLGNRCNSYDNLPHDNES EEEGGLLHIPALMSPHSAEDVDLSPPDIGVASLDFDPMSFQCSPPKA ESECLESGASFLDSPGYSKDKPSANKKDAETGSSQCQTPGSTASSE PVSPLQEKLSPFFTLDLSPTEDKSSKPSSFTEKVVYAFSPKIGRKLSK SPSMSISEPISVTLPPRVSEVIGTVSNTTAQNASSSTWDKCVEERDA TNRSPTQIVKMKTNETVAQEAYESEVQPLDQVAAEEVELPGKEDQ SVSSSQSKAVASGQTQTGTVCFPPFFL Rho GTPase-activating protein 32 MKSSVHSEEDDFVPELHRNVIIPRERPDWEETLSAMARGADVPEIP Variant 5 GDLTLKTCGSTASMKVKHVKKSTTPGLMGCDNIHRLPFTKGHFPK SEQ ID NO: 111 MAECAHFHYENVEFGSIQLSLSEEQNEVMKNGCESKELVYLVQIA CQGKSWIVKRSYEDFRVLDKHLHLCIYDRRFSQLSELPRSDTL Cytoskeletal Keratin 78 type II MEGHEASPAQVGQGDRGKVRFLEQQNKVLETKWHLLQQQGLSG Variant 2 SQQGLEPVFEACLDQLRKQLEQLQGERGALDAELKACRDQEEEYK SEQ ID NO: 112 SKYEEEAHRRATLENDFVVLKKDVDGVFLSKMELEGKLEALREYL YFLKHLNEEELGQLQTQASDTSVVLSMDNNRYLDFSSITTEVRARY EEIARSSKAEAEALYQTKYQELQVSAQLHGDRMQETKVQISQLHQ EIQRLQSQTENLKKQNASLQAAITDAEQRGELALKDAQAKVDELE AALRMAKQNLARLLCEYQELTSTKLSLDVEIATYRRLLEGEECRM SGECTSQVTISSVGGSAVMSGGVGGGLGSTCGLGSGKGSPGSCCTS IVTGGSNIILGSGKDPVLDSCSVSGSSAGSSCHTILKKTVESSLKTSIT Y Cytoskeletal Keratin 78 type II XDVEIATYRRLLEGEECSLGGRQRCHVWRSWWRLGEHLWTR Variant 3 SEQ ID NO: 113 Collagen type VI, alpha 3 MRKHRHLPLVAVFCLFLSGFPTTHAQQQQAAQDSADIIFLIDGSNN Variant 2 TGSVNFAVILDFLVNLLEKLPIGTQQIRVGVVQFSDEPRTMFSLDTY SEQ ID NO: 114 STKAQVLGAVKALGFAGGELANIGLALDFVVENHFTRAGGSRVEE GVPQVLVLISAGPSSDEIRYGVVALKQASVFSFGLGAQAASRAELQ HRTDDNLVFTVPEFRSFGDLQEKLLPYIVGVAQRHWLKPPTIVTQ VIEVNKRDIVFLVDGSSALGLANFNAIRDFIAKVIQRLEIGQDLIQV AVAQYADTVRPEFYFNTHPTKREVITAVRKMKPLDGSALYTGSAL DFVRNNLFTSSAGYRAAEGIPKLLVLITGGKSLDEISQPAQELKRSSI MAFAIGNKGADQAELEEIAFDSSLVFIPAEFRAAPLQGMLPGLLAP LRTLSGTPEVHSNKRDIIFLLDGSANVGKTNFPYVRDFVMNLVNSL DIGNDNIRVGLVQFSDTPVTEFSLNTYQTKSDILGHLRQLQLQGGS GLNTGSALSYVYANHFTEAGGSRIREHVPQLLLLLTAGQSEDSYLQ AANALTRAGILTFCVGASQANKAELEQIAFNPSLVYLMDDFSSLPA LPQQLIQPLTTYVSGGVEEVPLAQPESKRDILFLFDGSANLVGQFPV VRDFLYKIIDELNVKPEGTRIAVAQYSDDVKVESRFDEHQSKPEILN LVKRMKIKTGKALNLGYALDYAQRYIFVKSAGSRIEDGVLQFLVL LVAGRSSDRVDGPASNLKQSGVVPFIFQAKNADPAELEQIVLSPAFI LAAESLPKIGDLHPQIVNLLKSVIINGAPAPVSGEKDVVFLLDGSEG VRSGFPLLKEFVQRVVESLDVGQDRVRVAVVQYSDRTRPEFYLNS YMNKQDVVNAVRQLTLLGGPTPNTGAALEFVLRNILVSSAGSRIT EGVPQLLIVLTADRSGDDVRNPSVVVKRGGAVPIGIGIGNADITEM QTISFIPDFAVAIPTFRQLGTVQQVISERVTQLTREELSRLQPVLQPL PSPGVGGKRDVVFLIDGSQSAGPEFQYVRTLIERLVDYLDVGFDTT RVAVIQFSDDPKVEFLLNAHSSKDEVQNAVQRLRPKGGRQINVGN ALEYVSRNIFKRPLGSRIEEGVPQFLVLISSGKSDDEVDDPAVELKQ FGVAPFTIARNADQEELVKISLSPEYVFSVSTFRELPSLEQKLLTPIT TLTSEQIQKLLASTRYPPPAVESDAADIVFLIDSSEGVRPDGFAHIRD FVSRIVRRLNIGPSKVRVGVVQFSNDVFPEFYLKTYRSQAPVLDAI RRLRLRGGSPLNTGKALEFVARNLFVKSAGSRIEDGVPQHLVLVL GGKSQDDVSRFAQVIRSSGIVSLGVGDRNIDRTELQTITNDPRLVFT VREFRELPNIEERIMNSFGPSAATPAPPGVDTPPPSRPEKKKADIVFL LDGSINFRRDSFQEVLRFVSEIVDTVYEDGDSIQVGLVQYNSDPTD EFFLKDFSTKRQIIDAINKVVYKGGRHANTKVGLEHLRVNHFVPEA GSRLDQRVPQIAFVITGGKSVEDAQDVSLALTQRGVKVFAVGVRN IDSEEVGKIASNSATAFRVGNVQELSELSEQVLETLHDAMHETLCP GVTDAAKACNLDVILGFDGSRDQNVFVAQKGFESKVDAILNRISQ MHRVSCSGGRSPTVRVSVVANTPSGPVEAFDFDEYQPEMLEKFRN MRSQUPYVLTEDTLKVYLNKFRQSSPDSVKVVIHFTDGADGDLAD LHRASENLRQEGVRALILVGLERVVNLERLMHLEFGRGFMYDRPL RLNLLDLDYELAEQLDNIAEKACCGVPCKCSGQRGDRGPIGSIGPK GIPGEDGYRGYPGDEGGPGERGPPGVNGTQGFQGCPGQRGVKGSR GFPGEKGEVGEIGLDGLDGEDGDKGLPGSSGEKGNPGRRGDKGPR GEKGERGDVGIRGDPGNPGQDSQERGPKGETGDLGPMGVPGRDG VPGGPGETGKNGGFGRRGPPGAKGNKGGPGQPGFEGEQGTRGAQ GPAGPAGPPGLIGEQGISGPRGSGGAAGAPGERGRTGPLGRKGEPG EPGPKGGIGNRGPRGETGDDGRDGVGSEGRRGKKGERGFPGYPGP KGNPGEPGLNGTTGPKGIRGRRGNSGPPGIVGQKGDPGYPGPAGP KGNRGDSIDQCALIQSIKDKCPCCYGPLECPVFPTELAFALDTSEGV NQDTFGRMRDVVLSIVNDLTIAESNCPRGARVAVVTYNNEVTTEI RFADSKRKSVLLDKIKNLQVALTSKQQSLETAMSFVARNTFKRVR NGFLMRKVAVFFSNTPTRASPQLREAVLKLSDAGITPLFLTRQEDR QLINALQINNTAVGHALVLPAGRDLTDFLENVLTCHVCLDICNIDP SCGFGSWRPSFRDRRAAGSDVDIDMAFILDSAETTTLFQFNEMKK YIAYLVRQLDMSPDPKASQHFARVAVVQHAPSESVDNASMPPVK VEFSLTDYGSKEKLVDFLSRGMTQLQGTRALGSAIEYTIENVFESA PNPRDLKIVVLMLTGEVPEQQLEEAQRVILQAKCKGYFFVVLGIGR KVNIKEVYTFASEPNDVFFKLVDKSTELNEEPLMRFGRLLPSFVSSE NAFYLSPDIRKQCDWFQGDQPTKNLVKFGHKQVNVPNNVTSSPTS NPVTTTKPVTITKPVTITTKPVTITTKPVTIINQPSVKPAAAKPAPA KPVAAKPVATKMATVRPPVAVKPATAAKPVAAKPAAVRPPAAAA AKPVATKPEVPRPQAAKPAATKPATTKPMVKMSREVQVFEITENS AKLHWERAEPPGPYFYDLTVTSAHDQSLVLKQNLTVTDRVIGGLL AGQTYHVAVVCYLRSQVRATYHGSFSTKKSQPPPPQPARSASSSTI NLMVSTEPLALTETDICKLPKDEGTCRDFILKWYYDPNTKSCARF WYGGCGGNENKFGSQKECEKVCAPVLAKPGVISVMGT Collagen type VI, alpha 3 MRKHRHLPLVAVFCLFLSGFPTTHAQQQQAAQDSADIIFLIDGSNN Variant 3 TGSVNFAVILDFLVNLLEKLPIGTQQIRVGVVQFSDEPRTMFSLDTY SEQ ID NO: 115 STKAQVLGAVKALGFAGGELANIGLALDFVVENHFTRAGGSRVEE GVPQVLVLISAGPSSDEIRYGVVALKQASVFSFGLGAQAASRAELQ HRTDDNLVFTVPEFRSFGDLQEKLLPYIVGVAQRHWLKPPTIVTQ VIEVNKRDIVFLVDGSSALGLANFNAIRDFIAKVIQRLEIGQDLIQV AVAQYADTVRPEFYFNTHPTKREVITAVRKMKPLDGSALYTGSAL DFVRNNLFTSSAGYRAAEGIPKLLVLITGGKSLDEISQPAQELKRSSI MAFAIGNKGADQAELEEIAFDSSLVFIPAEFRAAPLQGMLPGLLAP LRTLSGTPEVHSNKRDIIFLLDGSANVGKTNFPYVRDFVMNLVNSL DIGNDNIRVGLVQFSDTPVTEFSLNTYQTKSDILGHLRQLQLQGGS GLNTGSALSYVYANHFTEAGGSRIREHVPQLLLLLTAGQSEDSYLQ AANALTRAGILTFCVGASQANKAELEQIAFNPSLVYLMDDFSSLPA LPQQLIQPLTTYVSGGVEEVPLAQPESKRDILFLFDGSANLVGQFPV VRDFLYKIIDELNVKPEGTRIAVAQYSDDVKVESRFDEHQSKPEILN LVKRMKIKTGKALNLGYALDYAQRYIFVKSAGSRIEDGVLQFLVL LVAGRSSDRVDGPASNLKQSGVVPFIFQAKNADPAELEQIVLSPAFI LAAESLPKIGDLIVQIVNLLKSVIANGAPAPVSGEKDVVFLLDGSEG VRSGFPLLKEFVQRVVESLDVGQDRVRVAVVQYSDRTRPEFYLNS YMNKQDVVNAVRQLTLLGGPTPNTGAALEFVLRNILVSSAGSRIT EGVPQLLIVLTADRSGDDVRNPSVVVKRGGAVPIGIGIGNADITEM QTISFIPDFAVAIPTFRQLGTVQQVISERVTQLTREELSRLQPVLQPL PSPGVGGKRDVVFLIDGSQSAGPEFQYVRTLIERLVDYLDVGFDTT RVAVIQFSDDPKVEFLLNAHSSKDEVQNAVQRLRPKGGRQINVGN ALEYVSRNIFKRPLGSRIEEGVPQFLVLISSGKSDDEVDDPAVELKQ FGVAPFTIARNADQEELVKISLSPEYVFSVSTFRELPSLEQKLLTPIT TLTSEQIQKLLASTRYPPPAVESDAADIVFLIDSSEGVRPDGFAHIRD FVSRIVRRLNIGPSKVRVGVVQFSNDVFPEFYLKTYRSQAPVLDAI RRLRLRGGSPLNTGKALEFVARNLFVKSAGSRIEDGVPQHLVLVL GGKSQDDVSRFAQVIRSSGIVSLGVGDRNIDRTELQTITNDPRLVFT VREFRELPNIEERIMNSFGPSAATPAPPGVDTPPPSRPEKKKADIVFL LDGSINFRRDSFQEVLRFVSEIVDTVYEDGDSIQVGLVQYNSDPTD EPPLKDFSTKRQIIDAINKVVYKGGRHANTKVGLEHLRVNHFVPEA GSRLDQRVPQIAFVITGGKSVEDAQDVSLALTQRGVKVFAVGVRN IDSEEVGKIASNSATAFRVGNVQELSELSEQVLETLHDAMHETLCP GVTDAAKACNLDVILGFDGSRDQNVFVAQKGFESKVDAILNRISQ MHRVSCSGGRSPTVRVSVVANTPSGPVEAFDFDEYQPEMLEKFRN MRSQHPYVLTEDTLKVYLNKFRQSSPDSVKVVIHFTDGADGDLAD LHRASENLRQEGVRALILVGLERVVNLERLMHLEFGRGFMYDRPL RLNLLDLDYELAEQLDNIAEKACCGVPCKCSGQRGDRGPIGSIGPK GIPGEDGYRGYPGDEGGPGERGPPGVNGTQGFQGCPGQRGVKGSR GFPGEKGEVGEIGLDGLDGEDGDKGLPGSSGEKGNPGRRGDKGPR GEKGERGDVGIRGDPGNPGQDSQERGPKGETGDLGPMGVPGRDG VPGGPGETGKNGGFGRRGPPGAKGNKGGPGQPGFEGEQGTRGAQ GPAGPAGPPGLIGEQGISGPRGSGGAAGAPGERGRTGPLGRKGEPG EPGPKGGIGNRGPRGETGDDGRDGVGSEGRRGKKGERGFPGYPGP KGNPGEPGLNGTTGPKGIRGRRGNSGPPGIVGQKGDPGYPGPAGP KGNRGDSIDQCALIQSIKDKCPCCYGPLECPVFPTELAFALDTSEGV NQDTFGRMRDVVLSIVNDLTIAESNCPRGARVAVVTYNNEVTTEI RFADSKRKSVLLDKIKNLQVALTSKQQSLETAMSFVARNTFKRVR NGFLMRKVAVFFSNTPTRASPQLREAVLKLSDAGITPLFLTRQEDR QLINALQINNTAVGHALVLPAGRDLTDFLENVLTCHVCLDICNIDP SCGFGSWRPSFRDRRAAGSDVDIDMAFILDSAETTTLFQFNEMKK YIAYLVRQLDMSPDPKASQHFARVAVVQHAPSESVDNASMPPVK VEFSLTDYGSKEKLVDFLSRGMTQLQGTRALGSAIEYTIENVFESA PNPRDLKIVVLMLTGEVPEQQLEEAQRVILQAKCKGYFFVVLGIGR KVNIKEVYTFASEPNDVFFKLVDKSTELNEEPLMRFGRLLPSFVSSE NAFYLSPDIRKQCDWFQGDQPTKNLVKFGHKQVNVPNNVTSSPTS NPVTTTKPVTITKPVTITTKPVTITTKPVTIINQPSVKPAAAKPAPA KPVAAKPVATKMATVRPPVAVKPATAAKPVAAKPAAVRPPAAAA AKPVATKPEVPRPQAAKPAATKPATTKPMVKMSREVQVFEITENS AKLHWERAEPPGPYFYDLTVTSAHDQSLVLKQNLTVTDRVIGGLL AGQTYHVAVVCYLRSQVRATYHGSFSTKKSQPPPPQPARSASSSTI NLMVSTEPLALTETDICKLPKDEGTCRDFILKWYYDPNTKSCARF WYGGCGGNENKFGSQKECEKVCAPVLAKPGVISVMGT Collagen type VI, alpha 3 MRKHRHLPLVAVFCLFLSGFPTTHAQQQQAVIEVNKRDIVFLVDG Variant 4 SSALGLANFNAIRDFIAKVIQRLEIGQDLIQVAVAQYADTVRPEFYF SEQ ID NO: 116 NTHPTKREVITAVRKMKPLDGSALYTGSALDFVRNNLFTSSAGYR AAEGIPKLLVLITGGKSLDEISQPAQELKRSSIMAFAIGNKGADQAE LEEIAFDSSLVFIPAEFRAAPLQGMLPGLLAPLRTLSGTPEESKRDIL FLFDGSANLVGQFPVVRDFLYKDDELNVKPEGTRIAVAQYSDDVK VESRFDEHQSKPEILNLVKRMKIKTGKALNLGYALDYAQRYIFVKS AGSRIEDGVLQFLVLLVAGRSSDRVDGPASNLKQSGVVPFIFQAKN ADPAELEQIVLSPAHLAAESLPKIGDLIVQIVNLLKSVIANGAPAPV SGEKDVVFLLDGSEGVRSGFPLLKEFVQRVVESLDVGQDRVRVAV VQYSDRTRPEFYLNSYMNKQDVVNAVRQLTLLGGPTPNTGAALE FVLRNILVSSAGSRITEGVPQLLIVLTADRSGDDVRNPSVVVKRGG AVPIGIGIGNADITEMQTISFIPDFAVAIPTFRQLGTVQQVISERVTQL TREELSRLQPVLQPLPSPGVGGKRDVVFLIDGSQSAGPEFQYVRTLI ERLVDYLDVGFDTTRVAVIQFSDDPKVEFLLNAHSSKDEVQNAVQ RLRPKGGRQINVGNALEYVSRNIFKRPLGSRIEEGVPQFLVLISSGK SDDEVDDPAVELKQFGVAPFTIARNADQEELVKISLSPEYVFSVSTF RELPSLEQKLLTPITTLTSEQIQKLLASTRYPPPAVESDAADIVFLIDS SEGVRPDGFAHIRDFVSRIVRRLNIGPSKVRVGVVQFSNDVFPEFYL KTYRSQAPVLDAIRRLRLRGGSPLNTGKALEFVARNLFVKSAGSRI EDGVPQHLVLVLGGKSQDDVSRFAQVIRSSGIVSLGVGDRNIDRTE LQTITNDPRLVFTVREFRELPNIEERIMNSFGPSAATPAPPGVDTPPP SRPEKKKADIVFLLDGSINFRRDSFQEVLRFVSEIVDTVYEDGDSIQ VGLVQYNSDPTDEFFLKDFSTKRQIIDAINKVVYKGGRHANTKVG LEHLRVNHFVPEAGSRLDQRVPQIAFVITGGKSVEDAQDVSLALTQ RGVKVFAVGVRNIDSEEVGKIASNSATAFRVGNVQELSELSEQVLE TLHDAMHETLCPGVTDAAKACNLDVILGFDGSRDQNVFVAQKGF ESKVDAILNRISQMHRVSCSGGRSPTVRVSVVANTPSGPVEAFDFD EYQPEMLEKFRNMRSQHPYVLTEDTLKVYLNKFRQSSPDSVKVVI HFTDGADGDLADLHRASENLRQEGVRALILVGLERVVNLERLMH LEFGRGFMYDRPLRLNLLDLDYELAEQLDNIAEKACCGVPCKCSG QRGDRGPIGSIGPKGIPGEDGYRGYPGDEGGPGERGPPGVNGTQGF QGCPGQRGVKGSRGFPGEKGEVGEIGLDGLDGEDGDKGLPGSSGE KGNPGRRGDKGPRGEKGERGDVGIRGDPGNPGQDSQERGPKGET GDLGPMGVPGRDGVPGGPGETGKNGGFGRRGPPGAKGNKGGPG QPGFEGEQGTRGAQGPAGPAGPPGLIGEQGISGPRGSGGAAGAPGE RGRTGPLGRKGEPGEPGPKGGIGNRGPRGETGDDGRDGVGSEGRR GKKGERGFPGYPGPKGNPGEPGLNGTTGPKGIRGRRGNSGPPGIVG QKGDPGYPGPAGPKGNRGDSIDQCALIQSIKDKCPCCYGPLECPVF PTELAFALDTSEGVNQDTFGRMRDVVLSIVNDLTIAESNCPRGARV AVVTYNNEVTTEIRFADSKRKSVLLDKIKNLQVALTSKQQSLETA MSFVARNTFKRVRNGFLMRKVAVFFSNTPTRASPQLREAVLKLSD AGITPLFLTRQEDRQLINALQINNTAVGHALVLPAGRDLTDFLENV LTCHVCLDICNIDPSCGFGSWRPSFRDRRAAGSDVDIDMAFILDSA ETTTLFQFNEMKKYIAYLVRQLDMSPDPKASQHFARVAVVQHAPS ESVDNASMPPVKVEFSLTDYGSKEKLVDFLSRGMTQLQGTRALGS AIEYTIENVFESAPNPRDLKIVVLMLTGEVPEQQLEEAQRVILQAKC KGYFFVVLGIGRKVNIKEVYTFASEPNDVFFKLVDKSTELNEEPLM RFGRLLPSFVSSENAFYLSPDIRKQCDWFQGDQPTKNLVKFGHKQ VNVPNNVTSSPTSNPVTTTKPVITTKPVTITTKPVTITTKPVTIINQ PSVKPAAAKPAPAKPVAAKPVATKMATVRPPVAVKPATAAKPVA AKPAAVRPPAAAAAKPVATKPEVPRPQAAKPAATKPATTKPMVK MSREVQVFEITENSAKLHWERAEPPGPYFYDLTVTSAHDQSLVLK QNLTVTDRVIGGLLAGQTYHVAVVCYLRSQVRATYHGSFSTKKSQ PPPPQPARSASSSTINLMVSTEPLALTETDICKLPKDEGTCRDFILKW YYDPNTKSCARFWYGGCGGNENKFGSQKECEKVCAPVLAKPGVI SVMGT Collagen type VI, alpha 3 MRKHRHLPLVAVFCLFLSGFPTTHAQQQQAAQDSADIIFLIDGSNN Variant 5 TGSVNFAVILDFLVNLLEKLPIGTQQIRVGVVQFSDEPRTMFSLDTY SEQ ID NO: 117 STKAQVLGAVKALGFAGGELANIGLALDFVVENHFTRAGGSRVEE GVPQVLVLISAGPSSDEIRYGVVALKQASVFSFGLGAQAASRAELQ HRTDDNLVFTVPEFRSFGDLQEKLLPYIVGVAQRHWLKPPTIVTQ VIEVNKRDIVFLVDGSSALGLANFNAIRDFIAKVIQRLEIGQDLIQV AVAQYADTVRPEFYFNTHIPTKREVITAVRKMKPLDGSALYTGSAL DFVRNNLFTSSAGYRAAEGIPKLLVLITGGKSLDEISQPAQELKRSSI MAFAIGNKGADQAELEEIAFDSSLVFIPAEFRAAPLQGMLPGLLAP LRTLSGTPEVHSNKRDIIFLLDGSANVGKTNFPYVRDFVMNLVNSL DIGNDNIRVGLVQFSDTPVTEFSLNTYQTKSDILGHLRQLQLQGGS GLNTGSALSYVYANHFTEAGGSRIREHVPQLLLLLTAGQSEDSYLQ AANALTRAGILTFCVGASQANKAELEQIAFNPSLVYLMDDFSSLPA LPQQLIQPLTTYVSGGVEEVPLAQPESKRDILFLFDGSANLVGQFPV VRDFLYKIIDELNVKPEGTRIAVAQYSDDVKVESRFDEHQSKPEILN LVKRMKIKTGKALNLGYALDYAQRYIFVKSAGSRIEDGVLQFLVL LVAGRSSDRVDGPASNLKQSGVVPFIFQAKNADPAELEQIVLSPAFI LAAESLPKIGDLIVQIVNLLKSVIANGAPAPVSGEKDVVFLLDGSEG VRSGFPLLKEFVQRVVESLDVGQDRVRVAVVQYSDRTRPEFYLNS YMNKQDVVNAVRQLTLLGGPTPNTGAALEFVLRNILVSSAGSRIT EGVPQLLIVLTADRSGDDVRNPSVVVKRGGAVPIGIGIGNADITEM QTISFIPDFAVAIPTFRQLGTVQQVISERVTQLTREELSRLQPVLQPL PSPGVGGKRDVVFLIDGSQSAGPEFQYVRTLIERLVDYLDVGFDTT RVAVIQFSDDPKVEFLLNAHSSKDEVQNAVQRLRPKGGRQINVGN ALEYVSRNIFKRPLGSRIEEGVPQFLVLISSGKSDDEVDDPAVELKQ FGVAPFTIARNADQEELVKISLSPEYVFSVSTFRELPSLEQKLLTPIT TLTSEQIQKLLASTRYPPPGEMGASEVLLGAFSI Collagen type VI, alpha 3 MRKHRHLPLVAVFCLFLSGFPTTHAQQQQAVIEVNKRDIVFLVDG Variant 6 SSALGLANFNAIRDFIAKVIQRLEIGQDLIQVAVAQYADTVRPEFYF SEQ ID NO: 118 NTHIPTKREVITAVRKMKPLDGSALYTGSALDFVRNNLFTSSAGYR AAEGIPKLLVLITGGKSLDEISQPAQELKRSSIMAFAIGNKGADQAE LEEIAFDSSLVFIPAEFRAAPLQGMLPGLLAPLRTLSGTPEVHSNKR DIIFLLDGSANVGKTNFPYVRDFVMNLVNSLDIGNDNIRVGLVQFS DTPVTEFSLNTYQTKSDILGHLRQLQLQGGSGLNTGSALSYVYAN HFTEAGGSRIREHVPQLLLLLTAGQSEDSYLQAANALTRAGILTFC VGASQANKAELEQIAFNPSLVYLMDDFSSLPALPQQLIQPLTTYVS GGVEEVPLAQPESKRDILFLFDGSANLVGQFPVVRDFLYKIIDELNV KPEGTRIAVAQYSDDVKVESRFDEHQSKPEILNLVKRMKIKTGKAL NLGYALDYAQRYIFVKSAGSRIEDGVLQFLVLLVAGRSSDRVDGP ASNLKQSGVVPFIFQAKNADPAELEQIVLSPAHLAAESLPKIGDLH PQIVNLLKSVIINGAPAPVSGEKDVVFLLDGSEGVRSGFPLLKEFVQ RVVESLDVGQDRVRVAVVQYSDRTRPEFYLNSYMNKQDVVNAV RQLTLLGGPTPNTGAALEFVLRNILVSSAGSRITEGVPQLLIVLTAD RSGDDVRNPSVVVKRGGAVPIGIGIGNADITEMQTISFIPDFAVAIPT FRQLGTVQQVISERVTQLTREELSRLQPVLQPLPSPGVGGKRDVVF LIDGSQSAGPEFQYVRTLIERLVDYLDVGFDTTRVAVIQFSDDPKV EFLLNAHSSKDEVQNAVQRLRPKGGRQINVGNALEYVSRNIFKRP LGSRIEEGVPQFLVLISSGKSDDEVDDPAVELKQFGVAPFTIARNAD QEELVKISLSPEYVFSVSTFRELPSLEQKLLTPITTLTSEQIQKLLAST RYPPPGEMGASEVLLGAFSI Collagen type VI, alpha 3 MRKHRHLPLVAVFCLFLSGFPTTHAQQQQAVIEVNKRDIVFLVDG Variant 7 SSALGLANFNAIRDFIAKVIQRLEIGQDLIQVAVAQYADTVRPEFYF SEQ ID NO: 119 NTHPTKREVITAVRKMKPLDGSALYTGSALDFVRNNLFTSSAGYR AAEGIPKLLVLITGGKSLDEISQPAQELKRSSIMAFAIGNKGADQAE LEEIAFDSSLVFIPAEFRAAPLQGMLPGLLAPLRTLSGTPEESKRDIL FLFDGSANLVGQFPVVRDFLYKIIDELNVKPEGTRIAVAQYSDDVK VESRFDEHQSKPEILNLVKRMKIKTGKALNLGYALDYAQRYIFVKS AGSRIEDGVLQFLVLLVAGRSSDRVDGPASNLKQSGVVPFIFQAKN ADPAELEQIVLSPAHLAAESLPKIGDLHPQIVNLLKSVIANGAPAPV SGEKDVVFLLDGSEGVRSGFPLLKEFVQRVVESLDVGQDRVRVAV VQYSDRTRPEFYLNSYMNKQDVVNAVRQLTLLGGPTPNTGAALE FVLRNILVSSAGSRITEGVPQLLIVLTADRSGDDVRNPSVVVKRGG AVPIGIGIGNADITEMQTISFIPDFAVAIPTFRQLGTVQQVISERVTQL TREELSRLQPVLQPLPSPGVGGKRDVVFLIDGSQSAGPEFQYVRTLI ERLVDYLDVGFDTTRVAVIQFSDDPKVEFLLNAHSSKDEVQNAVQ RLRPKGGRQINVGNALEYVSRNIFKRPLGSRIEEGVPQFLVLISSGK SDDEVDDPAVELKQFGVAPFTIARNADQEELVKISLSPEYVFSVSTF RELPSLEQKLLTPITTLTSEQIQKLLASTRYPPPAVESDAADIVFLIDS SEGVRPDGFAHIRDFVSRIVRRLNIGPSKVRVGVVQFSNDVFPEFYL KTYRSQAPVLDAIRRLRLRGGSPLNTGKALEFVARNLFVKSAGSRI EDGVPQHLVLVLGGKSQDDVSRFAQVIRSSGIVSLGVGDRNIDRTE LQTITNDPRLVFTVREFRELPNIEERIMNSFGPSAATPAPPGVDTPPP SRPEKKKADIVFLLDGSINFRRDSFQEVLRFVSEIVDTVYEDGDSIQ VGLVQYNSDPTDEFFLKDFSTKRQIIDAINKVVYKGGRHANTKVG LEHLRVNHFVPEAGSRLDQRVPQIAFVITGGKSVEDAQDVSLALTQ RGVKVFAVGVRNIDSEEVGKIASNSATAFRVGNVQELSELSEQVLE TLHDAMHETLCPGVTDAAKACNLDVILGFDGSRDQNVFVAQKGF ESKVDAILNRISQMHRVSCSGGRSPTVRVSVVANTPSGPVEAFDFD EYQPEMLEKFRNMRSQHPYVLTEDTLKVYLNKFRQSSPDSVKVVI HFTDGADGDLADLHRASENLRQEGVRALILVGLERVVNLERLMH LEFGRGFMYDRPLRLNLLDLDYELAEQLDNIAEKACCGVPCKCSG QRGDRGPIGSIGPKGIPGEDGYRGYPGDEGGPGERGPPGVNGTQGF QGCPGQRGVKGSRGFPGEKGEVGEIGLDGLDGEDGDKGLPGSSGE KGNPGRRGDKGPRGEKGERGDVGIRGDPGNPGQDSQERGPKGET GDLGPMGVPGRDGVPGGPGETGKNGGFGRRGPPGAKGNKGGPG QPGFEGEQGTRGAQGPAGPAGPPGLIGEQGISGPRGSGGAAGAPGE RGRTGPLGRKGEPGEPGPKGGIGNRGPRGETGDDGRDGVGSEGRR GKKGERGFPGYPGPKGNPGEPGLNGTTGPKGIRGRRGNSGPPGIVG QKGDPGYPGPAGPKGNRGDSIDQCALIQSIKDKCPFHGPLECPVFP TELAFALDTSEGVNQDTFGRMRDVVLSIVNDLTIAESNCPRGARV AVVTYNNEVTTEIRFADSKRKSVLLDKIKNLQVALTSKQQSLETA MSFVARNTFKRVRNGFLMRKVAVFFSNTPTRASPQLREAVLKLSD AGITPLFLTRQEDRQLINALQINNTAVGHALVLPAGRDLTDFLENV LTCHVCLDICNIDPSCGFGSWRPSFRDRRAAGSDVDIDMAFILDSA ETTTLFQFNEMKKYIAYLVRQLDMSPDPKASQHFARVAVVQHAPS ESVDNASMPPVKVEFSLTDYGSKEKLVDFLSRGMTQLQGTRALGS AIEYTIENVFESAPNPRDLKIVVLMLTGEVPEQQLEEAQRVILQAKC KGYFFVVLGIGRKVNIKEVYTFASEPNDVFFKLVDKSTELNEEPLM RFGRLLPSFVSSENAFYLSPDIRKQCDWFQGDQPTKNLVKFGHKQ VNVPNNVTSSPTSNPVTTTKPVITTKPVTITTKPVTITTKPVTIINQ PSVKPAAAKPAPAKPVAAKPVATKMATVRPPVAVKPATAAKPVA AKPAAVRPPAAAAAKPVATKPEVPRPQAAKPAATKPATTKPMVK MSREVQVFEITENSAKLHWERAEPPGPYFYDLTVTSAHDQSLVLK QNLTVTDRVIGGLLAGQTYHVAVVCYLRSQVRATYHGSFSTKKSQ PPPPQPARSASSSTINLMVSTEPLALTETDICKLPKDEGTCRDFILKW YYDPNTKSCARFWYGGCGGNENKFGSQKECEKVCAPVLAKPGVI SVMGT Collagen type VI, alpha 3 MRKHRHLPLVAVFCLFLSGFPTTHAQQQQADVKNGAAADIIFLVD Variant 8 SSWTIGEEHFQLVREFLYDVVKSLAVGENDFHFALVQFNGNPHTE SEQ ID NO: 120 FLLNTYRTKQEVLSHISNMSYIGGTNQTGKGLEYIMQSHLTKAAGS RAGDGVPQVIVVLTDGHSKDGLALPSAELKSADVNVFAIGVEDAD EGALKEIASEPLNMHMFNLENFTSLHDIVGNLVSCVHSSVSPERAG DTETLKDITAQDSADIIFLIDGSNNTGSVNFAVILDFLVNLLEKLPIG TQQIRVGVVQFSDEPRTMFSLDTYSTKAQVLGAVKALGFAGGELA NIGLALDFVVENHFTRAGGSRVEEGVPQVLVLISAGPSSDEIRYGV VALKQASVFSFGLGAQAASRAELQHRTDDNLVFTVPEFRSFGDLQ EKLLPYIVGVAQRHWLKPPTIVTQVIEVNKRDIVFLVDGSSALGLA NFNAIRDFIAKVIQRLEIGQDLIQVAVAQYADTVRPEFYFNTHIPTKR EVITAVRKMKPLDGSALYTGSALDFVRNNLFTSSAGYRAAEGIPKL LVLITGGKSLDEISQPAQELKRSSIMAFAIGNKGADQAELEEIAFDS SLVFIPAEFRAAPLQGMLPGLLAPLRTLSGTPEESKRDILFLFDGSA NLVGQFPVVRDFLYKIIDELNVKPEGTRIAVAQYSDDVKVESRFDE HQSKPEILNLVKRMKI Collagen type VI, alpha 3 PIGTQQIRVGVVQFSDEPRTMFSLDTYSTKAQVLGAVKALGFAGG Variant 9 ELANIGLALDFVVENHFTRAGGSRVEEGVPQVLVLISAGPSSDEIRY SEQ ID NO: 121 GVVALKQASVFSFGLGAQAASRAELQHRTDDNLVFTVPEFRSFG DLQEKLLPYIVGVAQRHWLKPPTIVTQEYGLNENW Proteasome subunit beta type-5 MALASVLERPLPVNQRGFFGLGGRADLLDLGPGSLSDGLSLAAPG Variant 2 WGVPEEPGIEMLHGTTTLAFKFRHGVIVAADSRATAGAYIASQTV SEQ ID NO: 122 KKVIEINPYLLGTMAGGAADCSFWERLLARQCRIYELRNKERISVA AASKLLANMVYQYKGMGLSMGTMICGWDKRGPVSEVLCLKPKS FGMYLFCGCAERIGNMARPLLRGQ Proteasome subunit beta type-5 MAGGAADCSFWERLLARQCRIYELRNKERISVAAASKLLANMVY Variant 3 QYKGMGLSMGTMICGWDKRGPGLYYVDSEGNRISGATFSVGSGS SEQ ID NO: 123 VYAYGVMDRGYSYDLEVEQAYDLARRAIYQATYRDAYSGGAVN LYHVREDGWIRVSSDNVADLHEKYSGSTP Proteasome subunit beta type-5 MALASVLERPLPVNQRGFFGLGGRADLLDLGPGSLSDGLSLAAPG Variant 4 WGVPEEPGIEMLHGTTTLAFKASTTWTVKGTGFQGPPSL SEQ ID NO: 124 Proteasome subunit beta type-5 XGIEMLHGTTTLAFKFRHGVIVAADSRATAGAYIASQTVKKVIEIN Variant 5 PYLLGTMAGGAADCSFWERLLARQCRIYELRNKERISVAAASKLL SEQ ID NO: 125 ANMVYQYKGMGLSMGTMICGWDKRGPG Heterogeneous nuclear MEREKEQFRKLFIGGLSFETTEESLRNYYEQWGKLTDCVVMRDPA ribonucleoproteins A2/B1 SKRSRGFGFVTFSSMAEVDAAMAARPHSIDGRVVEPKRAVAREES Variant 2 GKPGAHVTVKKLFVGGIKEDTEEHHLRDYFEEYGKIDTIEITTDRQS SEQ ID NO: 126 GKKRGFGFVTFDDHDPVDKIVLQKYHTINGIINAEVRKALSRQEM QEVQSSRSGRGGNFGFGDSRGGGGNFGPGPGSNFRGGSDGYGSGR GFGDGYNGYGGGPGGGNFGGSPGYGGGRGGYGGGGPGYGNQGG GYGGGYDNYGGGNYGSGNYNDFGNYNQQPSNYGPMKSGNFGGS RNMGGPYGGGNYGPGGSGGSGGYGGRSRY Heterogeneous nuclear MEREKEQFRKLFIGGLSFETTEESLRNYYEQWGKLTDCVVMRDPA ribonucleoproteins A2/B1 SKRSRGFGFVTFSSMAEVDAAMAARPHSIDGRVVEPKRAVAREES Variant 3 GKPGAHVTVKKLFVGGIKEDTEEHHLRDYFEEYGKIDTIEITTDRQS SEQ ID NO: 127 GKKRGFGFVTFDDHDPVDKIVLQKYHTINGIINAEVRKALSRQEM QEVQSSRSGRGGNFGFGDSRGGGGNFGPGPGSNFRGGSDGYGSGR GFGDGYNGYGGGPGGGNFGGSPGYGGGRGGYGGGGPGYGNQGG GYGGGYDNYGGGNYGSGNYNDFGNYNQQPSNYGPMKSGNFGGS RNMGGPYGGGNYGPGGSGGSGGYGGRSRY Heterogeneous nuclear MEKTLETVPLERKKREKEQFRKLFIGGLSFETTEESLRNYYEQWGK ribonucleoproteins A2/B1 LTDCVVMRDPASKRSRGFGFVTFSSMAEVDAAMAARPHSIDGRV Variant 4 VEPKRAVAREESGKPGAHVTVKKLFVGGIKEDTEEHHLRDYFEEY SEQ ID NO: 128 GKIDTIEITTDRQSGKKRGFGFVTFDDHDPVDKIVLQKYHTINGIINA EVRKALSRQEMQEDLEVAILEVAPVMEEEEEDMVVEDLDMATRV GATEVVMTTMEEEIMEVEITMILEITTSNLLTTVQ Beta enolase MAMQKIFAREILDSRGNPTVEVDLHTAKGRFRAAVPSGASTGIYE Variant 2 ALELRDGDKGRYLGKGVLKAVENINNTLGPALLQKKLSVVDQEK SEQ ID NO: 129 VDKFMIELDGTENKSKFGANAILGVSLAVCKAGAAEKGVPLYRIII ADLAGNPDLILPVPAFNVINGGSHAGNKLAMQEFMILPVGASSFKE AMRIGAEVYHHLKGVIKAKYGKDATNVGDEGGFAPNILENNEAL ELLKTAIQAAGYPDKVVIGMDVAASEFYRNGKYDLDFKSPDDPAR HITGEKLGELYKSFIKNYPVVSIEDPFDQDDWATWTSFLSGVNIQIV GDDLTVTNPKRIAQAVEKKACNCLLLKVNQIGSVTESIQACKLAQS NGWGVMVSHRSGETEDTFIADLVVGLCTGQIKTGAPCRSERLAKY NQLMRIEEALGDKAIFAGRKFRNPKAK Beta enolase MAMQKIFAREILDSRGNPTVEVDLHTAKGRFRAAVPSGASTGIYE Variant 3 ALELRDGDKGRYLGKGVLKAVENINNTLGPALLQKKLSVVDQEK SEQ ID NO: 130 VDKFMIELDGTENKSKFGANAILGVSLAVCKAGAAEKGVPLYRIII ADLAGNPDLILPVPAFNVINGGSHAGNKLAMQEFMILPVGASSFKE AMRIGAEVYHHLKGVIKAKYGKDATNVGDEGGFAPNILENNEAL ELLKTAIQAAGYPDKVVIGMDVAASEFYRNGKYDLDFKSPDDPAR HITGEKLGELYKSFIKNYPVVSIEDPFDQDDWATWTSFLSGVNIQIV GDDLTVTNPKRIAQAVEKKACNCLLLKVNQIGSVTESIQACKLAQS NGWGVMVSHRSGETEDTFIADLVVGLCTGQIKTGAPCRSERLAKY NQLMRIEEALGDKAIFAGRKFRNPKAK Beta enolase MAMQKIFAREILDSRGNPTVEVDLHTAKGRFRAAVPSGASTGIYE Variant 4 ALELRDGDKGRYLGKAKFGANAILGVSLAVCKAGAAEKGVPLYR SEQ ID NO: 131 HIADLAGNPDLILPVPAPNVINGGSHAGNKLAMQEFMILPVGASSF KEAMRIGAEVYHHLKGVIKAKYGKDATNVGDEGGFAPNILENNE ALELLKTAIQAAGYPDKVVIGMDVAASEFYRNGKYDLDFKSPDDP ARHITGEKLGELYKSFIKNYPVVSIEDPFDQDDWATWTSFLSGVNI QIVGDDLTVTNPKRIAQAVEKKACNCLLLKVNQIGSVTESIQACKL AQSNGWGVMVSHRSGETEDTFIADLVVGLCTGQIKTGAPCRSERL AKYNQLMRIEEALGDKAIFAGRKFRNPKAK Beta enolase MAMQKIFAREILDSRGNPTVEVDLHTAKGRFRAAVPSGASTGIYE Variant 5 ALELRDGDKGRYLGKGVLKAVENINNTLGPALLQKKLSVVDQEK SEQ ID NO: 132 VDKFMTELDGTENKSKFGANAILGVSLAVCKAGAAEKGVPLYRHI ADLAGNPDLILPVPAPNVINGGSHAGNKLAMQEFMILPVGASSFKE AMRIGAEVYHELKGVIKAKYGKDATNVGDEGG Beta enolase MAMQKIFAREILDSRGNPTVEVDLHTAKGRFRAAVPSGASTGIYE Variant 6 ALELRDGDKGRYLGKGVLKAVENINNTLGPALLQKKLSVVDQEK SEQ ID NO: 133 VDKFMTELDGTENKSKFGANAILGVSLAVCKAGAAEKGVPLYRHI ADLAGNPDLILPVPAPNVINGGSHAGNKLAMQEFMILPVGASSFKE AMRIGAEVYHELKGVI Beta enolase MAMQKIFAREILDSRGNPTVEVDLHTAKGRFRAAVPSGASTGIYE Variant 7 ALELRDGDKGRYLGKGVLKAVENINNTLGPALLQKKLSVVDQEK SEQ ID NO: 134 VDKFMTELDGTENKSKFGANAILGVSLAVCKAGAAEKGVPLYRHI ADLAGNPDLILPVP Beta enolase MAMQKIFAREILDSRGNPTVEVDLHTAKGRFRAAVPSGASTGIYE Variant 8 ALELRDGDKGRYLGKGVLKAVENINNTLGPALLQKKLSVVDQEK SEQ ID NO: 135 VDKFMTELDGTENKSKFGANAILGVSLAVCKAGAAEKGVPLYRHI ADLAGNPDLILPVP Beta enolase MAMQKIFAREILDSRGNPTVEVDLHTAKGRFRAAVPSGASTGIYE Variant 9 ALELRDGDKGRYLGKGVLKAVENINNTLGPALLQKKLSVVDQEK SEQ ID NO: 136 VDKFMTELDGTENKSKFGANAILGVSLAVCKAGAAEKGVPLYRHI ADLAGNPDLILPVPAFNVIN Beta enolase MAMQKIFAREILDSRGNPTVEVDLHTAK Variant 10 SEQ ID NO: 137 Glutathione 5-transferase P MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGS Variant 2 LKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAA SEQ ID NO: 138 LVDMVNDGVEDLRCKYISLIYTNYISFADYNLLDLLLIHEVLAPGC LDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ Glutathione 5-transferase P EAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQVSIWPHAVP Variant 3 SSPPSASRWTQVSPSLTTTCWTCC SEQ ID NO: 139 Glutathione 5-transferase Mu 3 MSCESSMVLGYWDIRGLAHAIRLLLEFTDTSYEEKRYTCGEAPDY Variant 2 DRSQWLDVKFKLDLDFPNLPYLLDGKNKITQSNAILRYIARKIINM SEQ ID NO: 140 CGETEEEKIRVDBENQVMDFRTQLIRLCYSSDHEKLKPQYLEELPG QLKQFSMFLGKFSWFAGEKLTFVDFLTYD Glutathione 5-transferase Mu 3 MSCESSMVLGYWDIRGLAHAIRLLLEFTDTSYEEKRYTCGEAPDY Variant 3 DRSQWLDVKFKLDLDFPNLPYLLDGKNKITQSNAILRYIARKIINM SEQ ID NO: 141 CGETEEEKIRVDIIENQVMDFRTQLIRLCYSSDHEKLKPQYLEELPG QLKQFSMFLGKFSWFAGEKLTFVDFLTYDILDQNRIFDPKCLDEFP NLKAFMCRFGDVLHFLYKTLTAPLGPADP Rho 23 GTPase-activating protein MNGVAFCLVGIPPRPEPRPPQLPLGPRDGCSPRRPFPWQGPRTLLL Variant 2 YKSPQDGFGFTLRHFIVYPPESAVHCSLKEEENGGRGGGPSPRYRL SEQ ID NO: 142 EPMDTIFVKNVKEDGPAHRAGLRTGDRLVKVNGESVIGKTYSQVI ALIQNSDDTLELSIMPKDEDILQLAYSQDAYLKGNEPYSGEARSIPE PPPICYPRKTYAPPARASTRATMVPEPTSALPSDPRSPAAWSDPGLR VPPAARAHLDNSSLGMSQPRPSPGAFPHLSSEPRTPRAFPEPGSRVP PSRLECQQALSHWLSNQVPRRAGERRCPAMAPRARSASQDRLEEV AAPRPWPCSTSQDALSQLGQEGWHRARSDDYLSRATRSAEALGPG ALVSPRFERCGWASQRSSARTPACPTRDLPGPQAPPPSGLQGLDDL GYIGYRSYSPSFQRRTGLLHALSFRDSPFGGLPTFNLAQSPASFPPE ASEPPRVVRPEPSTRALEPPAEDRGDEVVLRQKPPTGRKVQLTPAR QMNLGFGDESPEPEASGRGERLGRKVAPLATTEDSLASIPFIDEPTS PSIDLQAKHVPASAVVSSAMNSAPVLGTSPSSPTFTFTLGRHYSQD CSSIKAGRRSSYLLAITTERSKSCDDGLNTFRDEGRVLRRLPNRIPS LRMLRSFFTDGSLDSWGTSEDADAPSKRHSTSDLSDATFSDIRREG WLYYKQILTKKGKKAGSGLRQWKRVYAALRARSLSLSKERREPG PAAAGAAAAGAGEDEAAPVCIGSCLVDISYSETKRRHVFRLTTAD FCEYLFQAEDRDDMLGWIRAIRENSRAEGEDPGCANQALISKKLN DYRKVSHSSGPKADSSPKGSRGLGGLKSEFLKQSAARGLRTQDLP AGSKDDSAAAPKTPWGINIIKKNKKAAPRAFGVRLEECQPATENQ RVPLIVAACCRIVEARGLESTGIYRVPGNNAVVSSLQEQLNRGPGD INLQDERWQDLNVISSLLKSFFRKLPEPLFTDDKYNDFIEANRIEDA RERMRTLRKLIRDLPGHYYETLKFLVGHLKTIADHSEKNKMEPRN LALVFGPTLVRTSEDNMTDMVTHMPDRYKIVETLIQHSDWFFSDE EDKGERTPVGDKEPQAVPNIEYLLPNIGRTVPPGDPGSADLLEI ARHGAP23 MDTIFVKNVKEDGPAHRAGLRTGDRLVKVNGESVIGKTYSQVIAL Variant 3 IQNSDDTLELSIMPKDEDILQLAYSQDAYLKGNEPYSGEARSIPEPP SEQ ID NO: 143 PICYPRKTYA ARHGAP23 XFFSDEEDKGERTPVGDKEPQAVPNIEYLLPNIGRTVPPGDPGSDST Variant 4 TCSSAKSKVRMKAILKA SEQ ID NO: 144 ARHGAP23 XTFSDIRREGWLYYKQILTKKGKAEDRDDMLGWIRAIRENSRAEG Variant 5 EDPGCANQALISKKLNDYRKVSHSSGPKADSSPKGSRGLGGLKSEF SEQ ID NO: 145 LKQSAARGLRTQDLPAGSKDDSAAAPKTPWGINIIKKNKKAAPRA FGVRLEECQPATENQRVPLIVAACCRI ARHGAP23 IRDLPGHYYETLKFLVGHLKTIADHSEKNKMEPRNLALVFGPTLVR Variant 6 TSEDNMTDMVTHMPDRYKIVETLIQHSDWFFSDEEDKGERILPPV SEQ ID NO: 146 VQPSPRVRGPPRRSRTPGRCWRSPSSRPSTASARSGGRRGGWAA Rho 32 METESESSTLGDDSVFWLESEVIIQVTDCEEEEREEKFRKMKSSVH or Rho GTPase-activating protein 32 SEEDDFVPELHRNVIIPRERPDWEETLSAMARGADVPEIPGDLTLK (ARHGAP32) TCGSTASMKVKHVKKLPFTKGHFPKMAECAHFHYENVEFGSIQLS SEQ ID NO: 147 LSEEQNEVMKNGCESKELVYLVQIACQGKSWIVKRSYEDFRVLDK HLHLCIYDRRFSQLSELPRSDTLKDSPESVTQMLMAYLSRLSAIAG NKINCGPALTWMEIDNKGNHLLVHEESSINTPAVGAAHVIKRYTA RAPDELTLEVGDIVSVIDMPPKVLSTWWRGKHGFQVGLFPGHCVE LINQKVPQSVTNSVPKPVSKKHGKLITFLRTFMKSRPTKQKLKQRG ILKERVFGCDLGEHLLNSGFEVPQVLQSCTAHERYGIVDGIYRLSG VASNIQRLRHEFDSEHVPDLTKEPYVQDIHSVGSLCKLYFRELPNPL LTYQLYEKFSDAVSAATDEERLIKIHDVIQQLPPPHYRTLEFLMRHL SLLADYCSITNMHAKNLAIVWAPNLLRSKQIESACFSGTAAFMEVR IQSVVVEFILNHVDVLFSGRISMAMQEGAASLSRPKSLLVSSPSTKL LTLEEAQARTQAQVNSPIVTENKYIEVGEGPAALQGKFHTIIEFPLE RKRPQNKMKKSPVGSWRSFFNLGKSSSVSKRKLQRNESEPSEMKA MALKGGRAEGTLRSAKSEESLTSLHAVDGDSKLFRPRRPRSSSDAL SASFNGEMLGNRCNSYDNLPHDNESEEEGGLLHIPALMSPHSAED VDLSPPDIGVASLDFDPMSFQCSPPKAESECLESGASFLDSPGYSKD KPSANKKDAETGSSQCQTPGSTASSEPVSPLQEKLSPFFTLDLSPTE DKSSKPSSFTEKVVYAFSPKIGRKLSKSPSMSISEPISVTLPPRVSEVI GTVSNTTAQNASSSTWDKCVEERDATNRSPTQIVKMKTNETVAQE AYESEVQPLDQVAAEEVELPGKEDQSVSSSQSKAVASGQTQTGAV THDPPQDSVPVSSVSLIPPPPPPKNVARMLALALAESAQQASTQSL KRPGTSQAGYTNYGDIAVATTEDNLSSSYSAVALDKAYFQTDRPA EQFHLQNNAPGNCDHPLPETTATGDPIESNTTESGEQHHQVDLTG NQPHQAYLSGDPEKARITSVPLDSEKSDDHVSFPEDQSGKNSMPTV SFLDQDQSPPRFYSGDQPPSYLGASVDKLIIHPLEFADKSPTPPNLPS DKIYPPSGSPEENTSTATMTYMTTTPATAQMSTKEASWDVAEQPT TADFAAATLQRTHRTNRPLPPPPSQRSAEQPPVVGQVQAATNIGLN NSHKVQGVVPVPERPPEPRAMDDPASAFISDSGAAAAQCPMATAV QPGLPEKVRDGARVPLLHLRAESVPAIIPCGFPAPLPPTRMMESKM IAAIHSSSADATSSSNYHSFVTASSTSVDDALPLPLPVPQPKHASQK TVYSSFARPDVTTEPFGPDNCLHFNMTPNCQYRPQSVPPIIHNKLE QHQVYGARSEPPASMGLRYNTYVAPGRNASGHHSKPCSRVEYVS SLSSSVRNTCYPEDIPPYPTIRRVQSLHAPPSSMIRSVPISRTEVPPDD EPAYCPRPLYQYKPYQSSQARSDYHVTQLQPYFENGRVHYRYSPY SSSSSSYYSPDGALCDVDAYGTVQLRPLHRLPNRDFAFYNPRLQG KSLYSYAGLAPRPRANVTGYFSPNDIINVVSMPPAADVKHTYTSW DLEDMEKYRMQSIRRESRARQKVKGPVMSQYDNMTPAVQDDLG GIYVIHLRSKSDPGKTGLLSVAEGKESRHAAKAISPEGEDRFYRRH PEAEMDRAHHHGGHGSTQPEKPSLPQKQSSLRSRKLPDMGCSLPE HRAHQEASHRQFCESKNGPPYPQGAGQLDYGSKGIPDTSEPVSYH NSGVKYAASGQESLRLNHKEVRLSKEMERPWVRQPSAPEKHSRD CYKEEEHLTQSIVPPPKPERSHSLKLHHTQNVERDPSVLYQYQPHG KRQSSVTVVSQYDNLEDYHSLPQHQRGVFGGGGMGTYVPPGFPH PQSRTYATALGQGAFLPAELSLQIIPETQIHAE

As used herein the terms “sequence identity” or “sequence homology,” which can be used interchangeably, refer to an exact amino acid-to-amino acid correspondence of two polypeptide sequences. Typically, techniques for determining sequence identity include determining the amino acid sequence of a polypeptide, and comparing these sequences to a second amino acid sequence. Two or more sequences can be compared by determining their “percent identity,” also referred to as “percent homology.” The percent identity to a reference sequence, which may be a sequence within a longer molecule, may be calculated as the number of exact matches between two optimally aligned sequences divided by the length of the reference sequence and multiplied by 100. Percent identity may also be determined, for example, by comparing sequence information using the advanced BLAST computer program, including version 2.2.9, available from the National Institutes of Health. The BLAST program is based on the alignment method of Karlin and Altschul, Proc. Natl. Acad. Sci. USA 87:2264-2268 (1990) and as discussed in Altschul, et al., J. Mol. Biol. 215:403-410 (1990); Karlin and Altschul, Proc. Natl. Acad. Sci. USA 90:5873-5877 (1993); and Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997). Briefly, the BLAST program defines identity as the number of identical aligned symbols (i.e., nucleotides or amino acids), divided by the total number of symbols in the shorter of the two sequences. The program may be used to determine percent identity over the entire length of the sequences being compared. Default parameters are provided to optimize searches with short query sequences, for example, with the blastp program. The program also allows use of an SEG filter to mask-off segments of the query sequences as determined by the SEG program of Wootton and Federhen, Computers and Chemistry 17: 149-163 (1993). Ranges of desired degrees of sequence identity are approximately 80% to 100% and integer values in between. Percent identities between a disclosed sequence and a claimed sequence can be at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more, or complete (100%) sequence identity. In general, an exact match indicates 100% identity over the length of the reference sequence. In some cases, reference to percent sequence identity refers to sequence identity as measured using BLAST (Basic Local Alignment Search Tool). In other cases, ClustalW can be used for multiple sequence alignment. Still other programs for comparing sequences and/or assessing sequence identity include the Needleman-Wunsch algorithm and the Smith-Waterman algorithm (see, e.g., the EMBOSS Water aligner. Optimal alignment may be assessed using any suitable parameters of a chosen algorithm, including default parameters.

In one aspect, the sequence identity is at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (complete) sequence identity (homology). In one aspect, the sequence identity is over a region of at least about 10, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100. 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000 or more amino acids, or the full length of a polypeptide.

As used herein, the term “fragment” refers at least 10 consecutive amino acids of a polypeptide that can be detected using methods known in the art. Fragment may refer to an “active” fragment which is a portion of the polypeptide required for polypeptide function. The fragment can be an “immunogenic” fragment which is a portion of the polypeptide which binds an antibody.

As used herein, a “sample” or “biological sample” is meant to refer to any “biological specimen” collected from a subject, and that is representative of the content or composition of the source of the sample, considered in its entirety. A sample can be collected and processed directly for analysis, or be stored under proper storage conditions to maintain sample quality until analyses are completed. Ideally, a stored sample remains equivalent to a freshly-collected specimen. The source of the sample can be an internal organ, vein, artery, or even a fluid. Non-limiting examples of sample include blood, plasma, urine, saliva, sweat, organ biopsy, cerebrospinal fluid (CSF), tear, vaginal fluid, feces, skin, and hair. In one aspect, the sample is selected from the group consisting of blood, plasma, urine, saliva, sweat, organ biopsy, cerebrospinal fluid (CSF), tear, vaginal fluid, feces, skin, and hair. In certain aspects the sample is a blood sample and the subject is human. Blood samples include whole blood, plasma and serum.

The at least one protein refers to one or more proteins. In an aspect, the at least one polypeptide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more proteins. In one aspect the at least one protein is selected from the group consisting of Farnesyl pyrophosphate synthase, neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat Shock Protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof. In another aspect, the at least one protein is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147 or a fragment thereof.

In one aspect the at least one protein is selected from the group consisting of Farnesyl pyrophosphate synthase, neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat Shock Protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a combination thereof. In another aspect, the at least one protein is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147 or a combination thereof.

The biomarkers of the present invention may be used individually or in combinations for the diagnosis of cervical cancer. Any combination of the biomarkers listed above and in Table 1 can be used for the diagnosis of cervical cancers.

In another aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or fragment thereof and at least one polypeptide selected from neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof. In an additional aspect, the at least one polypeptide comprises a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 and at least one polypeptide selected from a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs:2-20 or a fragment thereof.

In one aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase and neurofibromin I; Farnesyl pyrophosphate synthase and Glyceraldehyde-3 phosphate dehydrogenase; Farnesyl pyrophosphate synthase and Protein 1 containing fibronectin domain type III; Farnesyl pyrophosphate synthase and Eukaryotic initiation factor 4A-I; Farnesyl pyrophosphate synthase and L-lactate dehydrogenase chain B; Farnesyl pyrophosphate synthase and Nuclear heterogeneous Ribonucleoprotein A1; Farnesyl pyrophosphate synthase and polycystic kidney disease protein 1-like 1; Farnesyl pyrophosphate synthase and heat shock protein Cognate 71 kDa; Farnesyl pyrophosphate synthase and Ankyrin-3; Farnesyl pyrophosphate synthase and Rho 23; Farnesyl pyrophosphate synthase and Rho 23-GTPase-activating protein; Farnesyl pyrophosphate synthase and Cytoskeletal Keratin 78 type II; Farnesyl pyrophosphate synthase and collagen chain (VI) Alpha-3; Farnesyl pyrophosphate synthase and Beta subunit of proteasome type-5; Farnesyl pyrophosphate synthase and Heterogeneous nuclear ribonucleoproteins A2/B1; Farnesyl pyrophosphate synthase and Histone H2B type 1-B; Farnesyl pyrophosphate synthase and homolog of DnaJ subfamily C member 13; Faresyl pyrophosphate synthase and Beta enolase; Farnesyl pyrophosphate synthase and Glutathione S-transferase P; Farnesyl pyrophosphate synthase and Glutathione S-transferase Mu 3; or fragments thereof.

In another aspect, the at least one polypeptide comprises SEQ ID NO:1 and SEQ ID NO:2; SEQ ID NO:1 and SEQ ID NO:3; SEQ ID NO:1 and SEQ ID NO:4; SEQ ID NO:1 and SEQ ID NO:5; SEQ ID NO:1 and SEQ ID NO:6; SEQ ID NO:1 and SEQ ID NO:7; SEQ ID NO:1 and SEQ ID NO:8; SEQ ID NO:1 and SEQ ID NO:9; SEQ ID NO:1 and SEQ ID NO:10; SEQ ID NO:1 and SEQ ID NO:11; SEQ ID NO:1 and SEQ ID NO:12; SEQ ID NO:1 and SEQ ID NO:13; SEQ ID NO:1 and SEQ ID NO:14; SEQ ID NO:1 and SEQ ID NO:15; SEQ ID NO:1 and SEQ ID NO:16; SEQ ID NO:1 and SEQ ID NO:17; SEQ ID NO:1 and SEQ ID NO:18; SEQ ID NO:1 and SEQ ID NO:19; SEQ ID NO:1 and SEQ ID NO:20; or fragments thereof.

In one aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof, neurofibromin or a fragment thereof, and at least one additional polypeptide selected from the group consisting of Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat Shock Protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 and a fragment thereof.

In another aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof, Glyceraldehyde-3 phosphate dehydrogenase or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, collagen chain (VI) Alpha-3, Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 and a fragment thereof.

In one aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof, Protein 1 containing fibronectin domain type III or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, Glyceraldehyde-3 phosphate dehydrogenase, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, collagen chain (VI) Alpha-3, Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 and a fragment thereof.

In another aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof, Eukaryotic initiation factor 4A-I or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, collagen chain (VI) Alpha-3, Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, and Glutathione S-transferase Mu 3 and a fragment thereof.

In one aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof, L-lactate dehydrogenase chain B or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, Nuclear heterogeneous Ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, collagen chain (VI) Alpha-3, Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 and a fragment thereof.

In another aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof, Nuclear heterogeneous Ribonucleoprotein A1 or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, polycystic kidney disease protein 1-like 1, heat shock protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, collagen chain (VI) Alpha-3, Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 and a fragment thereof.

In one aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof, polycystic kidney disease protein 1-like 1 or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, heat shock protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, collagen chain (VI) Alpha-3, Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 and a fragment thereof.

In another aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof, heat shock protein Cognate 71 kDa or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, collagen chain (VI) Alpha-3, Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 and a fragment thereof.

In one aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof, Ankyrin-3 or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein Cognate 71 kDa, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, collagen chain (VI) Alpha-3, Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 and a fragment thereof.

In another aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof, Rho 23 GTPase-activating protein or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein Cognate 71 kDa, Ankyrin-3, Cytoskeletal Keratin 78 type II, collagen chain (VI) Alpha-3, Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 and a fragment thereof.

In one aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof, Cytoskeletal Keratin 78 type II or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, collagen chain (VI) Alpha-3, Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 and a fragment thereof.

In another aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof, collagen chain (VI) Alpha-3 or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 and a fragment thereof.

In one aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof, Beta subunit of proteasome type-5 or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, collagen chain (VI) Alpha-3, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 and a fragment thereof.

In another aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof, Heterogeneous nuclear ribonucleoproteins A2/B1 or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type II Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, collagen chain (VI) Alpha-3, Beta subunit of proteasome type-5, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 and a fragment thereof.

In one aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof, Histone H2B type 1-B or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type II Eukaryotic initiation factor 4A-L L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, collagen chain (VI) Alpha-3, Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 and a fragment thereof.

In another aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof, homolog of DnaJ subfamily C member 13 or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, collagen chain (VI) Alpha-3, Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 and a fragment thereof.

In one aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof, Beta enolase or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type II, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, collagen chain (VI) Alpha-3, Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Glutathione S-transferase P, Glutathione S-transferase Mu 3 and a fragment thereof.

In another aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof, Glutathione S-transferase P or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, collagen chain (VI) Alpha-3, Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase Mu 3 and a fragment thereof.

In one aspect, the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof, Glutathione S-transferase Mu 3 or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, collagen chain (VI) Alpha-3, Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P and a fragment thereof.

In one aspect, the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof, and a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:2 or a fragment thereof, and at least one additional polypeptide having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs:3-20 and a fragment thereof.

In another aspect, the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof, and a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:3 or a fragment thereof, and at least one additional polypeptide having at least about 70% sequence identity to a polypeptide an amino acid sequence selected from the group consisting of SEQ ID NOs:2 and 4-20 and a fragment thereof.

In one aspect, the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof, and a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:4 or a fragment thereof, and at least one additional polypeptide having at least about 70% sequence identity to a polypeptide an amino acid sequence selected from the group consisting of SEQ ID NOs:2-3 and 5-20 and a fragment thereof.

In another aspect, the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof, and a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:5 or a fragment thereof, and at least one additional polypeptide having at least about 70% sequence identity to a polypeptide an amino acid sequence selected from the group consisting of SEQ ID NOs:2-4 and 6-20 and a fragment thereof.

In one aspect, the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof, and a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:6 or a fragment thereof, and at least one additional polypeptide having at least about 70% sequence identity to a polypeptide an amino acid sequence selected from the group consisting of SEQ ID NOs:2-5 and 7-20 and a fragment thereof.

In another aspect, the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof, and a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:7 or a fragment thereof, and at least one additional polypeptide having at least about 70% sequence identity to a polypeptide an amino acid sequence selected from the group consisting of SEQ ID NOs:2-6 and 8-20 and a fragment thereof.

In one aspect, the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof, and a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:8 or a fragment thereof, and at least one additional polypeptide having at least about 70% sequence identity to a polypeptide an amino acid sequence selected from the group consisting of SEQ ID NOs:2-7 and 9-20 and a fragment thereof.

In another aspect, the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof, and a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:9 or a fragment thereof, and at least one additional polypeptide having at least about 70% sequence identity to a polypeptide an amino acid sequence selected from the group consisting of SEQ ID NOs:2-8 and 10-20 and a fragment thereof.

In one aspect, the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof, and a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:10 or a fragment thereof, and at least one additional polypeptide having at least about 70% sequence identity to a polypeptide an amino acid sequence selected from the group consisting of SEQ ID NOs:2-9 and 11-20 and a fragment thereof.

In another aspect, the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof, and a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:11 or a fragment thereof, and at least one additional polypeptide having at least about 70% sequence identity to a polypeptide an amino acid sequence selected from the group consisting of SEQ ID NOs:2-10 and 12-20 and a fragment thereof.

In one aspect, the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof, and a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:12 or a fragment thereof, and at least one additional polypeptide having at least about 70% sequence identity to a polypeptide an amino acid sequence selected from the group consisting of SEQ ID NOs:2-11 and 13-20 and a fragment thereof.

In another aspect, the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof, and a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:13 or a fragment thereof, and at least one additional polypeptide having at least about 70% sequence identity to a polypeptide an amino acid sequence selected from the group consisting of SEQ ID NOs:2-12 and 14-20 and a fragment thereof.

In one aspect, the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof, and a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:14 or a fragment thereof, and at least one additional polypeptide having at least about 70% sequence identity to a polypeptide an amino acid sequence selected from the group consisting of SEQ ID NOs:2-13 and 15-20 and a fragment thereof.

In another aspect, the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof, and a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:15 or a fragment thereof, and at least one additional polypeptide having at least about 70% sequence identity to a polypeptide an amino acid sequence selected from the group consisting of SEQ ID NOs:2-14 and 16-20 and a fragment thereof.

In one aspect, the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof, and a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:16 or a fragment thereof, and at least one additional polypeptide having at least about 70% sequence identity to a polypeptide an amino acid sequence selected from the group consisting of SEQ ID NOs:2-15 and 17-20 and a fragment thereof.

In another aspect, the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof, and a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:17 or a fragment thereof, and at least one additional polypeptide having at least about 70% sequence identity to a polypeptide an amino acid sequence selected from the group consisting of SEQ ID NOs:2-16 and 18-20 and a fragment thereof.

In one aspect, the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof, and a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:18 or a fragment thereof, and at least one additional polypeptide having at least about 70% sequence identity to a polypeptide an amino acid sequence selected from the group consisting of SEQ ID NOs:2-17 and 19-20 and a fragment thereof.

In another aspect, the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof, and a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:19 or a fragment thereof, and at least one additional polypeptide having at least about 70% sequence identity to a polypeptide an amino acid sequence selected from the group consisting of SEQ ID NOs:2-18 and 20 and a fragment thereof.

In one aspect, the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof, and a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:20 or a fragment thereof, and at least one additional polypeptide having at least about 70% sequence identity to a polypeptide an amino acid sequence selected from the group consisting of SEQ ID NOs:2-19 and a fragment thereof.

In a further aspect, the detecting is by protein microarray, fluorescence detection, flow cytometry, microfluidic device, lateral flow assay, vertical flow assay or immunoassay. In a specific aspect, the detecting is by lateral flow.

In one aspect, the method also includes administering a treatment to the subject. In an additional aspect, the treatment is surgery, radiation, chemotherapy, targeted therapy and/or immunotherapy.

The term “treatment” is used interchangeably herein with the term “therapeutic method” and refers to both 1) therapeutic treatments or measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic conditions or disorder, and 2) and prophylactic/preventative measures. Those in need of treatment may include individuals already having a particular medical disorder as well as those who may ultimately acquire the disorder (i.e., those needing preventive measures).

The terms “therapeutically effective amount”, “effective dose,” “therapeutically effective dose”, “effective amount,” or the like refer to that amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.

The terms “administration of” and or “administering” should be understood to mean providing a pharmaceutical composition in a therapeutically effective amount to the subject in need of treatment. Administration routes can be enteral, topical or parenteral. As such, administration routes include but are not limited to intracutaneous, subcutaneous, intravenous, intraperitoneal, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, transdermal, transtracheal, subcuticular, intraarticulare, subcapsular, subarachnoid, intraspinal and intrasternal, oral, sublingual buccal, rectal, vaginal, nasal ocular administrations, as well infusion, inhalation, and nebulization. The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration. The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. Suitable unit dosage forms, include, but are not limited to powders, tablets, pills, capsules, lozenges, suppositories, patches, nasal sprays, injectables, implantable sustained-release formulations, lipid complexes, etc.

The biomarkers and polypeptides disclosed herein are useful for the diagnosis of cervical cancer. As used herein, the term “diagnosis” refers to any method of detecting or determining that a subject has cervical cancer.

In another embodiment, the present invention provides a method of diagnosing cervical cancer in a subject by detecting at least one polypeptide in a sample from a subject; wherein the at least one polypeptide is selected from Farnesyl pyrophosphate synthase, neurofibromin 1, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type II Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat shock protein cognate protein 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof, or a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence to a polypeptide having the amino acid sequence selected from SEQ ID NOs: 1-147 or a fragment thereof; and diagnosing cervical cancer based on the detection of at least one polypeptide. In one aspect, the at least one polypeptide is a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs:1-20 or a fragment thereof.

In one aspect, the sample is blood, plasma, urine, saliva, sweat, organ biopsy, cerebrospinal fluid (CSF), tear, vaginal fluid, feces, skin, and hair. In certain aspects, the sample is a blood sample and the subject is human.

In an additional aspect, the at least one polypeptide is selected is Farnesyl pyrophosphate synthase or a fragment thereof and at least one polypeptide selected from neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Cognate thermal shock protein 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof. In a further aspect, the at least one polypeptide is a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof and at least one polypeptide with at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs:2-20 or a fragment there of.

In another aspect, the detecting is by protein microarray, fluorescence detection, flow cytometry, microfluidic device, lateral flow assay, vertical flow assay or immunoassay. In a specific aspect, the detecting is by lateral flow. In one aspect, the method also includes administering a treatment to the subject. In certain aspects, the treatment is surgery, radiation, chemotherapy, targeted therapy and/or immunotherapy.

In some embodiments, diagnosing, predicting, and/or monitoring the status or outcome of a cancer may comprise determining a therapeutic regimen. Determining a therapeutic regimen may comprise administering an anti-cancer therapeutic. Alternatively, determining the treatment for the cancer may comprise modifying a therapeutic regimen. Modifying a therapeutic regimen may comprise increasing, decreasing, or terminating a therapeutic regimen.

Treatment options for cervical cancer include surgery, radiation, chemotherapy, targeted therapy, and immunotherapy.

Surgical Treatment for cervical cancer depends on the type and stage of cervical cancer. For precancerous lesion surgical interventions include ablation and excision surgery. Surgical intervention for advanced cervical cancer include hysterectomy (simple or radical) and Trachelectomy.

Radiation is used to treat cervical cancer and to treat cervical cancer recurrence. There are two types of radiation typically used for treating cervical cancer, external beam radiation and brachytherapy. External beam radiation therapy (EBRT) aims x-rays at the cancer from a machine outside the body. Treatment is much like getting a regular x-ray, but the radiation dose is stronger. When EBRT is used as the main treatment for cervical cancer, it is usually combined with chemotherapy. Brachytherapy, or internal radiation therapy, puts a source of radiation in or near the cancer. Brachytherapy is mainly used in addition to EBRT as a part of the main treatment for cervical cancer.

Chemotherapy is also used to treat cervical cancer, wither alone or in combination with another method. Chemotherapy may include Cisplatin, Carboplatin, Paclitaxel (Taxol), Topotecan, docetaxel (Taxotere), ifosfamide (Ifex), 5-fluorouracil (5-FU), irinotecan (Camptosar), gemcitabine (Gemzar) and mitomycin. Targeted therapy for the treatment of cervical cancer includes Bevacizumab. Immunotherapy for the treatment of cervical cancer includes Pembrolizumab (PD-1 inhibitor).

In an additional embodiment, the present invention provides a method of treating cervical cancer in a subject in need thereof, the method is detecting at least one polypeptide in a sample from a subject; wherein the at least one polypeptide is selected from Farnesyl pyrophosphate synthase, neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof, or a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NOs: 1-147 or a fragment thereof, diagnosing cervical cancer based on the detection of the at least one polypeptide; and administering a treatment to the subject. In one aspect, the sample is a blood sample. In one aspect, the at least one polypeptide is a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs:1-20 or a fragment thereof.

In an additional aspect, the at least one polypeptide is Farnesyl pyrophosphate synthase and at least one polypeptide selected from neurofibromin L Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type II Eukaryotic initiation factor 4A-L L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof. In a further embodiment, the at least one polypeptides is a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof and at least one polypeptide with at least about 70% sequence identity to a polypeptide with an amino acid sequence selected from SEQ ID NOs:2-20 or a fragment thereof.

In another aspect, the detecting is by protein microarray, fluorescence detection, flow cytometry, microfluidic device, lateral flow assay or immunoassay. In a specific aspect, the detecting is by lateral flow assay. In an additional aspect, the treatment is selected from the group consisting of surgery, radiation, chemotherapy, targeted therapy and immunotherapy. In a further aspect, the chemotherapy is Cisplatin, Carboplatin, Paclitaxel, Topotecan, docetaxel, ifosfamide, 5-fluorouracil, irinotecan, gemcitabine or mitomycin. In certain aspects, the targeted therapy is bevacizumab and the immunotherapy is pembrolizumab.

The biomarkers of the present invention can be used to predict response to treatment for cervical cancer.

In a further embodiment, the present invention provides methods of predicting a response to treatment for a subject having cervical cancer by detecting at least one polypeptide in a sample from a subject; wherein the at least one polypeptide is selected from Farnesyl pyrophosphate synthase, neurofibromin L Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type II, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof; or a polypeptide with at least about 70% sequence identity to a polypeptide having amino acid sequence selected from SEQ ID NOs: 1-147 or a fragment thereof; and predicting a response to treatment based on the detection of the at least one polypeptide. In one aspect, the at least one polypeptide is a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs:1-20 or a fragment thereof.

In one aspect, the at least one polypeptide is Farnesyl pyrophosphate synthase or a fragment thereof and at least one polypeptide selected from neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof. In another aspect, the at least one polypeptide is a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof and at least one polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs:2-20 or a fragment thereof.

In an additional aspect, the detecting is by protein microarray, fluorescence detection, flow cytometry, microfluidic device, lateral flow assay, vertical flow or immunoassay. In a further aspect, the detecting is by lateral flow assay. In certain aspects, the treatment is surgery, radiation, chemotherapy, targeted therapy and immunotherapy.

The biomarkers of the present application are useful for determining the stage of cervical cancer. Cervical cancer can be classified on different scales. The Papanicolau system classifies the lesions in degrees of severity, from grade I that corresponds to normal cytology, to grade V that corresponds to invasive squamous cancer of the cervix. The Richart classification system classifies the results of acytology into: Negative, Reactive or not classifiable squamous atypical, HPV infection, Cervical intraepithelial neoplasia (CIN) grades I, II and III, carcinoma in situ invasive squamous cancer of the cervix. Finally, the Bethesda nomenclature classifies the results of a cytology as: Negative, ASCUS-ASCH, low-grade intraepithelial lesions, high-grade intraepithelial lesions and invasive squamous cancer of the cervix.

The FIGO (International Federation of Gynecology Obstetrics) staging system is used most often for cancers of the female reproductive organs, including cervical cancer. For cervical cancer, the clinical stage is used and is based on the results of the doctor's physical exam, biopsies, imaging tests, and a few other tests that are done in some cases, such as cystoscopy and proctoscopy.

TABLE 2 FIGO Stage Stage description I IA The cancer cells have grown from the surface of the cervix into deeper tissues of the cervix. Cancer has not spread to nearby lymph nodes. Cancer has not spread to distant sites. It has not spread to distant sites. IA1 The area of cancer can only be seen with a microscope and is less than 3 mm (about ⅛-inch) deep. It has not spread to nearby lymph nodes. It has not spread to distant sites. IA2 The area of cancer can only be seen with a microscope and is between 3 mm and 5 mm (about ⅕-inch) deep. It not has not spread to nearby lymph nodes. It has not spread to distant sites. IB This includes stage I cancer that has spread deeper than 5 mm (about ⅕ inch) but is still limited to the cervix. It has not spread to nearby lymph nodes. It has not spread to distant sites. IB1 The cancer is deeper than 5 mm (about ⅕-inch) but not more than 2 cm (about ⅘-inch) in size. It has not spread to nearby lymph nodes. It has not spread to distant sites. IB2 The cancer is at least 2 cm in size but not larger than 4 cm. It has not spread to nearby lymph nodes. It has not spread to distant sites. IB3 The cancer is at least 4 cm in size and limited to the cervix. It has not spread to nearby lymph nodes. It has not spread to distant sites. II The cancer has grown beyond the cervix and uterus, but hasn't spread to the walls of the pelvis or the lower part of the vagina. It has not spread to nearby lymph nodes. It has not spread to distant sites. IIA The cancer has grown beyond the cervix and uterus but has not spread into the tissues next to the cervix (called the parametria). It has not spread to nearby lymph nodes. It has not spread to distant sites. IIA1 The cancer is not larger than 4 cm (about 1⅗ inches). It not has not spread to nearby lymph nodes. It has not spread to distant sites. IIA2 The cancer is 4 cm or larger. It has not spread to nearby lymph nodes. It has not spread to distant sites. IIB The cancer has grown beyond the cervix and uterus and has spread into the tissues next to the cervix (the parametria). It has not spread to nearby lymph nodes. It has not spread to distant sites. III The cancer has spread to the lower part of the vagina or the walls of the pelvis. The cancer may be blocking the ureters (tubes that carry urine from the kidneys to the bladder). It might or might not have not spread to nearby lymph nodes. It has not spread to distant sites. IIIA The cancer has spread to the lower part of the vagina but not the walls of the pelvis. It has not spread to nearby lymph nodes. It has not spread to distant sites. IIIB The cancer has grown into the walls of the pelvis and/or is blocking one or both ureters causing kidney problems (called hydronephrosis). It has not spread to nearby lymph nodes. It has not spread to distant sites. IIIC The cancer can be any size. Imaging tests or a biopsy show the cancer has spread to nearby pelvic lymph nodes (IIIC1) or para-aortic lymph nodes (IIIC2). It has not spread to distant sites. IV The cancer has grown into the bladder or rectum or to far away organs like the lungs or bones. IVA The cancer has spread to the bladder or rectum or it is growing out of the pelvis. IVB The cancer has spread to distant organs outside the pelvic area, such as distant lymph nodes, lungs or bones.

In another embodiment, the present invention provides methods for determining the stage of cervical cancer in a subject in need thereof by detecting at least one polypeptide in a sample from the subject; wherein the at least one polypeptide is selected from Farnesyl pyrophosphate synthase, neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1polycystic kidney disease, heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof, or a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs: 1-147 or a fragment thereof; and determining the stage of cervical cancer in the subject based on the detection of the at least one polypeptide. In one aspect, the at least one polypeptide is a polypeptide having the amino acid sequence selected from SEQ ID NOs:1-20 or a fragment thereof.

In one aspect, the at least one polypeptide is Farnesyl pyrophosphate synthase or a fragment thereof and at least one polypeptide selected from neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof. In another aspect, the at least one polypeptide is a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof and at least one polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs:2-20 or a fragment thereof.

In an additional aspect, the detecting is by protein microarray, fluorescence detection, flow cytometry, microfluidic device, lateral flow assay, vertical flow assay or immunoassay. In a specific aspect, the detecting is by lateral flow assay. In a further aspect, the method also includes administering a treatment to the subject. In certain aspects, the treatment is surgery, radiation, chemotherapy, targeted therapy or immunotherapy. In one aspect, the cervical cancer is stage I, stage II, stage III or stage IV.

In one embodiment, the present invention provides a kit with a sample collection unit; a lateral flow device; and instructions for using the lateral flow device.

Sample collection device is any device that can be used to collect a sample. The sample blood, plasma, urine, saliva, sweat, organ biopsy, cerebrospinal fluid (CSF), tear, vaginal fluid, feces, skin, and hair.

A lateral flow device is a simple to use diagnostic device used to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in a sample. The most commonly known type of lateral flow rapid test strip is the pregnancy test.

Typically lateral flow assays use a device comprises several pads (made of a series of capillary beds, capable of transporting a fluid): a sample pad to receive the liquid sample; a conjugate pad, including reactive molecules used to visualize positive control, a positive line and a test line.

For the detection of a target protein, the conjugate pad includes antibodies specific for the target protein conjugated to a detectable tag; a positive line (positive control) is generated comprising fixed anti-anti-target protein antibodies (for example anti IgG antibodies), and a test line was generated comprising fixed anti-target protein antibodies. When the sample pad is contacted with a sample containing the target protein, the target protein reacts with the anti-target protein antibodies conjugated to a detectable tag in the conjugate pad. As the liquid flows to the test and positive lines, the target protein present in the sample, conjugated with the labeled antibodies reacted with the fixed anti-target protein antibodies on the test line, and anti-target protein antibodies conjugated to the detectable tag but not conjugated to the target protein reacts with the fixed anti-Ig antibodies on the positive line. Both reactions generate a positive reading on the test line, and on the positive line.

In one aspect, the lateral flow device detects at least one polypeptide selected from Farnesyl pyrophosphate synthase, neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof; or a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs: 1-147 or a fragment thereof. In one aspect, the at least one polypeptide is a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs:1-20 or a fragment thereof.

In an additional aspect, the at least one polypeptide is Farnesyl pyrophosphate synthase or a fragment thereof and at least one polypeptide selected from neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alph-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof. In a further aspect, the at least one polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof and at least one polypeptide selected from a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NO:2-20 or a fragment thereof.

In another aspect, the lateral flow device detects the at least one polypeptide by an immunoassay. In one aspect, the sample collection unit collects a blood sample.

In an additional embodiment, the present invention provides a use of the detection of at least one polypeptide for the diagnosis of cervical cancer in a subject in need thereof, wherein the at least one polypeptide is selected from Farnesyl pyrophosphate synthase, neurofibromin L Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof; or a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs: 1-147 or a fragment thereof. In one aspect, the at least one polypeptide is a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs:1-20 or a fragment thereof.

In a further aspect, the at least one polypeptide is detected in a sample from the subject and the sample is a blood sample. In another aspect, the at least one polypeptide is Farnesyl pyrophosphate synthase or a fragment thereof and at least one polypeptide selected from neurofibromin L Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type II Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alph-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof. In one aspect, the at least one polypeptide is a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof and at least one polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from SEQ ID NOs:2-20 or a fragment thereof.

In another aspect, the detecting is by protein microarray, fluorescence detection, flow cytometry, microfluidic device, lateral flow assay, vertical flow assay or immunoassay. In certain aspects, the detecting is by lateral flow assay.

The following examples are provided to further illustrate the embodiments of the present invention, but are not intended to limit the scope of the invention. While they are typical of those that might be used, other procedures, methodologies, or techniques known to those skilled in the art may alternatively be used.

EXAMPLES Example 1 Secretome Analysis of Cervical Cancer Cell Lines

In order to identify cervical cancer biomarkers, a secretome analysis of cervical cancer cells was performed using cervical cancer cell line HeLa (cervical adenocarcinoma, positive for HPV18), SiHa cells (grade II, squamous cell cervical carcinoma, positive for HPV16), and C-33A (cervical carcinoma, negative for HPV) and the HaCaT cell line as a negative control. These lines were selected because they represent the most frequent histological types and viral genotypes in cervical intraepithelial lesions and in CC; and were either cultured (in vitro secretome), or inoculated into mice (ex vivo secretome).

HeLa and SIHa cells were cultured in serum-free Advanced RPMI 1640 supplemented with 2 mM L-glutamine and Penicillin-Streptomycin at 1% v/v, at 37° C. and with 5% CO2 until a 70-80% confluence was reached. The cells were washed three times with sterile physiological solution (0.9% NaCl (w/v)). As illustrated in FIG. 2, there was no significant growth differences between the cells at day 6, when the cells reached 70% confluence.

For in vitro secretome analysis, the cells were then incubated in serum-free RPMI 1640 without phenol red (Gibco, Invitrogen) for 20 hours, and the medium collected and centrifuged at 1,500 g for 5 minutes. The supernatant was passed through a 0.22 μm size PVDF membrane (Millex, Millipore) and stored at −70° C. until further use (see FIG. 1).

For the ex vivo secretome analysis, the secreted proteins were collected from tumors collected on female Nu/Nu mice (4-6 weeks) inoculated with 10⁷ HeLa or SiHa cells. After 30, 45 and 50 days after inoculation, the tumors were collected (triplicate) and washed 3 times with 50 mL of physiological solution and then incubated for 20 hours with serum free RMPI medium without phenol red. The medium was removed and centrifuged at 1,500×g for 5 minutes, the supernatant was passed through a 0.22 μm pore size membrane PVDF membrane (Millex, Millipore) and stored at −70° C. until further use (see FIG. 1). The secreted proteins collected in vitro and ex vivo were lyophilized and resuspended in 1 mL of ultrapure water. Protein isolation was performed by phenol extraction.

To identify the proteins secreted by the different cell lines, the proteins were separated by electrophoresis on an SDS-PAGE matrix and stained with bright Coomassie blue (see FIG. 3A). Each lane containing 30 μg protein was cut into 20 lines throughout the column, the proteins contained were extracted and digested with trypsin. The generated peptides were analyzed in a nano LC-MS/MS system (Q-TOF Synapt G2 MS; Waters). The identification of peptides and proteins was performed using the MASCOT search engine through the MASCOT Distiller interface (Matrix Science). The databases consulted were Swiss-Prot and NCBI.

1662 secretome proteins were identified (see FIG. 3B). As illustrated in the Venn diagram of FIG. 3C, showing the intersection between the shared proteins of the CC cell lines and their negative control, 20 proteins were shared in the 3 CC cell lines and absent in the negative control (see Table 3). These proteins were candidates for use in a rapid diagnostic test. In addition to the qualitative study, a quantitative analysis of 200 secreted proteins was performed using the label-free quantification (LFQ) technique. As shown in FIG. 4A, 92 proteins were found over-expressed in the 3 CC cell lines according to their Log 2value (CC cell lines vs. HaCaT). For HeLa: 45 over-expressed proteins, SiHa: 35 over-expressed proteins, C-33A: 12 over-expressed proteins. As shown in FIG. 4B, 6 secreted proteins: Glyceraldehyde-3-phosphate dehydrogenase, cognate heat shock protein 71 kDa, L-lactate dehydrogenase chain B, beta subunit of proteasome type-5 and nuclear ribonucleoproteins heterogeneous A2/B1 were found over expressed in the 3 CC cell lines compared to its negative control. Further, and as shown in FIG. 4C (which represents the Heat map of proteins expressed in cell lines, where the complete linkage hierarchical grouping shows the values in Log 2 (protein expression/HSP71) on a color scale), the hierarchy analysis by cluster in the heat map revealed a similarity in protein expression between the HPV positive cell lines (SiHa and HeLa). These analyzes allowed obtaining a set of common over-expressed proteins for the HPV and CC lines.

TABLE 3 Gene Protein Name NF1 NF1_HUMAN Neurofibromin GAPDH G3P_HUMAN Glyceraldehyde-3 phosphate dehydrogenase FNDC1 FNDC1_HUMAN Protein 1 containing fibronectin domain type III EIF4A1 IF4A1_HUMAN Eukaryotic initiation factor 4A-I LDHB LDHB_HUMAN L-lactate dehydrogenase chain B HNRNPA1 ROA1_HUMAN Nuclear heterogeneous Ribonucleoprotein A1 PKD1L1 PK1L1_HUMAN Polycystic kidney disease protein 1-like 1 FDPS FPPS_HUMAN Farnesyl pyrophosphate synthase HSPA8 HSP7C_HUMAN Heat Shock Protein Cognate 71 kDa ANK3 ANK3_HUMAN Ankirin-3 ARHGAP23 ARHG23_HUMAN Rho 23 GTPase-activating protein KRT78 K2C78_HUMAN Cytoskeletal Keratin 78 type II COL6A3 CO6A3_HUMAN Alpha-3 collagen chain (VI) PSMB5 PSB5_HUMAN Beta subunit of proteasome type-5 HNRNPA2B1 ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 HIST1H2BB H2B1B_HUMAN Histone H2B type 1-B RME8 DNAJC13 homolog of DnaJ subfamily C member 13 ENO3 ENOB_HUMAN Beta enolase GSTP1 GSTP1_HUMAN Glutathione S-transferase P GSTM3 GSTM3_HUMAN Glutathione S-transferase Mu 3

Example 2 Detection of Cervical Tumors

To evaluate if the proteins identified in the in vitro secretome analysis could be used as biomarkers for the detection of cervical tumors, female mice were inoculated with DC cells to develop tumors, and secreted proteins were measured in the serum of the animals (see FIG. 5A).

A cohort of 9mice was generated, with 3different cell lines and their controls established at 3different times of the PT (tumor progression). The mice were inoculated with 10⁷ cells DC tumor cell lines (either HeLa or SiHa cells), and the sera were collected 30, 45and 50 days post inoculation. Sera were subjected to a Western blot with 20 μg protein per sample. The tests were performed in triplicate and were presented as means (± standard deviation). A statistical Student's t-test was performed.

As illustrated in FIG. 5B, illustrating the example of the detection of one of the protein of the secretome identified in Example 1; it was found by Western blot that the farnesyl pyrophosphate synthase protein was detectable in the sera of the mice inoculated with HeLa awl SIHa (sera from uninoculated mice were used as controls). The protein was found expressed in all sera of the tumor-bearing mice, an as detailed in FIG. 5C, the level of expression was found to increase levels over time in the sera of the mice inoculated with SiHa.

The validation of the protein Farnesyl pyrophosphate synthase as a biomarker in sera was further performed in serum obtain from patients with CC:

The serum of 10 patients with CC and 10 negative controls for CC were tested, and the expression of Farnesyl pyrophosphate synthase was assessed by western blot. As illustrated in FIGS. 6A and 6B, all the patients analyzed presented Farnesyl pyrophosphate synthase expression, and no expression of Farnesyl pyrophosphate synthase was found in the sera of the controls. It was also observed that the level of expression was variable among patients (see FIG. 6C). As further illustrated in FIGS. 7A-7C, Ankyrin-3 was also demonstrated as a promising biomarker that can be used to detect cervical cancer in the serum of patient, by presenting with a significantly higher level of expression as compared to the serum of control patients. The proteome analysis of the secretome, identified 20 proteins present in CC cells and absent in negative control; and among the 6 overexpressed proteins Farnesyl pyrophosphate synthase and Ankyrin-3, used an a proof-of-principle were used to demonstrate that its level of expression (i.e., overexpression) could be analyzed in the serum of patient, showing that these proteins may be a useful promising candidate in the identification of this disease.

Example 3 Detection of Pre-Cancerous Cervical Lesions

To evaluate if the proteins identified in the in vitro secretome analysis could be used as biomarkers to detect pre-cancerous cervical lesions, the serum of patient presenting pre-cancerous cervical lesions were assessed for the detection of the biomarkers by western blot.

The serum of patients with pre-neoplasic lesions, with cervical cancer or with no lesions (control) were collected and analyzed for the expression of Ankyrin-3, Rho 23 GTPas-activating protein, Alpha-3 collagen chain (IV), Beta enolase, Farnesyl pyrophosphate synthase, Histone H2B type 1-BB, Heterogeneous nuclear ribonucleoproteins A2/B1, Heat shock protein cognate 71 kDa, Cytoskeletal Keratin 78 type I, Beta subunit of proteasome type-5 and homolog of DnaJ subfamily C member 13.

As illustrated in FIGS. 8A-8C, it was demonstrated that Farnesyl pyrophosphate synthase was detectable in the serum of patient having pre-cancerous cervical lesions L1 and L2, as compared to control sera. Specifically, it was found that Farnesyl pyrophosphate synthase expression was 12-times higher in the serum of patient with pre-cancerous lesions as compared to control (see FIG. 8D), demonstrating that pre-cancerous lesions, as well as cancerous (see example 2) can be detected in the serum of patient, by detecting the expression of Farnesyl pyrophosphate synthase in the serum, which can be used as a biomarker for the detection of precancerous cervical lesions.

As illustrated in FIGS. 9A-9C, it was demonstrated that Ankyrin-3was detectable in the serum of patient having pre-cancerous cervical lesions L1 and L12, as compared to control sera. Specifically, it was found that Ankirin-3 expression was 10-times higher in the serum of patient with pre-cancerous lesions as compared to control (see FIG. 9D), demonstrating that pre-cancerous lesions, as well as cancerous (see example 2) can be detected in the serum of patient, by detecting the expression of Ankyrin-3 in the serum, which can be used as a biomarker for the detection of precancerous cervical lesions.

Similar results were obtained when the quantification of the proteins was intended by ELISA instead of by Western blot.

Example 4 Lateral Flow Assay for the Detection of Cervical Tumor and Precancerous Lesions

For lateral flow assay, strip containing dried spot antibodies for test lines and positive lines were prepared, and samples collected from patients were tested for the detection of Farnesyl pyrophosphate synthase.

Blood samples collected from patients were either directly diluted in Chase buffer at a 1/5 dilution rate (for serum sample), or further absorbed onto blood separator pad (for whole blood sample) prior to being diluted in Chase buffer. 70 ul of diluted sample were used for each test.

The strip was assembled by removing the membrane section of the protective cover and apply CN-95 membrane. Two pieces of protective cover were removed from sections above where the nitrocellulose was placed. A 21 mm wick pad was then applied by aligning the top of the wick pad with the top of the backing card edge, and the excess backing card below the membrane, was cut off, leaving just the membrane and wick pad. The strips were cut to 5.0 mm width using Kinematic Guillotine and package in pouch with desiccant.

The test and positive lines were then prepared on the strip by spot drying antibodies. 1.0 μL of test line antibody was applied around 9 mm from the bottom of the nitrocellulose on 20 pre-cut test strips; and 1 μL of control line antibody was applied around 15 mm up from the bottom of the nitrocellulose on each pre-cut and spotted test strip. The strips were tapped down on piece of paper and place in 40 C oven for 1-hour. Once dried, the strips were packaged with desiccant. The antibodies were previously conjugated with gold (using colloidal gold) or biotinylated.

For the assay, each conjugate were diluted to 0.02% solids using 50 mM borate, 0.5% casein, 1% tween. 8 μL of conjugate were pipetted into glass tube, followed by 10 μL of serum. Half of the strip was place in glass tube, with bottom of nitro submerged in the testing solution to allow conjugate/serum solution to run up strip. 50 μL of 1×PBS, 1% tween 20 were then added to glass tube to chase sample.

Using the FLI assay described herein, it was demonstrated that Farnesyl pyrophosphate synthase expression level could be determined a liquid sample collected from a patient, such as the serum, and that therefore pre-cancerous lesions of low and high grade, as well as cancerous cervical lesions could be detected using the device.

Although the invention has been described with reference to the above examples, it will be understood that modifications and variations are encompassed within the spirit and scope of the invention. Accordingly, the invention is limited only by the following claims. 

1. A method comprising: a) detecting at least one polypeptide in a sample from a subject; wherein the at least one polypeptide comprises: i) Farnesyl pyrophosphate synthase, neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat Shock Protein Cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof, or ii) a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NOs: 1-20 or a fragment thereof; b) diagnosing cervical cancer based on the detection of the at least one polypeptide; and c) administering a treatment to the subject.
 2. The method of claim 1, wherein the sample is selected from the group consisting of blood, plasma, urine, saliva, sweat, organ biopsy, cerebrospinal fluid (CSF), tear, vaginal fluid, feces, skin, and hair.
 3. The method of claim 2, wherein the sample is a blood sample.
 4. The method of claim 1, wherein the subject is human.
 5. The method of claim 1, wherein the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof and at least one polypeptide selected from the group consisting of neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 and a fragment thereof.
 6. The method of claim 1, wherein the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof and at least one polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NOs:2-20 and a fragment thereof.
 7. The method of claim 1, wherein the detecting is by protein microarray, fluorescence detection, flow cytometry, microfluidic device, lateral flow assay, vertical flow or immunoassay.
 8. The method of claim 7, wherein the detecting is by lateral flow assay.
 9. (canceled)
 10. The method of claim 1, wherein the treatment is selected from the group consisting of surgery, radiation, chemotherapy, targeted therapy and immunotherapy.
 11. A method of diagnosing, predicting, and/or monitoring the status or outcome of cervical cancer in a subject comprising: a) detecting at least one polypeptide in a sample from a subject; wherein the at least one polypeptide comprises: i) Farnesyl pyrophosphate synthase, neurofibromin 1, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat shock protein cognate protein 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof, or ii) a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NOs: 1-20 or a fragment thereof, and b) diagnosing cervical cancer based on the detection of the at least one polypeptide, thereby diagnosing, predicting, and/or monitoring the status or outcome of cervical cancer.
 12. The method of claim 11, wherein the sample is selected from the group consisting of blood, plasma, urine, saliva, sweat, organ biopsy, cerebrospinal fluid (CSF), tear, vaginal fluid, feces, skin, and hair.
 13. (canceled)
 14. (canceled)
 15. The method of claim 11, wherein the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof and at least one polypeptide selected from the group consisting of neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Cognate thermal shock protein 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 and a fragment thereof.
 16. The method of claim 11, wherein the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment thereof and at least one polypeptide with at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs:2-20 and a fragment thereof.
 17. The method of claim 11, wherein the detecting is by protein microarray, fluorescence detection, flow cytometry, microfluidic device, lateral flow assay, vertical flow assay or immunoassay.
 18. (canceled)
 19. The method of claim 11, further comprising administering a treatment to the subject.
 20. (canceled)
 21. A method of treating cervical cancer in a subject in need thereof comprising: a) detecting at least one polypeptide in a sample from a subject; wherein the at least one polypeptide comprises: i) Farnesyl pyrophosphate synthase, neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 or a fragment thereof, or ii) a polypeptide with at least about 70% sequence identity to a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NOs: 1-20 or a fragment thereof, b) diagnosing cervical cancer based on the detection of the at least one polypeptide; and c) administering a treatment to the subject, thereby treating the subject.
 22. The method of claim 21, wherein the sample is selected from the group consisting of a blood, plasma, urine, saliva, sweat, organ biopsy, cerebrospinal fluid (CSF), tear, vaginal fluid, feces, skin, and hair.
 23. The method of claim 21, wherein the at least one polypeptide comprises Farnesyl pyrophosphate synthase or a fragment thereof and at least one polypeptide selected from the group consisting of neurofibromin I, Glyceraldehyde-3 phosphate dehydrogenase, Protein 1 containing fibronectin domain type III, Eukaryotic initiation factor 4A-I, L-lactate dehydrogenase chain B, Nuclear heterogeneous Ribonucleoprotein A1, 1-like protein 1 polycystic kidney disease, Heat shock protein cognate 71 kDa, Ankyrin-3, Rho 23 GTPase-activating protein, Cytoskeletal Keratin 78 type II, Alpha-3 collagen chain (VI), Beta subunit of proteasome type-5, Heterogeneous nuclear ribonucleoproteins A2/B1, Histone H2B type 1-B, homolog of DnaJ subfamily C member 13, Beta enolase, Glutathione S-transferase P, Glutathione S-transferase Mu 3 and a fragment thereof.
 24. The method of claim 21, wherein the at least one polypeptide comprises a polypeptide with at least about 70% sequence identity to a polypeptide having the sequence of SEQ ID NO:1 or a fragment thereof and at least one polypeptide with at least about 70% sequence identity to a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NOs:2-20 and a fragment thereof.
 25. The method of claim 21, wherein the detecting is by protein microarray, fluorescence detection, flow cytometry, microfluidic device, lateral flow assay, vertical flow assay or immunoassay.
 26. (canceled)
 27. The method of claim 21, wherein the treatment is selected from the group consisting of surgery, radiation, chemotherapy, targeted therapy and immunotherapy. 28-57. (canceled) 